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Abstract 
Introduction: 
Patients with laryngeal carcinoma often present early due to the change in 
their voice. The treatment for T1aN0M0 carcinoma varies throughout the 
world, but whether radiotherapy (RT) or endolaryngeal laser excision is 
performed both result in excellent local control of the tumour and five year 
survival rates. There are advantages and disadvantages of either treatment 
but there are no appropriately powered randomised controlled trials 
comparing them. Over recent decades external beam RT has become the 
more popular choice and this is partly due to a perception of poor voice 
outcomes from surgical excision. However with the development of 
technology allowing surgical precision, transoral laser microsurgery (TLM) has 
resulted in low morbidity and good voice outcomes.  
 
Objective: 
This research has three main objectives: 
a. To describe acoustic parameters of ‘normal’ voice; 
b. To compare voice outcomes in patients treated with TLM with those 
treated with radiotherapy for T1a SCC of the glottis; 
c. To investigate longitudinal changes in voice quality in patients 
undergoing TLM for T1a SCC of the glottis. 
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Methods: 
The research was divided into three main parts. The first part was to analyse 
the acoustic parameters of ‘normal’ voice. To describe the parameters of 
‘normal’ voice, adults with no history of voice disorders who scored zero on 
the voice questionnaire (Voice Handicap Index - 10) were included. The 
second part comprised a comparative cohort study of 40 patients with 
T1aN0M0 laryngeal carcinoma, treated with either TLM (20 patients) or RT 
(20 patients) to compare voice outcomes at least one year following 
treatment. The third part involved a prospective cohort study of 30 patients 
with T1aN0M0 laryngeal carcinomas who were treated with TLM, comparing 
voice qualities before and after treatment. All patients were recruited from 
those attending the regional Head and Neck centre in Aintree University 
Hospital.  
The same methodology was adopted for voice recordings for all three parts of 
the study. Participants were asked to read a phonetically balanced passage 
and produce a prolonged vowel sound. In a sound proof room the voice 
recording included simultaneous audio and electrolaryngograph readings. The 
voice recordings were scored according to the GRBAS voice scale by an 
experienced rater. Acoustic analysis was performed form the 
electrolaryngograph recording using the SpeechStudioTM software. Several 
objective acoustic parameters were calculated from both sustained vowels 
and connected speech. These include: fundamental frequency (Fx), jitter, 
shimmer, harmonics to noise ratio (HNR) and normalized noise energy (NNE). 
In the comparative study of TLM versus RT and the prospective TLM study, 
patients were asked to complete voice-specific and quality of life 
19 
 
questionnaires. The voice-specific questionnaires were the Voice Symptom 
Scale (VoiSS) and the Voice Handicap Index-10 (VHI-10). The quality of life 
questionnaire adopted was the University of Washington Quality of Life 
(UWQoL) version 4.  
 
Results: 
In the acoustic analysis of sustained vowels in normal speech, females have a 
statistically significantly higher Fx than males (adjusted p=<0.05). There is no 
other statistically significant difference across the domains for sustained 
vowels in normal speech. In the analysis of connected speech, Fx is again 
higher in females (p<0.001). There is no statistically significant difference in 
amplitude (Ax) or contact quotient (Qx).   
In the comparison of voice post TLM and RT, there is no statistical difference 
in voice-specific questionnaires between the groups. The UW-QoL4 found a 
statistically significantly higher QoL score in the TLM compared with the RT 
group for appearance (p=0.003), recreation (p=0.048), chewing (p=0.015) and 
saliva (p=0.016), however these are not statistically significant when adjusted 
for age. Overall for QoL, the RT group have a statistically significantly lower 
median score compared to TLM in physical function (p=0.004) and this 
remains statistically significant when adjusted for age (p=0.036). There is no 
statistically significant difference for social function (p=0.441). There is no 
statistically significant difference in perceptual rating (GRBAS score) between 
RT and TLM groups (total mean 5.49 vs. 5.12, p=0.254). Most domains as 
part of the acoustic analysis of sustained vowels show no statistically 
significant difference between RT and TLM. The mean Fx analysis on 
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connective speech is statistically significantly higher in the TLM group 
(161.2Hz vs. 131.1Hz, adjusted p=0.001). Coherence of frequency is 
statistically significantly higher in the TLM group (48.6% vs. 36.0%, adjusted 
p=0.027) and pitch irregularity is statistically significantly higher in the RT 
group (26.7% vs. 14.9%, adjusted p=0.013). There is no statistically 
significant difference in mean amplitude between the two groups. Coherence 
of amplitude is statistically significantly higher in the TLM group (adjusted 
p=0.006) and amplitude irregularity is statistically significantly higher in the RT 
group, (12.4% vs. 6.3%, adjusted p=0.005). There is no statistically significant 
difference in mean contact quotient (p=0.368), coherence (p=0.236) or 
irregularity (p=0.125) when comparing TLM and RT.  
In the comparison of voice pre and post TLM, there is no statistical difference 
in voice-specific questionnaires between the groups. There is no statistically 
significant difference in the UW-QOLv4 domain scores or composite scores in 
patients pre- and post- TLM. There was no statistically significant difference in 
mean score for ‘G’,’R’,’B’ and ‘S’ indicators as part of perceptual rating 
between pre and post TLM patients, although asthenia was statistically 
significantly lower post-TLM (0.97 vs. 0.94, adjusted p=0.015). There is no 
statistically significant difference in any of the domains in the acoustic analysis 
of sustained vowels pre and post TLM. In the acoustic analysis of connected 
speech, the mean DFx is statistically significantly higher in the post TLM 
group (adjusted p=0.001). There is no statistically significant difference in the 
coherence of frequency or pitch irregularity when comparing pre and post 
TLM. There is no statistically significant difference in the mean DAx (p=0.121), 
coherence (p=0.472) or irregularity of amplitude (p=0.184) when comparing 
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pre and post TLM. There is no statistically significant difference in the mean 
DQx (adjusted p=0.904), coherence (adjusted p=0.293) or irregularity of the 
contact quotient (adjusted p=0.400) when comparing pre and post TLM. 
 
Conclusion: 
The treatment of T1a laryngeal carcinoma with either TLM or RT has been 
shown to have comparably good local control. There are advantages and 
disadvantages of both treatments, however TLM is often preferred by patient 
and clinician as it is a day case procedure, can provide histological clearance 
and leaves the option to use RT in the future. However voice outcomes of the 
procedures have been debated with various reports in the literature. There are 
challenges when comparing the two treatment modalities due to a number of 
tumour, patient and surgical factors. It is not surprising that the voice is 
affected by whatever treatment is performed to treat the glottic carcinoma. 
This study shows that voice quality is good, however it is measured, for after 
both TLM and RT.  
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Glossary of acronyms  
 AUH  Aintree University Hospital, NHS Foundation Trust  
 CPP  Cepstral peak prominence 
 DAx  Distribution of amplitude 
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 EGG  Electroglottography 
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 QoL  Quality of life 
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 SD  Standard deviation 
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 UW-QoLv4 University of Washington quality of life version 4 
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 VoiSS  Voice symptom scale 
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1. Introduction   
 
1.1 Laryngeal anatomy  
The larynx is a complex structure in the neck consisting of a framework of 
cartilages connected by ligaments, membranes and muscles. It is in a midline 
position in the anterior neck and its role is to provide voice as well as 
protecting the airway from the digestive tract. Figure 1 demonstrates the 
position of the larynx in the anterior neck.  
 
Figure 1: Location of the larynx  
 
Source: Adobe stock images
1
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Embryologically the larynx develops from the ectodermal, endodermal and 
mesodermal tissues from the third, fourth and sixth pharyngeal arches and 
pouches. At the fourth week of intra-uterine life the laryngotracheal groove 
appears at the ventral wall of the larynx. This eventually deepens and the 
edges fuse to form the laryngotracheal tube which separates it from the 
pharynx and oesophagus. The laryngotracheal tube is lined with endoderm 
from which the epithelium of the airway develops. In the fifth to sixth week the 
primordial epiglottis and arytenoids arise from the third and fourth pharyngeal 
arches.2 The thyroid cartilage develops from the fourth and the cricoid from 
the sixth pharyngeal arch after the eighth week. The laryngeal 
muscles develop from the fourth and sixth pairs of pharyngeal arches and are 
innervated by branches of the vagus nerves (recurrent and superior laryngeal 
nerves).2  
The growth of the larynx and epiglottis is rapid during the first 3 years after 
birth, following which the epiglottis has reached its adult form. There is 
gradual descent of both structures during early childhood. The lower postion 
of the larynx in an adult enables a greater range of vocalization. The postion 
of the larynx also decreases the risk of aspiration and allows enough space 
for the vocal cords to lengthen.3  The laynx is higher in the neck in adult 
humans compared to non-human primates. The extra space in adult humans 
allows improved tongue movements and a greater frequency range in humans 
compared to other primates.4    
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1.1.1 Laryngeal cartilages  
The larynx is formed by three unpaired cartilages (epiglottic, thyroid and 
cricoid) and four paired cartilages (arytenoids, cuneiform, corniculate and 
tritiate). Figure 2 illustrates the position of the thyroid and cricoid cartilage in 
relation to the trachea and hyoid bone.  
 
 
Source: Modified image of larynx from Gray’s Anatomy
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The thyroid, cricoid and the greater part of the arytenoid cartilages consist of 
hyaline cartilage whilst the epiglottic, cuneiform and corniculate cartilages and 
the apices of the arytenoid are composed of elastic fibrocartilage. Elastic 
cartilage contains elastin fibres giving it greater flexibility compared to hyaline 
cartilage and allowing it to return to its normal shape. This is important due to 
Figure 2: Laryngeal cartilages 
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the movement of the larynx during swallowing and speech. Hyaline cartilage 
contains high levels of collagen, which provides added strength and structure 
to the larynx. There is progressive  mineralization and ossification of the 
laryngeal cartilages with age.5 
Epiglottic cartilage 
The epiglottis is a thin leaf-like plate of elastic fibrocartilage which protects the 
airway by diverting food and drink away from the laryngeal inlet and into the 
oesophagus. The epiglottic cartilage projects upwards behind the tongue and 
is attached anteriorly to the hyoid bone, posteriorly to the arytenoids (see 
figure 3) and inferiorly to the thyroid cartilage.  
 
Figure 3: Posterior view of larynx  
 
 
Source: Anatomy of the human body, Gray.
7
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Inferiorly the epiglottic cartilage has a long and narrow stalk known as the 
petiole. It is connected to the thyroid cartilage by the thyroepiglottic ligament. 
The sides of the petiole are connected to the arytenoid cartilage by 
aryepiglottic folds whilst the superior portion of the cartilage remains 
unattached. Anteriorly, the lingual surface is covered by a non-keratinised, 
stratified, squamous mucosa. The lingual surface is attached anteriorly to the 
hyoid bone by the hyoepiglottic ligament.  
Posteriorly, the laryngeal surface of the epiglottic cartilage is smooth and 
covered by ciliated pseudostratified respiratory epithelium. In this posterior 
part of the epiglottis there are numerous small mucous glands which help 
lubricate the larynx. This is important for voice production as the vocal folds 
do not have any mucous glands.  
 
Thyroid cartilage 
The thyroid cartilage is the largest cartilage in the larynx and acts to protect 
the internal anatomy of the larynx. 8 The thyroid cartilage is located inferior to 
the hyoid bone and superior to the cricoid cartilage. The thyroid cartilage 
consists of two quadrilateral laminae (or alae) fused at the midline and 
opening posteriorly. In males, anterior borders of each lamina are at an 
approximate right angle, forming the laryngeal prominence or ‘Adam’s apple’. 
In females, this angle is about 120 degrees and therefore the laryngeal 
prominence is much less pronounced.9 The more acute angle in men allows 
for a greater length of the vocal folds which, amongst other factors, results in 
29 
 
a deeper pitch of the voice. Thus the length of the vocal folds in female adults 
is 13-17mm compared to male adults of 15-23mm.10 
 
Figure 4: Posterior view of thyroid cartilage 
 
 
Source: Anatomy of the human body, Gray.
7
 
 
The thyroid laminae are separated superiorly by the thyroid notch. A 
cadaveric study demonstrated that the midline vertical distance from the 
thyroid notch to the inferior border of the thyroid cartilage ranges from 
23.8mm (+/- 3.9mm) in males and 15.0mm (+/-2.1mm) in females.11 The 
anterior commissure is found at the midpoint between these landmarks and is 
defined as the anterior point where the vocal folds meet.8  
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The laminae of the thyroid cartilage continue posteriorly to form the superior 
and inferior horn or cornu as demonstrated in figure 4. The inferior cornu 
articulates with the cricoid cartilage to form the cricothyroid joint. This synovial 
joint allows rotation of the cricoid cartilage with respect to the thyroid cartilage. 
The movement at this joint enables the vocal fold tension to be varied. The 
superior cornu attaches to the greater cornu of the hyoid bone through the 
lateral thyrohyoid ligament. The thyroid cartilage is also attached to the hyoid 
bone by the thyrohyoid membrane. The thyrohyoid membrane is thicker in the 
middle to make up the median thyrohyoid membrane.  
There is an oblique line that passes along the external surface of each lamina 
of the thyroid cartilage. This is where the thyrohyoid, sternothyroid and inferior 
constrictor muscles insert into the thyroid cartilage. 
A perichondrium layer lines the thyroid cartilage except at the inner surface at 
the anterior commissure. At the commissure there are ligamentous 
attachments to the laryngeal folds, the thyroepiglottic ligament, bilateral 
vestibular ligaments (false cords) and bilateral vocal ligaments (vocal folds). 12 
Broyle’s ligament is where the vocal folds meet anteriorly at the anterior 
commissure and the fibres pass to the thyroid cartilage. This is a potential 
route for malignancy to spread from the larynx.13  
Cricoid cartilage 
The cricoid cartilage forms a complete ring around the airway resembling a 
signet ring, with a broad posterior lamina and a thinner anterior arch.14 It 
forms the base for the entire larynx and also supports the arytenoid cartilages. 
It provides attachments for the cartilages, ligaments and muscles involved in 
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opening and closing the airway and controlling voice production. Figure 5 
illustrates the location of the muscular attachments to the posterior aspect of 
the cricoid.   
The cricoid is attached to the thyroid cartilage through the median cricothyroid 
ligament and postero-laterally by the cricothyroid joints. The cricoid cartilage 
also articulates superiorly to the arytenoid cartilage via the synovial 
cricoarytenoid joint. Inferiorly, the cricoid cartilage is attached to the trachea 
via the cricotracheal ligament.  
 
Figure 5: Cricoid cartilage 
 
 
Source: Anatomy of the human body, Gray. 
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Arytenoid cartilages 
The paired arytenoid cartilages are small, pyramidal structures which allow 
the vocal folds to be tensed or relaxed. Figure 6 illustrates the pyramidal 
shape of the arytenoid cartilage. The arytenoids are located at the posterior, 
superior border of the cricoid cartilage. The arytenoid cartilage has two 
processes: the vocal and the muscular process. The vocal process projects 
forward, and attaches to the vocal ligament. The muscular process projects 
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laterally, and gives attachment to the posterior cricoarytenoid muscles and the 
lateral cricoarytenoid muscles.  
 
Figure 6: Arytenoid, corniculate and cuneiform cartilages 
 
Source: Anatomy of the human body, Gray. 
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Corniculate cartilage 
The corniculate cartilages are two small conical cartilages which articulate 
with the apices of the arytenoid cartilages. Figure 7 demonstrates how they 
are situated in the posterior parts of the aryepiglottic mucosal folds, and form 
the posterior aspect of the laryngeal inlet.  
Cuneiform cartilage 
The cuneiform cartilages are two small, elongated, nodules of elastic 
fibrocartilage. They sit on either side of the aryepiglottic fold, anterosuperior to 
the corniculate cartilages, and form the lateral aspect of the laryngeal inlet. 
The corniculate and cuneiform cartilages result in small bulges on the surface 
of the mucous membrane (see figure 7) and help prevent collapse of the 
larynx during inspiration and swallowing.  
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Figure 7: Endoscopic view of larynx
 
 
Source: National Cancer Institute (2010).
15
 
 
Tritiate cartilage 
The tritiate cartilages are two small nodules situated within the thyrohyoid 
membrane and help to strengthen the thyrohyoid membrane.    
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1.1.2 Joints of the larynx 
The joints in the larynx include the cricothyroid, cricoarytenoid and 
arytenocorniculate joints. The joints help stabilize the larynx but also allow 
movement to assist in swallowing, vocalizing and breathing.  
 
 
Cricothyroid joints 
The cricothyroid joints are synovial joints situated between the inferior cornu 
of the thyroid cartilage and the sides of the cricoid cartilage. Each joint is 
enveloped by a capsular ligament, strengthened posteriorly by fibrous bands. 
Both capsule and ligaments are rich in elastin fibres. The primary movement 
at the joint is rotation around a transverse axis, moving the lamina of the 
thyroid cartilage and the arch of the cricoid cartilage closer together. This 
movement is important to allow changes in voice pitch by permitting 
elongation of the vocal folds.16  
                                       
                                                  
Cricoarytenoid joint 
The cricoarytenoid joints are a pair of synovial joints between the lateral parts 
of the upper border of the cricoid cartilage and the bases of the arytenoids. 
There are two main movements at this joint: rotation of the arytenoid 
cartilages at right angle to the long axis of the cricoid; and gliding of the 
arytenoids towards or away from each other, in an anterior and posterior 
direction. By their movements, the joints facilitate alteration of the distance 
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between the vocal processes of the two arytenoids, and between each vocal 
process and the anterior commissure. This movement of the arytenoid 
cartilage changes the shape and tension of the vocal folds thereby changing 
voice quality. Rheumatoid arthritis causes inflammation in the synovium of 
joints. The rheumatoid arthritis can involve the cricoarytenoid joint and cause 
an abnormal voice (dysphonia) as well as airway obstruction.17  
 
Arytenocorniculate joints 
The arytenocorniculate joints are very small and link the arytenoid and 
corniculate cartilages. They are of no clinical significance. 
 
1.1.3 Muscles of the larynx  
The muscles of the larynx may be divided into extrinsic or intrinsic groups.  
The Extrinsic laryngeal muscles 
The extrinsic muscles connect the larynx to the neighbouring structures and 
are responsible for moving it vertically during phonation and swallowing. The 
muscles that suspend the larynx and elevate it during swallowing are: 
thyrohyoid; stylohyoid; digastric; geniohyoid; mylohyoid; and stylopharyngeus 
muscles (illustrated in figure 8). Opposing muscles pull the larynx down and 
include: omohyoid; sternothyroid; and sternohyoid muscles. The middle 
constrictor, inferior constrictor, and cricopharyngeus muscles are important in 
the swallowing reflex. The extrinsic muscles of the larynx have little impact on 
voice production and will therefore not be described in further detail.  
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Source: Anatomy of the human body, Gray. 
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The Intrinsic laryngeal Muscles 
The intrinsic muscles of the larynx are confined to the larynx in their 
attachments and their function is to modify the size of the glottic opening (rima 
glottidis) along with changing the length and tension on the vocal folds. The 
intrinsic muscles include: cricothyroid; posterior and lateral cricoarytenoid; 
transverse and oblique arytenoid; aryepiglottic; thyroarytenoid; vocalis; and 
thyroepiglotticus muscles (illustrated in figure 9). All the intrinsic muscles, 
except the transverse arytenoid muscle, are paired, and work synchronously.  
Figure 8: Extrinsic laryngeal muscles 
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Source: Anatomy of the human body, Gray.
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Cricothyroid muscle 
The cricothyroid muscle is attached anteriorly to the external surface of the 
arch of the cricoid cartilage. Its fibres pass backwards and diverge into two 
portions, lower oblique and straight. On contraction of the cricothyroid muscle 
the cricoid rotates at the cricothyroid joint. This brings the anterior arch of the 
Figure 9: Intrinsic laryngeal muscles 
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cricoid superiorly towards the inferior border of the thyroid laminae. Whilst, at 
the same time causing the posterior cricoid lamina and the arytenoid 
cartilages to move inferiorly. This inferior displacement increases the distance 
between the vocal processes and the anterior commissure. This 
approximation of the thyroid and cricoid cartilage has been referred to the 
‘closing of the visor’.18 The results of this are to lower, elongate, and thin the 
vocal folds while bringing them into a paramedian position. The stretching of 
the vocal fold tightens the edge of the vocal fold and passively stiffens the 
component layers of the vocal fold. This results in a sound of higher frequency 
produced by the vocal folds.  
 
Posterior cricoarytenoid muscle 
The posterior cricoarytenoid muscle (illustrated in figure 10) arises from the 
posterior surface of the cricoid lamina. The posterior cricoarytenoid muscles 
are the only laryngeal muscles that abduct the vocal folds. Its fibres run 
laterally and converge to insert on the upper and posterior surfaces of the 
muscular process of the ipsilateral arytenoid cartilage. The muscles also 
elongate, and thin the vocal folds while causing the vocal fold edge to be 
rounded.  
 
Lateral cricoarytenoid muscles 
The lateral cricoarytenoid muscles are attached anteriorly to the upper border 
of the cricoid arch. They run obliquely backwards to be attached to the front of 
the muscular process of the ipsilateral arytenoid cartilage. The lateral 
cricoarytenoid rotates the arytenoid cartilage in a direction opposite to that of 
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posterior cricoarytenoid and so closes the rima glottidis (space between the 
vocal folds).  
 
Figure 10: Posterior Cricoarytenoid (labelled crycoarytenoideus posterior) 
 
Source: Anatomy of the human body, Gray.
7
  
 
 
Oblique and transverse arytenoid muscles 
The oblique and transverse arytenoid muscles aid the adduction of the vocal 
folds. The oblique arytenoid muscles lie superficial to the transverse arytenoid 
and aryepiglotticus muscles. The muscles cross each other obliquely at the 
40 
 
back of the larynx, each extending from the posterior surface of the muscular 
process of one arytenoid cartilage to the apex of the opposite one. Some 
fibres continue laterally round the arytenoid apex into the aryepiglottic fold, 
forming the aryepiglotticus muscle. The oblique arytenoids and aryepiglotticus 
muscles act as a sphincter of the laryngeal inlet by adducting the aryepiglottic 
folds and approximating the arytenoid cartilages to the tubercle of the 
epiglottis.  
 
Transverse arytenoid muscle 
The transverse arytenoid muscle is a single unpaired muscle deep to the 
oblique arytenoid muscle. It bridges the gap at the back of the larynx between 
the two arytenoid cartilages. It attaches to the back of the muscular process 
and adjacent lateral borders of both arytenoids. The transverse arytenoid 
muscle moves the arytenoid cartilages towards each other, closing the 
posterior portion of the vocal folds.  
 
Thyroarytenoid muscles 
The thyroarytenoid muscles are broad and thin and lie lateral to the vocal 
folds as shown in figure 11. These muscles can be divided into the 
thyroarytenoid internus and externus muscles. The more developed internus 
muscles lie deep to the externus muscle. The thyroarytenoid internus are also 
known as the vocalis muscle. It attaches at the anterior commissure and 
inserts onto the vocal process. The thyroarytenoid internus contracts to 
adduct, shorten, thicken, and lower the vocal fold while rounding its edge. The 
thyroarytenoid externus arises from the anterior commissure and inserts onto 
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the lateral surface of the arytenoid cartilage. On contraction it contracts to 
bring the vocal process and anterior commissure closer to each other. The 
majority of fibres in internus are slow-twitch and those in externus fast-twitch. 
The structure of the thyroarytenoid muscle varies between mammals and the 
ratio of different fibres in humans helps to create a unique speech function.19 
In the elderly there is muscle atrophy and change of the ratio of slow and fast-
twitch fibres which contributes to a change in voice with age.20 
 
Thyroepiglotticus muscle 
A few muscle fibres of the thyroarytenoid externus muscle run through the 
quadrangular membrane to establish the thyroepiglotticus muscle. The 
thyroepiglotticus muscle narrows the rima glottitis and can widen the inlet of 
the larynx by their action on the aryeplgottic folds.  
 
 
Figure 11: Thyroarytenoid muscle (labelled as thyro-arytenoideus)  
 
Source: Anatomy of the human body, Gray.
7
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1.1.4 Ligaments and membranes of the larynx  
There are extrinsic and intrinsic ligaments of the larynx which support the 
laryngeal superstructure and enable movement. The extrinsic ligaments 
include: the thyrohyoid membrane, hyoepiglottic ligament and the 
cricotracheal ligament. The intrinsic ligaments include: the quadrangular 
membrane of the supraglottic larynx, conus elasticus and the vocal ligaments. 
The quadrangular membrane and the overlying mucosa form the aryepiglottic 
folds, constituting the medial wall of each of the piriform sinuses. It attaches to 
the lateral side of the epiglottis anteriorly, and attaches posteriorly to the 
arytenoid and corniculate cartilages. The conus elasticus is a thick elastic 
structure, which attaches inferiorly at the superior border of the cricoid 
cartilage, and superiorly to the anterior commissure of the thyroid cartilage 
and the vocal process of the arytenoid. Between the two superior 
attachments, it forms the vocal ligament.  Anteriorly the conus elasticus forms 
the cricothyroid membrane, in the midline becomes the cricothyroid ligament, 
and superiorly extends to become the thyroglottic membrane. This thyroglottic 
membrane lies parallel to the superior surface of the true vocal fold. It is 
usually incomplete, and so forms an incomplete barrier to prevent extension of 
transglottic cancers.  
 
1.1.5 Vasculature 
The arterial supply to the larynx is from the superior and inferior laryngeal 
arteries. The superior laryngeal artery is formed from the superior thyroid 
artery, a branch of the external carotid artery, at the level of the hyoid. The 
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superior laryngeal artery runs alongside the internal branch of the superior 
laryngeal nerve and enters the thyrohyoid membrane inferior to the nerve. The 
artery enters the mucosa of the piriform sinus before being branching to 
perfuse other internal laryngeal structures.  
The inferior laryngeal artery is formed from the inferior thyroid artery, a branch 
of the thryocervical trunk from the subclavian artery. The inferior laryngeal 
artery runs alongside the recurrent laryngeal nerve to the posterior of the 
cricothyroid joint. The artery then supplies the remainder of the internal larynx, 
forming multiple anastomoses with the superior laryngeal artery. The venous 
supply runs parallel to the arterial system.  
 
1.1.6 Lymphatics 
Understanding the lymphatic system in the neck aids diagnosis and treatment 
of cancer of the larynx. It is divided into superficial intramucosal and deep 
submucosal networks. The deep submucosal network is a key factor in the 
spread of cancer. It comprises of a right and left half, with limited 
communication between them. Each half is divided into: supraglottic, glottic, 
and subglottic regions. The drainage of the supraglottic structures follows the 
superior laryngeal and superior thyroid vessels, from the piriform sinus 
through the thyrohyoid membrane to the deep jugular chain at the carotid 
bifurcation. The ventricle in the supraglottic region drains into the paraglottic 
space, through the cricothyroid membrane and into the ipsilateral lobe of the 
thyroid, hence it requires resection during laryngectomy. The true vocal folds 
are not drained by a lymphatic network, and therefore there is a good 
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treatment success for cancers in this area.18 The epiglottis is drained by the 
glottis network, and drains bilaterally.  
The subglottic area comprises of two systems: one follows the inferior thyroid 
vessels to the deep jugular, subclavian, paratrachial and tracheoesophageal 
chains; and the other travels through the cricothyroid membrane to bilateral 
middle deep cervical nodes and prelaryngeal nodes, receiving lymphatics 
from both sides of the larynx.  
 
1.1.7 Innervation 
The larynx is innervated by the superior and inferior laryngeal nerves which 
are branches of the vagus nerve. The superior laryngeal nerve branches from 
the vagus high in the neck and divides into internal and external branches. 
The internal branch runs alongside the superior laryngeal artery through the 
thyrohyoid membrane, providing the sensory supply to the supraglottis. The 
external branch innervates the cricothyroid and inferior constrictor muscles.  
The inferior laryngeal nerve originates from the recurrent laryngeal nerve and 
runs within the tracheoesophageal groove. It passes posteriorly to the 
cricothyroid joint before entering the larynx. It supplies motor innervation to all 
the intrinsic muscles of the larynx except the cricothyroid muscle. The 
recurrent laryngeal nerve also contains sensory and secretomotor fibres to the 
glottis and subglottis.  
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1.1.8 Vocal folds 
There are two pairs of vocal folds: false (vestibular) and true vocal folds. The 
false (vestibular) folds are formed by mucosa overlying the vestibular 
ligament. The true folds are formed by mucosa overlying the vocal ligament 
and the vocal process of the arytenoid. Clinically, the true vocal folds are 
referred to as the vocal cords although the terms are often used 
synonymously with no consensus on terminology. Figure 12 shows an 
endoscopic image of the vocal folds.   
 
Figure 12: Endoscopic image of vocal folds 
 
Source: Endoscopic image taken by author  
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Each fold consists of five layers: the mucosa, three layers of lamina propria 
and the vocalis muscle. The mucosa overlying the vocal fold is thin and gives 
the vocal fold a pearly white appearance. It is attached to the underlying 
lamina propria by a basement membrane. The most superficial layer of the 
lamina propria consists of loose collagen and elastic fibres, loosely attached 
to the underlying vocal ligament. 
This produces a potential space (Reinke’s space) extending along the length 
of the free margin of the vocal ligament and a little way onto the superior 
surface of the cord. Fluid readily collects in this space when disease is 
present causing swelling or oedema of the vocal folds. The intermediate layer 
of the lamina propria consists of elastic fibres and the deep layer is formed of 
collagen fibres. These two layers collectively form the vocal ligament.  Fibres 
of the vocalis muscles form the fifth layer of the vocal folds.  
The free edge of the vocal folds is covered with stratified squamous 
epithelium whilst the supraglottis and posterior glottis is lined with 
pseudostratified ciliated epithelium. The ciliated epithelium contains mucous 
producing cells and allows for adequate lubrication of the vocal folds. Surgery 
or RT of this area, causing scarring (fibrosis), can disturb this layer and 
resulting in a lack of mucous to the vocal folds.  
 
1.2 Laryngeal Physiology  
The larynx has three primary functions: protection of the airway; respiration; 
and phonation. Phonation occurs when air is directed against the vocal folds, 
causing them to vibrate and produce sounds through columns of air in the 
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pharynx, nose and mouth. Phonation is not simply reliant on laryngeal 
movement, but also relies on lips, tongue, jaw, and nasal passages.  
 
1.2.1 Vocal fold movement 
The vibrations of the vocal folds are passive and represent the basis of the 
aerodynamic theory of sound production. Vibration of the vocal folds changes 
direct current airflow into alternating airflow, converting aerodynamic to 
acoustic energy. This is aided by movement of intrinsic and extrinsic laryngeal 
muscles, which shape and change the tension of the glottis during phonation. 
The laryngeal muscles are capable of a great degree of control, due to a high 
number of nerve cells. The laryngeal muscles contract around 100 to 200ms 
before the onset of phonation.12  
The vibratory cycle is described as having three phases: opening, closing, and 
closed. The cycle begins with the vocal folds closed. The lateral 
cricoarytenoids and intercartilaginous muscles are contracted, which keep the 
folds closed (adducted). During the opening phase, the subglottic pressure 
increases, overcoming the muscular adduction, and forces the vocal folds 
apart from inferior to superior edges until the glottis opens. Air escapes and 
releases the subglottic pressure. Contraction of the posterior cricoarytenoid 
muscles aids the vocal folds to move apart (abduction).  
The vocal folds will close if the adductive tension of the folds is sustained. In 
addition the rapid closure is aided by the physical process known as the 
‘Bernoulli Effect’. This is the forcing of air from a region of high to low pressure 
through a narrow space. This creates a kinetic energy at the edge of the 
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space causing a negative pressure which brings the folds together.18 This 
subsequently leads to a rise in the subglottal pressure and the cycle is 
repeated. The effect is to cause the release of a series of small amounts of air 
into the supralaryngeal vocal tract at a frequency of many times per second.18 
 
1.2.2 Variations in phonation 
The sound that results from phonation is due to: frequency of air release, 
perceived as pitch; pressure of air release, perceived as loudness; and timbre, 
perceived as voice quality.18  
The frequency (pitch) depends on: vibratory mass of the vocal folds; tension 
of the folds; changing the size of the glottal opening; and subglottic pressure. 
The fundamental frequency is determined by the resting length of the vocal 
cords, which varies with age and sex. The frequency range of humans is from 
60 to 500Hz, with an average of 120Hz in males, 200Hz in females and 
270Hz in children.21 Variations in frequency are determined by the relationship 
of the length, tension and thickness of the vocal cords. An increase in the 
length of the vocal cords, or an increase in tension in the cords causes the 
frequency (pitch) to rise. The actions of the cricothyroid, posterior 
cricoarytenoid and vocalis muscles lead to changes in length of the vocal 
cords. Inflamed and swollen vocal cords are thicker than normal and result in 
a hoarse voice. At puberty, growth of the thyroid cartilage in males lengthens 
the vocal cords and lowers the fundamental frequency. During panic the vocal 
cords may be tensed causing a high pitched squeek.  
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The greater the pressure of air against the vocal cords, the louder the sound. 
This is performed by changing the opening period of the glottis. The energy 
from the airstream is then used by other parts of the vocal tract to generate 
sound, normally by constricting or stopping the airflow. The perceived 
character of sound created is largely related to resonation through the 
supraglottic vocal tract, including the pharynx, tongue, palate, oral cavity, and 
nose.  
 
1.2.3 Voice disorders 
‘Voice’ is the acoustic output from the vocal tract that is characterized by their 
dependence on vocal fold vibration 22. Voice disorders or dysphonia refer to 
breakdowns of phonation, which may be due to difficulties with: the air 
pressure system; the vibratory system; or the resonating system (vocal tract). 
A problem with the air pressure system would include an ineffective expulsion 
of air out of the lungs. This would lead to a weak voice and can be further 
affected by shortness of breath. This may be caused by lung disease, such as 
asthma, lung cancer or emphysema leading to difficulties in speaking loudly or 
for long periods of time. Changes to the vibratory system leading to 
compromise in vocal fold vibration can cause hoarseness or other problems 
with voice production. For example, swelling of vocal folds due to common 
cold or other respiratory viruses can lead to hoarseness and air leak due to 
nerve damage to the vocal folds, preventing them from adducting, can lead to 
a ‘breathy’ voice. Further dysphonia can be caused by problems with the 
resonating tract including pathology of the pharynx, oral and nasal cavity.  
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1.3 Epidemiology of laryngeal carcinoma  
Laryngeal cancer accounts for 1% of all new cases of cancer in males and 
0.2% in females.23 It accounts for 0.5% of deaths from cancer in the UK and is 
the 18th most common cause of cancer death among males in the UK. There 
were 2,315 new laryngeal carcinomas in 2013, 83% of these were in males. 
This calculates as 6.1 new laryngeal cancers for every 100,000 males and 1.2 
for every 100,000 females in the UK. 
In the UK the highest rates are in parts of Scotland and northern England with 
the lowest rates being in southern England.24 Throughout Europe laryngeal 
carcinomas are more common in males than in females although there are 
wide variations in the ratio of male to female. This variation is likely to reflect 
the differences in prevalence of smoking and alcohol consumption. There is a 
higher incidence of laryngeal carcinoma as age increases. In the UK between 
2010 and 2012, 40% of laryngeal cancer mortality were in adults over 75 
years.23   
In the UK over the past 40 years the incidence rates have decreased in males 
but remained stable in females (see figure 13). The reasons for the decline in 
males are thought to be due to several reasons including decrease in smoking 
prevalence and improved diet. 25,26 
The mortality rate shows that there are 2 laryngeal cancer deaths for every 
100,000 males in the UK and 0.5 for every 100,000 females.23 The mortality 
rate is related to age with the highest mortality in older males and females. 
However there has been an overall decrease laryngeal cancer mortality rates 
in the UK over the past 40 years. Along with the majority of cancers the 
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relative survival for laryngeal caner is improving. This can be generally 
attributed to faster diagnosis and improvements in treatment. In general the 
improvements have been slow and increasing cancer survival remains a 
priority and there are national strategies to improve this including a national 
awareness campaign.27 
 
Figure 13: Laryngeal cancer (C32), European age-standardised mortality rates, UK, 
1971-2012 
 
Source: Cancer Research UK
23
 
 
 
More than 90% of laryngeal cancers are squamous cell carcinomas (SCC). 
There are a number of risk factors for squamous cell carcinoma. It is 
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associated with tobacco and excess alcohol use.  Cigarette smoke in 
particular is the major risk factor but alcohol excess has been demonstrated to 
have an additional carcinogenic effect 25,28. Other risk factors have been 
identified, including human papilloma virus (HPV)29, gastro-oesophageal 
reflux and toxic inhalations (such as asbestos and mustard gas)30. There is a 
wide range in the reported incidence of HPV positive patients in the larynx. A 
systematic review of 1712 cases(by Isayeva et al. in 2012) has shown it to be 
up to 23.6%.31 Although a study in our region (by Upile et al. 2014) assessing 
the rate of HPV positive patients in tumours outside the oropharynx showed 
the HPV rate to be only 3.2% in the larynx compared to 70% of tumours in the 
oropharynx.32 SCC has been found to be more prevalent in low 
socioeconomic groups, likely due to these risk factors.33  
The presenting features of laryngeal carcinoma include dysphonia, 
impairment in swallowing (dysphagia), coughing of blood originating from the 
respiratory tract (haemoptysis), neck mass, aspiration (inhalation of gastric or 
oropharygneal contents into the lower airway), pain when swallowing 
(odynophagia), ear pain (otalgia) and airway compromise.  
Laryngeal cancers most commonly arise from the true vocal folds or the 
glottis. The majority of these patients present early with normal vocal cord 
movement, no lymph node involvement or extension beyond the larynx.  
Due to the fact that minimal change in the vocal cords will result in voice 
change, patients often seek attention in a timely manner and laryngeal 
cancers are often picked up at an earlier stage. Up to three quarters of 
patients present early, with mobile vocal folds, no nodal involvement or 
extension beyond the larynx.34   Early stage laryngeal SCC is characterised 
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by low tumour volume and low rate of regional metastasis. This is partly due 
to the poor lymphatic drainage from this area. For these reasons early 
laryngeal SCC has a relatively high chance of cure and low chance of 
metastatic spread.  
The TNM (tumour, node, and metastasis) classification is used for the staging 
of laryngeal carcinoma (see table 1). This has been classified by the American 
Joint Committee on Cancer (AJCC, seventh edition, 2010).35 The larynx is 
subdivided into three anatomical regions for classification of the tumour site: 
supraglottis, glottis and subglottis. The glottis includes the true vocal cords as 
well as the anterior and posterior commissure. According to the AJCC the 
superior boundary of the glottis is a horizontal line through the apex of the 
laryngeal ventricle and the inferior boundary is 1cm below this line.35  Glottic 
T1aN0M0 are tumours confined to one vocal cord with normal mobility, no 
metastases to cervical lymph nodes and no distant metastases. T1bN0M0 
involves both vocal cords but there is still normal mobility. In T2N0M0 the 
tumour extends to the subglottis and/or supraglottis and/or with impaired vocal 
cord mobility.  
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Table 1: TNM Staging of Glottis carcinoma 
Glottis 
T1 
 
Tumour limited to the vocal cord(s) (may involve anterior or posterior 
commissure) with normal mobility.  
T1a 
 
Tumour limited to one vocal cord.  
 
T1b 
 
Tumour involves both vocal cords.  
T2 
 
Tumour extends to supraglottis and/or subglottis and/or with impaired vocal 
cord mobility.  
T3 
 
Tumour limited to the larynx with vocal cord fixation and/or invasion of 
paraglottic space and/or inner cortex of the thyroid cartilage.  
 
T4a 
 
Moderately advanced local disease. 
Tumour invades through the outer cortex of the thyroid cartilage and/or 
invades tissues beyond the larynx (e.g., trachea, soft tissues of neck 
including deep extrinsic muscle of the tongue, strap muscles, thyroid, or 
oesophagus).  
T4b 
 
Very advanced local disease.  
Tumour invades prevertebral space, encases carotid artery, or invades 
mediastinal structures.  
 
Source: Reproduced from AJCC, seventh edition, 2010.
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The laryngeal cancers can also be classified into stages, with Stage I relating 
to T1N0M0 and Stage II relating to T2N0M0 (table 2). 
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Table 2: Staging of Laryngeal Carcinoma 
Stage T N M 
0 
Tis N0 M0 
I 
T1 N0 M0 
II 
T2 N0 M0 
III 
T3 N0 M0 
T1 N1 M0 
T2 N1 M0 
T3 N1 M0 
IVA 
T4a N0 M0 
T4a N1 M0 
T1 N2 M0 
T2 N2 M0 
T3 N2 M0 
T4a N2 M0 
IVB 
 
T4b Any N M0 
Any T N3 M0 
IVC Any T Any N M1 
 
Source: Reproduced from AJCC, seventh edition, 2010.
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1.4 Management of early laryngeal carcinoma 
The aim of the treatment of early laryngeal carcinoma is to achieve survival 
through local control, avoiding total laryngectomy, and maintaining voice 
quality. In addition, quality of life, cost-effectiveness and convenience are 
other key aims of treatment.  
The UK head and neck cancer multidisciplinary management guidelines 
(2011) state that early stage laryngeal carcinoma (stage I and II) can be 
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treated with open surgery (an external approach via a neck incision), 
endolaryngeal excision (removal using a scope through the mouth) or RT.36 
Endolaryngeal excision can be undertaken using cold steel resection or laser 
excision. There is much variation and conflict between centres and countries 
as to which is the optimal treatment 37, nowadays, all are accepted modalities 
and the reported five-year-survival following any form of treatment exceeds 
85%.34,38 However historically RT was the main treatment with good control 
rates and low morbidity and there was some controversy as transoral laser 
microsurgery (TLM) became more popular.39  
Voice quality, cost-effectiveness and convenience are also key indicators that 
may influence decisions regarding optimal treatment options.  
Open surgery is not commonly used in the UK for early laryngeal carcinomas 
due to the increased morbidity of the treatment, temporary requirement for 
tracheostomy and aspiration and significant dysphonia. Due to these reasons 
open surgery has been excluded from further discussion.  
 
1.4.1 Endolaryngeal surgery  
1.4.1.1 Cold Steel  
Endolaryngeal surgery involves excision of the laryngeal carcinoma through 
access via the mouth. This can be performed with or without the use of lasers. 
The procedure is performed in a similar way to the laser but using cold steel 
dissection for removal of the tumour. Kleinsasser in Germany published a 
large series of his work in 1974 on endoscopic cordectomies that were 
performed using cold instruments.40 However since the development and 
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wider availability of lasers, cold steel dissection has become a less popular 
amongst surgeons.  
 
1.4.1.2 Trans-oral laser microsurgery  
Laser is an acronym for Light Amplification by stimulated Emission of 
Radiation and the first working laser was built by Maiman in 196041. C.K.N 
Patel42 developed the carbon dioxide laser in 1963 and it was introduced into 
surgery soon after. In 1972, Strong and Jako in America first described using 
the carbon dioxide (CO2) laser for resection of laryngeal cancers.
43 
Light is part of the electromagnetic spectrum and can act as an 
electromagnetic wave and as particle radiation (photons).44 The energy 
released by electromagnetic process is known as electromagnetic radiation. 
This electromagnetic radiation can be classified by its wavelength into radio, 
microwave, visible, ultraviolet, X-rays and gamma rays. For a laser beam to 
produce a thermal effect, the energy contained must be converted into heat. 
The shorter the wavelength of an electromagnetic disturbance the more 
energy each photon contains.  
E=hc / s 
This is where energy (E) equates to the speed of the electromagnetic field (c) 
multiplied by the constant (h) divided by the electromagnetic wavelength (s).  
The high intensity power of the laser is generated through light amplification 
which is made possible by forcing a large group of atoms in the optical cavity 
of the laser.45 This optical cavity is created with mirrors and the atoms are 
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stimulated along this cavity into an excited state. Amplification of these visible 
light particles (photons) are reflected off the mirrors and can be emitted.  
 
The total energy of the laser beam equates to the sum of all the single-photon 
energy in Joules (J). The power of a laser (watts, W) is calculated when 
delivering the laser beam to an area for 1 second (s).44   
P=J/s 
When the area (metres, m) the laser beam is targeting is included in the 
equation then the power density and energy density can be calculated. The 
laser power density in a single pulse = W/m2 and energy density = J/m2.44   
The visible spectrum includes light visible to the human eye 390 to 700nm 
(nanometres).  A laser emits light through amplification, however this includes 
not only visible light but also infrared and ultraviolet. The longer the 
wavelength the lower its frequency and the lower the energy of the individual 
photons, the CO2 laser is the most commonly used in ORL-HNS surgery and 
has a wavelength of 10,600nm which is invisible. An aiming beam is therefore 
required; accordingly, a red beam from a helium-neon laser is commonly 
used. This wavelength (10,600nm) is at the peak of water absorption and as 
soft tissues are 90% water it enables concentration of energy and vaporising 
of tissues with minimal collateral damage. For example the AcuPulseTM 
(model 30 UltraPulse SurgiTouchTM CO2 laser system, produced by Lumenis
® 
Surgical, USA) has a user-defined penetration depth of  0.2 to 2.0 mm.46 
Thus by controlling power density the surgeon can control the effects of the 
laser. For an accurate incision a small spot size is used with a high power 
density. To minimise thermal damage of surrounding tissues pulsing of the 
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laser can be performed which still allows a high density delivery.47 The effects 
of surrounding tissues will also depend on the wavelength, power, duration 
and spot size of the laser (see table 3).  
 
Table 3: Power Density and tissue effects 
Power Density Effect on Tissues 
0-500 Heating 
500-1500 Contracture, denaturing 
1500-5000 Ablation, partial vaporisation 
5000-20,000 Incision, complete vaporisation 
20,000-100,000 Rapid deep incision 
 
Source: Fagan et al., TLM of cancers of and other pathology of the upper aerodigestive tract 
(open access atlas of otolaryngology, head & neck operative surgery 
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The smaller and sharper the target red spot indicates that the laser is more 
accurately focused. Spot sizes of 0.5mm to 0.8mm allows a good compromise 
between depth of focus and cutting ability.49 Newer lasers and 
micromanipulators enable this to be as small as 200µm. For coagulation the 
laser power density is adjusted so that the tissues are heated and not 
vaporised. The spot size can be altered to become more diffuse and thus 
reducing the power density. A monopoloar suction diathermy is an alternative 
for haemostasis without using the laser.   
Continuous wave (CW) laser creates a laser output range of energy whilst 
pulsed laser is the energy of a single pulse. The units of the energy are stated 
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in Joules (J). Super pulse (SP) is when several thousand energy bursts of 
high peak power laser pulses emitted per second while the foot pedal is 
depressed. The bursts are spaced apart and this enables cooling to reduce 
thermal damage to surrounding tissues.  
In laryngeal surgery the laser beam is delivered from the laser via an 
articulated arm to a micromanipulator mounted on an operating microscope. 
This allows the helium-neon aiming beam (and therefore the CO2 laser beam) 
to be accurately focused on the target. The operating microscope also 
provides illumination, magnification and frees up both hands for operating. 
The working distance is the distance from the microscope lens to the focus 
point on the larynx. At a distance of 400mm there is enough space for both 
hands to work under the microscope. The surgery is performed at high 
magnification for maximum control and precision. The operating microscopes 
have a variable magnification and a zoom control for optimizing the view of 
the surgical field.   
Since lasers have been introduced into surgery it has increased in popularity 
and is well suited for use with a microscope, allowing accurate resection and 
causing minimal collateral damage to normal tissue 50. The CO2 laser is 
commonly used in ORL-HNS for other conditions including benign laryngeal 
disease such as laryngeal papillomata. Papillomata regularly require 
numerous laser microlarynogoscopy procedures and therefore the ORL-HNS 
surgeon is often familiar and confident at using the laser.47 This has improved 
the learning curve of TLM with many transferable skills.  
Between 1979 to 1991 Otolaryngologist Wolfgang Steiner successfully 
demonstrated the use of lasers for endolaryngeal resection of laryngeal 
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tumours, rather than more traditional open surgery.51 This has been repeated 
in a number of studies showing overall 5 year survival rate of more than 85% 
with low rates of recurrence.51-53 There is published data, from our own 
department, of early and moderately advanced laryngeal cancers treated with 
TLM.54 The respective 3-year local control, overall survival, disease-specific 
survival and disease-free survival for the cohort as a whole, were 92%, 92%, 
98%, and 86 % for glottic carcinomas. 
 
1.4.1.2.1 Patient selection for TLM 
There are patient and/or tumour reasons why TLM may be contraindicated in 
any given patient. A general anaesthetic is required and the individual may not 
be suitable for surgery due to co-morbidities. Poor endoscopic access may 
also be a contraindication for TLM and may result from a combination of poor 
extension of the cervical spine, prominent incisor teeth or trismus.  
Tumour-related contraindications to TLM include a tumour with poorly-defined 
edges. Although this may technically be possible to excise it would lead to an 
extensive resection which would have significant adverse effects for the 
patient. When the tumour is positioned at certain areas such as the anterior 
commissure then the access may be difficult. Also the contralateral vocal fold 
can be damaged if the tumour is at the anterior commissure. There is an 
increase risk of recurrence at the anterior commissure and for these reasons 
an alternative treatment may be preferred rather than laser excision. 55 
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1.4.1.2.2 The procedure of trans-oral laser microsurgery  
The procedure is performed under general anaesthesia with the patient in the 
supine position. Under direct laryngoscopy a conical metal endoscope, such 
as Steiner laryngoscope is inserted, as demonstrated in figure 14. Once the 
scope is in position, with a view of the larynx and the tumour, it is placed in 
suspension using a suspension platform which is attached to the operating 
table. This allows fine manoeuvres to be performed bimanually under the 
microscope.  
 
Figure 14: Microlaryngoscope with C02 laser attached  
 
Source: Photograph taken by author in operating theatre in AUH 
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Surgical exposure is important and the patient is in the supine position with 
the neck extended. The operating microscope can then be focused and the 
laser attached so that the resection may begin. The laser settings are selected 
depending on the type of tissue being resected, the depth and haemostasis. 
Although TLM was first described by Strong and Jako 43 in the 1970s, it was 
not until the work by Steiner in the 1980s and 1990s, that the laser gained 
popularity in the treatment of laryngeal carcinoma.51 Rather than an en bloc 
resection the tumour is divided with the laser to assess the depth and the 
extent of invasion (see figures 15 and 16). This technique enables a minimal 
resection,49 thus removing only the required amount of tissue and minimising 
effect on adjacent structures that may affect the voice outcome. Each 
individual section can be removed and pinned out.  There is a constant 
challenge to balance adequate resection with preservation of structures. High 
magnification is used and where possible, the epithelium is retracted and 
dissected off the vocal ligament. Narrow margins (1mm) or the width of the 
laser have been used for many years to help preserve vocal function.56  
 
Figure 15: Tumour divided with laser to evaluate depth 
 
Source: Fagan J, Open access atlas of otolaryngology, head & neck operative surgery
48
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Figure 16: Example of sequence of TLM incisions 
 
Source: Fagan J, Open access atlas of otolaryngology, head & neck operative surgery
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The European Laryngological Society has produced a classification for 
endolaryngeal microsurgery 57. The classification comprises eight types of 
cordectomy (excision of part or all of the vocal cords, figure 17):  
 subepithelial cordectomy (type I), resection of the epithelium;  
 subligamental cordectomy (type II), resection of the epithelium, 
Reinke’s space and vocal ligament; 
 transmuscular cordectomy (type III), resection of above and vocalis 
muscle;  
 total cordectomy (type IV);  
 extended cordectomy (type Va), including the contralateral vocal fold 
and the anterior commissure;  
 extended cordectomy (type Vb), including the arytenoids;  
 extended cordectomy (type Vc), including the subglottis;  
 extended cordectomy (type Vd), including the ventricle. 
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The commonest cordectomy types used for an early glottic carcinoma are 
types I-IV. In a study by Bocciolini et al.58, 64 T1a glottic carcinomas were 
treated by TLM. The commonest type cordectomy performed was a Type III 
with 34 cases (53%). This was followed by 17 (27%) type IV, 11 (17%) type II 
and two cases (3%) requiring type V.  
 
 
Figure 17: Classification of Cordectomy (Type I-IV illustrated) 
 
Source: Remarcle M et al., European Laryngological Society proposed classification of 
endoscopic cordectomy (2000). 
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The more extensive resections will be associated with more morbidity for the 
patient, particularly with respect to voice. The anterior commissure is another 
challenging area. Involvement of this area can make wide margin resection 
difficult and there is also the concern of cartilage invasion. The anterior 
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commissure may heal with scarring bridging the vocal cords (webbing). This is 
associated with a poor voice and can be difficult to treat. One option is to 
operate in a two-stage procedure. This would require a unilateral resection of 
the tumour and once this has re-reepithelialised to return for contralateral 
resection. However this generally applies to T1b laryngeal tumours which 
were not included in this research.  
Once excised the lesion must be orientated properly and mounted to allow the 
histopathologist to interpret the specimen and make a comments on 
malignancy and completeness of excision. This is one of the advantages of 
TLM over RT in that the histological sample can be analysed and margins 
discussed in the MDT.  The Glasgow technique is to mount the orientated 
resected tumour on dehydrated cucumber. This allows accurate assessment 
of histological margins by enabling the entire specimen to be processed 
intact.59  There is a risk of residual disease in patients with close (<1mm) or 
involved margins.60   The consensus document on TLM in early glottic cancer 
states that if the surgical margins are clear but the histological margins are 
involved then a repeat microlaryngoscopy is recommended in 6-8 weeks.61 
Peretti et al. 62 argued that surveillance post treatment may be easier 
following TLM due to decrease in oedema and mucousitis associated with RT. 
More recently narrow band imaging (NBI) has been performed to improve 
detecting early mucosal lesions as well as delineating the tumour 
intraoperatively.63 NBI is an optical technique that adds narrow band spectrum 
filters onto the endoscope to enhance the mucosal abnormalities. Along with a 
high definition screen this will continue to improve diagnosis of early glottis 
carcinomas and assess for recurrence.64  
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Normally the patient is discharged the same day but occasionally requires an 
overnight stay. This may depend on co-morbidities and the effects from the 
general anaesthesia.  
Following surgery the pathology is reviewed in the multidisciplinary team 
(MDT) Head & Neck meeting. If there are involved margins or marginal 
biopsies then a decision will be made for either a second look in 6-8 weeks 
time or further excision.61  
There are possible complications from TLM. Early complications of laser 
surgery include dental/gum injury, sore throat and lingual nerve injury. This is 
due to pressure and traction from the endoscope to gain good visualization of 
the larynx. A mouth guard is used as standard to protect the teeth and sore 
throat usually settles after a few days. There is the risk of voice change and 
this will be covered further in section 1.4.3.2 (comparison of voice outcomes 
between the two modalities) and voice rest is advised for 48 hours post 
surgery.  Although rare there is also a risk of bleeding, airway obstruction, 
aspiration, laser burns and airway fire. Later complications include incomplete 
resection, granuloma, webbing and chondronecrosis. Granuloma and 
chondronecrosis may occur when cartilage has been exposed.  
 
1.4.2 Radiotherapy 
Following the discovery of x-rays by Wilhelm Röntgen in 1895 and radium by 
Marie Curie in 1898, speculation began as to whether radiation could be used 
as a treatment or therapy for many different ailments from tuberculosis to 
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malignancies.65 A French radiation oncologist Henri Coutard pioneered the 
use of fractionated RT in a variety of tumours. In 1934, Coutard published a 
paper including a series of 126 patients with laryngeal cancer treated from 
1920 until 1930 with RT.66 
By the 1950s advances in radiation therapy allowed less advanced laryngeal 
tumours to be cured without sacrificing the voice.67 A review of the literature in 
1970 by Vermund67 showed the 5 year survival to be about 80% with either 
RT or surgery (including laryngofissure or cordectomy surgery) for T1N0 
glottic carcinomas. Due to the preservation of voice, RT became the preferred 
choice across the Developed World for the treatment of early laryngeal 
tumours.68,69 
There have been many advances in the delivery of RT since its inception. 
Recently it has greatly improved due to advances in cancer imaging, 
treatment planning computer software and developments in radiation delivery 
technology.36 The treatment is delivered by computer driven linear 
accelerators with sub-millimetre accuracy and therefore minimising radiation 
to healthy tissue. The development of intensity modulated radiation (IMRT) 
over the past decade has continued to improve RT. IMRT matches the dose 
to the target in 3 dimensions and thus reducing the volume of normal tissues 
receiving high doses and the potential side effects. 
RT works by damaging DNA of cancerous cells and this damage is caused by 
energy from photons or charged particles. Radiation-induced apoptosis also 
results from radiation damaging the plasma membrane. The three separate 
pathways that may result from DNA damage are cell cycle arrest, DNA repair 
and apoptosis.  This outcome depends on the time of the cell division and the 
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tissue structure. Cancer cells which divide more rapidly will thus show more 
effects than cells with a slower division.22 
RT traditionally has been delivered in divided doses. A single delivered dose 
of radiation is known as a fraction. Traditionally, RT is delivered in daily 
fractions, five days a week. Although this fits the typical working week there is 
evidence from the Danish head and neck cancer group (DAHANCA) that 
shortening the overall treatment time by increasing the weekly fraction is 
beneficial. 70 There was no overall survival but disease-specific survival 
improved and now in Denmark, RT for SCC of the Head and Neck is delivered 
in six-fractions per week.  
The reasons for fractionation are to allow normal cells time to recover 
between treatments and for RT to act on tumour cells in different stages of 
their cell cycle. The Royal College of Radiologists’ Faculty Board of Clinical 
Oncology states that there is no single regimen of treatment delivery that will 
be appropriate for all tumours in all patients.71 The dose of radiation used in 
photon radiation therapy is measured in Gray (Gy). The generally accepted 
fractionated regime has developed over many years and is typically 1.8-2Gy, 
total dose of 60-70 Gy, over 6.5-7 weeks. There is evidence, Le et al. 72, that 
a daily fraction rate of 1.8Gy for T1a glottis carcinomas gives a local control of 
79% compared to a control rate of 94% with a dose >2.25Gy per day. 
However it is possible to treat with 1.8Gy by treating for more than 5 days per 
week.73 The UK Head and Neck Cancer multidisciplinary management 
guidelines recommend hypofractionated RT schedules, using a fraction size 
greater than 2Gy, which results in equivalent outcomes to longer schedules, 
without increased toxicity.36  
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The recommendations from the Royal College of Radiologists is that patients 
with Stage I or II laryngeal cancer can be treated with either short or 
conventional regimens 71,74:  
- 64-70Gy in daily 2 Gy fractions over 6.5-7 weeks 
- 54-55 Gy in 20 daily fractions over 4 weeks 
- 50-52.5 Gy in 16 daily fractions over 3 weeks (small volume only) 
Patients are treated in the supine position in an immobilisation fixation device 
such as a perspex or thermoplastic shell (figure 18). The spine is kept straight 
and the shoulders are fixed in the thermoplastic shell.75 To allow lateral 
radiation beams, the shoulders are fixed as inferiorly as possible.  
 
Figure 18: Thermoplastic shell  
 
Source: Adobe stock images
1
 
 
A simulator is used to plan the RT dosage to maximise tumour treatment and 
minimise toxicity of adjacent normal tissues. At the time of conducting this 
study, the method of RT was that opposing lateral beams were set with 
superior boundary being the mid body of the hyoid, inferiorly the inferior 
border of cricoid cartilage, anterior to skin and posterior anterior vertebral 
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column (see figure 19). In recent years IMRT has gained popularity in head 
and neck cancer by reducing unnecessary radiation to neighbouring healthy 
tissue. Recent studies have shown that IMRT to be comparable with 
conventional RT in local control and survival.76 
 
Figure 19: Simulator film showing lateral portals in relation to bony landmarks before 
and after spinal cord shielding  
 
Source: Murthy et al., Postoperative Radiotherapy in Head and Neck Cancer. 
Otorhinolaryngology clinics, open access (2010). 
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The benefit of radiation is that it avoids risks associated with surgical 
intervention, such as bleeding and infection, and historically has been 
considered to result in better voice outcomes.68 It is generally well tolerated 
with few severe adverse effects.74 In a series of T1-T2 glottic carcinomas 
treated with RT there were no reported severe adverse effects or acute 
complications.78 Severe complications were defined if a treatment break 
resulted.   
Voice change is expected and will depend on the position of the tumour.  
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Most patients towards the end of treatment will develop some skin changes. 
This can vary from the neck feeling tight and uncomfortable, itchy, 
erythematous to skin breakdown. Other side effects include mucositis 
(inflammation of the lining of the throat), odynophagia, hair loss from the neck 
and laryngeal swelling (oedema). Dry mouth (xerostomia) is common risk of 
RT to the head and neck but is prevented by using the protective shell to 
shield the salivary glands. Most of these effects resolve 4–6 weeks after 
completion of treatment. More unusual complications would include 
oesophageal stricture, laryngeal fibrosis, chondronecrosis and hypothyroidism 
although these are extremely rare following RT for a glottic carcinoma. Should 
tumour recurrence occur then surgery would be necessary. The salvage 
options would include TLM, partial laryngeal surgery or total laryngectomy. 
 
1.4.3 Comparison of laser and radiotherapy 
There are a limited number of randomised controlled trials comparing the 
treatment options of early laryngeal SCC. The UK EaStER (Early Stage 
Glottic Cancer Endoscopic Excision versus Radiotherapy) trial outlines the 
difficulty in conducting a randomised controlled trial in this area.79 The 
EaStER feasibility trial was approved for funding in 2004. The aim of the study 
was to evaluate the outcome of patients treated with either endoscopic 
excision or standard RT. The trial included Tis, T1 and T2 laryngeal 
carcinomas and compared the treatments of TLM and RT. The primary 
outcome was local regional recurrence and secondary measures included 
voice quality, quality of life, morbidity, mortality and cost effectiveness.80  
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Patients were randomised 1:1 to receive either TLM or RT. The RT doses 
were 50Gy for Tis and (non bulky) T1 tumours. A dose of 55 Gy was given for 
bulky T1 and T2 tumours. However due to recruitment failure to enlist 
adequate numbers, the trial was closed down in 2009. An investigation into 
the reasons for poor recruitment was undertaken and found many issues.79 
These issues included surgeons and recruiters did not all accept the primary 
outcome as the rationale for the trial. The equal success of the treatments 
meant that surgery was often preferred because of its convenience and in 
some centres there were logistical issues preventing recruitment.  
 
1.4.3.1 Oncology results 
The Cochrane collaboration review comparing RT and endolaryngeal surgery 
(with and without laser) was performed in 2002 and updated in 2004, 2007, 
2010 and 2014. The most recent review includes research up to September 
2014.81 Four randomised control trials 82-85 comparing surgery and RT were 
identified although they excluded all but one of these due to inadequate 
numbers, lack of specification of randomization or staging data. There were 
limitations of the one trial included by Ogoltsova 199082 and was rated as 
having a high risk of bias due to missing data and selection bias. The 
Cochrane authors concluded that “for patients with early laryngeal cancer 
there remains uncertainty as to the comparative benefits and societal costs of 
different treatment modalities.” The limited number of studies that were 
identified by the Cochrane review illustrates the limitation of high quality 
comparative studies. 
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The randomised controlled trial by Ogoltsova 199082, indicated an improved 
result with surgery regarding mortality and control of local disease. This trial 
included both T1N0M0 (n=111) and T2N0M0 (n=158) patients. The five year 
survival was 91.7% following RT and 100% following surgery. The five-year 
loco-regional recurrence was 71.1% following RT and 100% following surgery. 
However the number of patients in comparator arms was unbalanced with 76 
patients having surgery compared to 126 having RT.  
Cochrane only include randomised controlled trials in their reviews. Therefore 
there are likely to be a significant number of other relevant studies that have 
been excluded. Higgins et al. performed a systematic review and meta-
analysis in 2009 including all published studies comparing the oncological 
outcomes of TLM and RT for early glottic carcinoma.86 They identified 26 
studies of which six were direct comparisons of the two treatments. There was 
no statistically significant difference in local control between the treatment 
types, OR 0.81, 95% CI 0.51, 1.3 (p=0.38).  
Laryngeal preservation refers to maintaining a functioning larynx and avoiding 
a total laryngectomy. This can include performing partial laryngectomies 
(either endoscopic or open)87 but avoiding the more radical total 
laryngectomy. A total laryngectomy is reserved for salvage surgery following 
failed treatment although is more relevant for larger laryngeal tumours. 
Laryngeal preservation, following TLM treatment for early glottic carcinoma is 
over 90%.88,89 Steiner 90 reported  a laryngeal preservation rate of 97% 
following TLM with only 8 patients out of 158 (5%) requiring a total 
laryngectomy. Johansen 91 reported a 89% laryngeal preservation following 
RT for T1a laryngeal cancer and Schrijvers 88 reported 77% laryngeal 
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preservation after RT. A reason for this higher rate of preservation in the TLM 
patients is that if recurrence occurs after endolaryngeal surgery, there is the 
option of further TLM or RT. 
Local control of disease and other treatment outcomes will also depend on the 
location and size of the tumour. Tumours involving the anterior commissure 
have a higher risk of recurrence.92 This may be due to a number of different 
reasons; as access to this area for TLM can be more challenging and there is 
a concern about excising excess tissue which may affect voice outcome due 
to webbing or scarring.  
 
1.4.3.2 Comparison of voice outcomes between the two modalities 
Although both TLM and RT are likely to affect voice quality, historically RT has 
been thought to have better voice outcomes than laser resection.39 However 
more recent studies have shown similar voice outcomes when comparing 
laser and RT.93-95 
The studies published have used different methods of comparing voice 
outcomes. The most common methods include self-evaluation of voice (self 
reporting questionnaires), voice quality perceptual ratings, aerodynamics, 
acoustic analysis and videolaryngostroboscopy. The European Laryngological 
Society (ELS) has produced a protocol in attempt to standardise functional 
voice outcomes and to allow comparison of the literature.96 However the 
majority of these tools are subjective with no actual or objective method 
available.  
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1.4.3.2.1 Self-evaluation of voice 
There are number of different self reporting questionnaires used to evaluate 
voice. These include the VHI (Voice Handicap Index)97,  VoiSS (Voice 
Symptom Scale) questionnaire 98, Vocal Performance Questionnaire (VPQ)99 
and VRQOL (voice related quality of life).100 In terms of voice questionnaires 
the VHI is the most commonly used (Appendix 2). Two versions exist - a 10 or 
30 item self reported scale. A meta-analysis by Cohen 93 in 2006 assessed six 
studies comparing TLM against RT and the results demonstrated no 
statistically significant difference in the VHI between the two treatments. The 
six studies compared 202 T1a laryngeal carcinoma patients treated with TLM 
and 91 patients treated with RT.  The VHI was chosen as it is the most 
common self reporting instrument used. The post VHI scores showed no 
statistically significant difference between the two treatment groups. Only one 
study, Peretti et al.,  included pre-treatment VHI scores.101 This study found 
the average VHI pre-treatment to be 22.9 (range 0-80) and the post treatment 
mean scores were 6.23 (type II cordectomy), 16.5 (type III cordectomy), 15.8 
(type IV cordectomy), 15.7 (type V cordectomy). The authors found that the 
mean VHI score doubled comparing type II cordectomy compared with more 
extensive resections. The VRQOL was assessed in a comparative 
prospective study by Oridate et al. 95, comparing 34 RT with 23 TLM for 
treatment of T1 glottic cancer. This study failed to find a statistically significant 
difference between the treatment modalities. The average social/emotional 
scores were 93.9 (RT) vs. 96.3 (laser), p=0.66; and physical scores were 91.6 
(RT) vs. 90.0 (laser), p=0.82.  
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1.4.3.2.2 Perceptual rating of voice 
Voice recordings can be analysed via a number of methods. Hirano’s102 
GRBAS (grade, roughness, breathiness, asthenicity, strain) scale is one of the 
most popular scales used in both the literature and in routine clinical care.103 
Each domain is rated 0 to 3 in which 0 is normal, 1 represents a slight voice 
problem, 2 moderate and 3 is severe. This has been shown to be a reliable 
test but depends on an expert rater to make it reliable and reproducible.104 
Sjogren et al. 94 compared voice quality in 16 patients who had RT to 18 who 
had TLM for treatment of T1a glottic carcinoma. The GRBAS system was 
used to perform perceptual analysis following treatment. Although a small 
group, all the TLM patients had type I or II cordectomy. The results revealed 
the voices of 50% of both groups to be rated as dysfunctional. The RT group 
showed mixed pattern of roughness and breathiness whilst the post-TLM 
voices had higher breathiness scores. Over all there was no statistically 
significant difference between the very small groups. Rydell 105 et al. 
compared 36 patients (18 TLM and 18 RT) and found voice outcomes 
statistically significantly better in the post RT group compared to the TLM 
group. The results revealed decreased breathiness, asthenia and strain 
scores in the irradiated group. However Loughran et al. 106 also assessed 
voice outcomes in 18 patients on each treatment arm. The GRBAS 
assessment showed no difference between groups in any of the subscales.  
Peretti et al. 107 and Vilaseca et al. 108 not surprisingly, found worsening 
GRBAS with more extensive laser cordectomy. In the Peretti study the TLM 
patients underwent types I-V cordectomy. The GRBAS scores were higher as 
the extent of cordectomy increased. Types I and II cordectomy patients had 
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the lowest score, of less than 1, for all subscales. Vilaseca et al. performed 
voice outcomes on 42 males following TLM including 35 patients with T1a 
glottis carcinoma. The patients had different types of cordectomy and the 
GRBAS score was higher with the more extensive cordectomy. Sixty-six 
percent of type I cordectomy patients had a normal perceptual voice analysis 
(the GRBAS score of the TLM patients were compared to a control group). 
Only a quarter of patients with more extensive resections involving muscle or 
anterior commissure had normal voice outcomes.  
 
1.4.3.2.3 Aerodynamic analysis 
The most common type of aerodynamic analysis is Maximum Phonation Time 
(MPT). This involves producing a prolonged sound (/a/) for as long as possible 
after maximum inspiration and at a comfortable volume and pitch. The result 
used is the best time in seconds over three attempts.109 It is susceptible to 
bias due to the differing size of lungs as well as a fatigue effect. Tamura et al. 
110 comparing 10 TLM patients with 5 RT patients found similar MPT in both 
groups. Sjogren et al. 94 in a cohort study found no statistically significant 
difference in MPT in 18 patients after laser cordectomy compared to 15 post 
RT patients. Mendelsohn et al. 111 collected data at different time periods on 
11 patients undergoing TLM for T1 and T2 glottic carcinoma patients. The 
voice outcomes pre-operatively were compared to post-operative period of 4 
months and more than 6 months. MPT showed substantial decrease in the 
initial postoperative period. The MPT did improve post-operative (as the soft 
tissue recovers) but did not return to pre-operative levels. However in this 
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group of patients there was a more extensive cordectomy (type III, IV and V) 
and also seven patients with T2 glottic carcinoma were included.  
 
1.4.3.2.4 Acoustic analysis  
Acoustic analysis of the voice signal is another method of assessment that 
provides an evaluation of sound and physical properties of voice. Acoustic 
analysis measures different characteristics of the sound waveform.  The most 
common parameters collected are fundamental frequency, shimmer, jitter and 
noise-to-harmonic ratio (HNR) and will be discussed in more detail in section 
1.5.5. Many studies using acoustic analysis have focused only on sustained 
isolated vowels (such as /a/); asking the patient to hold the pitch and loudness 
as constant as possible. A major downside of this technique is that it involves 
production of prolonged vowels which are not representative of connected 
speech.112 Sjogren94, McGuirt 113 and Tamura 110 found no significant 
statistical difference in the acoustic analysis between the two groups treated 
with RT or TLM. Sjogren et al. 94 analysed the voice outomes of 16 RT 
patients and 18 TLM patients using the mid section of a prolonged vowel 
recording. The Jitter %, fundamental frequency and shimmer % in the RT 
group were marginally higher than the TLM group but not found to be 
statistically significant. McGuirt et al. 113 compared 13 patient treated with RT 
compared to 11 treated with TLM for T1a glottic carcinoma. There was no 
statistically significant difference in either acoustic parameter between the two 
groups. 
 Tamura et al. 110 comparing 22 patients having laser surgery with eight 
patients treated with RT assessed fundamental frequency, Jitter, Shimmer 
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and HNR post treatment. The scores of all these parameters were similar in 
both groups.  
Wedman et al. 114 measured the Jitter, Shimmer, fundamental frequency in 
nine RT patients and 15 TLM patients treated for T1a glottic carcinoma. There 
was no statistically significant difference in the groups.  
Van Gogh et al. 115 assessed voice outcomes before and up to 2 years after 
treatment in 67 TLM patients and 39 RT patients. Using prolonged vowels, 
average fundamental frequency, jitter, shimmer and normalized noise energy 
(NNE) were analysed. In the TLM group there was an improvement in the 
NNE, jitter, shimmer and fundamental frequency at 3 months compared to 
pre-treatment. The jitter and shimmer scores were better in the TLM group at 
3 months post-operatively compared to the RT. The RT patients took longer 
for the jitter, shimmer and NNE to become normal. The fundamental 
frequency was higher in the TLM group compared to the RT patients. This 
was the only long term difference between the two groups. This increase in 
fundamental frequency is thought to be due to increased stiffness of the vocal 
cords due to scar tissue formed following TLM. In addition, it was noted that 
there was an increase in the fundamental frequency in both groups pre-
operatively compared to a normal cohort. This is thought to be due to the 
tumour causing increased vocal fold stiffness. Agarwal et al. 116 when 
analysing  patients undergoing RT for early glottic carcinoma also noted the 
elevated fundamental frequency before treatment. The tumour can also cause 
a decrease in HNR due to an incomplete closure of the glottis and escape of 
air through the glottic gap.   
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1.4.3.2.5 Videolaryngostroboscopy  
Peretti 107 assessed voice a year after laser cordectomy with a 
videolaryngostroboscopic examination. This was performed in clinic using a 
700 rigid endoscope and the movement of the vocal folds were evaluated by a 
panel of otolaryngologists and speech therapists using the rating system by 
Sittel.117 There was no mention of whether the raters were blinded to the 
different treatment arms. They found the 89% (16 out of 18 patients) of 
patients with type I and II cordectomy to have complete glottic closure.  
The amount of tissue excised with the laser and/or the extent of the 
cordectomy is related to the voice outcome. Hirano 102 emphasised the 
importance of preserving the vocal fold’s lamina propria to reduce scarring.  
Wedman 114 demonstrated no difference in mucosal waveform in 24 patients 
who had either RT or TLM for T1a laryngeal cancer. The stroboscopy showed 
excellent movement in both groups with only minor irregularities visible. There 
was no difference in symmetry or glottis closure between the groups.   Roh et 
al. 118 from South Korea assessed 85 patients with T1 glottic carcinomas  
treated with TLM. Different cordectomies were performed depending on the 
position and extent of the tumour. The patients were divided into three groups 
depending on the extent of the surgery: type I and II cordectomy (group A), 
type III or IV cordectomy (group B) and extended type V cordectomy (group 
C).  Video strobolaryngoscopic recordings were evaluated pre and (median of 
20 months) post-operatively.  Videostroboscopic examination revealed larger 
glottis gaps, scarring and decreased mucosal wave in groups B and C. 
Certainly, as might be predicted, the larger the tumour and the greater the 
surgical cordectomy the worse off the voice will be.108 
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Peretti et al. 107 concluded that, if oncologically possible, preservation of the 
anterior commissure and most of the vocalis muscle will help preserve the 
voice comparable to controls. It follows that the taking of as narrow as 
possible margins around the carcinoma during  laser cordectomy 56 will help 
to preserve normal tissue and help preserve vocal function. Therefore type I 
and II cordectomies which are subligamentous and preserve muscle will have 
better voice outcomes.  
 
1.4.3.3 Health-Related Quality of Life (HRQoL) 
The comparison of health related quality of life following treatment with either 
RT or TLM has been performed for early glottic carcinomas. Smith 119 and 
Stoeckli 120 compared the HRQoL between RT and endoscopic laser surgery 
for early glottic cancer and found no statistically significant difference between 
the treatment modalities. Stoeckli assessed quality of life (QoL) using two 
validated questionnaires the European organization for research and 
treatment of cancer, quality of life questionnaire core 30 (EORTC QLQ-C30) 
and the head and neck specific EORTC QLQ-H&N35. He found a negative 
impact of RT on the ability of swallowing solid food and xerostomia.  Whilst 
Smith 119 assessed quality of life using a revised version of the University of 
Washington Quality of Life Questionnaire version 4 (UW-QoLv4)  and the 
Performance Status Scale for Head and Neck Cancer Patients (PSS-HN). 
Peeters 121 also did not find any difference between functional health status 
using the COOP/WONCA charts between RT and TLM. These functional 
assessment charts COOP/WONCA (Care Co- operative/World Organization 
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of Colleges, Academics and Academic Associations of General 
Practicioners/Family Physicians) are also validated in the assessment of 
quality of life.122 
 
1.4.3.4 Cost 
In the current climate within the National Health Service in the United 
Kingdom, cost implications are more important than ever before and with two 
different treatments showing similar good local control then health care trusts 
may be justified in considering the cost implications. Goor 123 and 
Brandenburg124 demonstrated that there is a vast difference between the two 
treatments with RT being much more expensive (table 4).  Smith119 also 
outlines societal costs including patient travel, days of work missed, and 
impact on quality of life. Goor et al. averaged costs over three stages: the 
diagnostic, treatment and follow up in TLM and RT patients. RT had higher 
costs of €8322 during the treatment stage due to an average of 23.4 sessions 
compared to TLM costs of €4434.  
Brandenburg et al. 124 averaged three patient bills per procedure for 
carcinoma in situ and T1 glottic carcinoma treated with TLM or RT. RT was 
found to be $27460 more expensive than TLM.  Myers et al. 125 calculated an 
average of 10 patient bills per procedure for T1 glottic carcinoma. They found 
that in 1992 TLM cost $12,956 compared to $32,588 for RT. Foote et al. 126 
based in the Mayo Clinic estimated costs from surgery and RT by totalling 
billing fees (from 1995) with the appropriate procedure. Also outpatient and 
inpatient costs were included. Due to separate fee schedules in different 
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areas and some patients having medical insurance a proportional value was 
calculated. This found that TLM to be 100 healthcare charge while RT would 
be 137. Adding extra cost including inpatient stay and outpatient 
appointments the median charge for TLM was a health care charge value 174 
and RT and RT 409.   
Part of this additional cost is due to the number of appointments required for 
RT. RT patients require an average of 35 treatments, with three times as 
much time off work.119 
 
Table 4: Publications summarising costs of RT and TLM for early laryngeal carcinoma 
Author 
Year of 
Publication 
Number of 
patients RT 
Number of 
patients TLM 
Average Costs 
RT 
Average Costs 
TLM 
Myers 
125
 1994 25 25 $32588 $12956 
Foote 
126
 1997 57 106 
409 
(proportion no 
unit) 
174 (proportion no 
unit) 
Brandenburg 
124
 2001 41 30 $ 29353 $ 1893 
Goor 
123
 2007 35 54 € 8322 € 4434 
 
 
Although these cost related studies have been performed in different countries 
and different health care systems the overall conclusion is that TLM is a 
cheaper treatment modality compared to RT. However the cost is only a 
relevant aspect if local control, morbidity, laryngeal preservation, voice quality 
and health related quality of life are comparable.  
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1.5 Measurements of voice quality  
When comparing the impact of different treatment modalities on laryngeal 
function, voice outcomes are important and there are many methods to 
measure voice quality. There have been attempts to standardize voice 
outcomes to enable comparison of the literature.96 This would enable 
comparison of different phonosurgical techniques. Guidelines from the 
European Laryngological Society (ELS) have recommended a set of 
assessments to be considered.127 There are three main areas in which voice 
quality is measured: 
1. Subjective self evaluation of voice  
2. Perceptual rating of voice 
3. Objective/instrumental measures  
 
Perceptual ratings of voice and self-assessment (subjective) questionnaires 
are the most common tools used in the clinical and research setting. There 
are recommended methods in how to acquire a voice sample for analysis and 
electroglottography is another method of acquiring vocal fold activity. The 
objective measures include acoustic analysis, aerodynamics and 
videostrobscopy. They are often referred to as instrumental methods as there 
are such variations in the measurements. However, in addition to the above, 
there are other methods of assessment of voice that are not commonly used 
and will not be covered further.  These include digital high-speed pictures 
where multiple images of the larynx are recorded and played back at a slower 
rate. Another imaging technique for assessing vocal fold movement is high-
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speed single-line scanning (video-kymography).128 In this method a video 
recording of the larynx focuses on a single line and monitors it at high speed.  
 
1.5.1 Self-evaluation of voice 
Well-designed and validated patient reported questionnaires are important as 
they inform us of how the voice affects the patient in everyday life. It is the 
patient that has to live with their voice and the effect that it has on them and 
therefore it can be argued, that the patient is the most important assessor of 
voice quality. It is important to appreciate however, that social and cultural 
differences are likely to be relevant when considering voice quality. The main 
aim of any voice assessment is to assess the variation of voice quality, the 
severity of disability and effect on quality of life. There are a number of 
different questionnaires which have been developed in an attempt to do this. 
These include: Voice Handicap Index (VHI), Voice Symptom Scale (VoiSS) 
and Voice Performance Questionnaire (VPQ). These questionnaires were all 
developed in different ways but have been validated and assessed for 
reliability and reproducibility (test-retest reliability).  
 
1.5.1.1 Voice handicap index (VHI) 
Jacobsen et al. developed the Voice Handicap Index (VHI) in 1997.97 A 
handicap as described by the World Health Organization is a social, economic 
or environmental disadvantage resulting from an impairment or disability.129 
Thus it cannot be assessed only using an objective voice assessment as by 
definition the impact will vary depending on the patient’s lifestyle and 
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aspiration. The original VHI self-assessment tool comprised 30 questions 
divided into three categories: functional, physical and emotional aspects of 
voice disorder.  
The VHI has been assessed for reliability and validity. The VHI was derived 
retrospectively by review and analysis of the subject’s symptoms and thus  
physician-centred in its development.130 Due to this it has been questioned 
whether this may cause selection bias as the developers of the tool define 
what voice related problems are.131  
A shortened version of the VHI was subsequently developed known as the 
VHI-10 (Appendix 2). The shortened version comprising 10 questions takes 
less time to complete and results in no loss of validity.132 It also assesses and 
evaluates the overall state of voice handicap. Despite the criticisms in its 
development the VHI-10 provides a concise tool for initial and follow-up 
assessment of all types of patients with a voice disorder.132 It has been 
adapted to different languages and is used worldwide both in the clinical 
setting and for research purposes.133-135 
 
1.5.1.2 Voice performance questionnaire (VPQ) 
The Voice Performance Questionnaire (VPQ) is a 12 item questionnaire. It 
assesses the physical symptoms and socio-economic impact of voice 
disorder.136 For each of the 12-items the patient chooses the best answer for 
each question. The questionnaire was designed by Carding et al. 100,136 for a 
study into the treatment of 45 patients with nonorganic dysphonia. The 
development was not as rigorous as that of the VoiSS (see section 1.5.1.3).  
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Deary et al.137 compare the VHI-10 and VPQ in 330 adults and found them to 
be highly correlated. The VPQ and VHI-10 are both short questionnaires 
which makes them useful in the busy clinical setting.  
 
1.5.1.3 Voice symptom scale (VoiSS) 
The VoiSS questionnaire developed by Dreary et al. in 200398 is a patient- 
designed self-assessment questionnaire (Appendix 3). It was developed by 
collecting an inventory of voice symptoms in adult dysphonia clinics.131 An 
open ended questionnaire was used and this yielded 467 difficulties and 
problems related to their voice. This is unlike other questionnaires such as the 
VHI where the voice problems and questions were compiled by physicians. 
The VoiSS questionnaire was developed in several stages: firstly an open-
ended problem sheet was compiled by the patients prior to a prototype which 
summarized the common problems131. A modified scale was created and then 
finally psychometric analysis to create the 30 item VoiSS. The process 
involved responses from over 800 subjects. The psychology team reviewed 
the difficulties perceived by the subjects and three distinct factors emerged: 
impairment, emotional and physical symptoms. There was no distinct testing 
of the subscales in the creation of the VHI questionnaire.132 Thus the VHI 
assesses the overall state of voice handicap rather than individual subscales. 
The VoiSS questionnaire has had a robust development and compared to VHI 
and VPQ is the more extensively validated self-report voice measure.98   
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1.5.1.4 Voice related quality of life 
Voice Related Quality of Life (V-RQOL) this is a 10 item self-administered 
validated voice outcome measure.138 Developed by Hogikyan et al. 138 from 
Michigan in the United States and published in 1999, scores are reported in 
two domains (social-economic and physical functioning) and as a total score, 
each ranging from 0 to 100. A higher score indicates a better voice-related 
QOL. It has been validated and the developers proposed use of the 
instrument was for assessment of dysphonic patients and particularly for 
monitoring treatment outcomes.138  
 
1.5.2 Acquisition of a voice sample for analysis 
A high quality audio recording is required for voice assessment. The 
recordings can be stored and analysed at a later date. It also enables blinded 
evaluation by more than one rater. Digital recordings have made the data 
easier to use, store and analyse.  
In 1994, at a workshop on voice, Titze et al. 139 made recommendations on 
voice recordings in an attempt to standardize them. These recommendations 
included recordings to be produced in a sound-proofed room, although a quiet 
room with ambient noise of less than 50dB is acceptable. The mouth to 
microphone distance needs to be at a constant distance of 10cm. A head-
mounted microphone enables this distance to be measured and kept 
constant. Off-axis positioning (45-90o from the mouth axis) reduces 
aerodynamic noise from the mouth during speech production.139 
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There are a number of readily available passages which are phonetically 
balanced and which have been developed for use in the assessment of voice. 
Phonetically balanced sentences were developed for speech research, where 
standardized and repeatable sequences of speech are required. The Harvard 
Sentences are phonetically balanced English language sentences which were 
developed during World War II to test military communication systems.140 
Phonetically balanced passages include a broad range of English-language 
sounds, or phonemes, distributed in proportions similar to ordinary 
conversation. The passages should be easy to read and examples of 
commonly used passages in order to obtain samples of voice analysis include 
‘My Grandfather’ (Appendix 1) 141, ‘The Rainbow Passage’142 and ‘Arthur the 
Rat’.143 The texts are approximately two minutes in length. This length of 
passage ensures it is not too tiring to read whilst being long enough to provide 
a range of intonation patterns and sufficient information for statistically reliable 
measures of fundamental frequency.144 A comparison of these reading 
passages was performed by Powell et al..145 Powell compared the 
characteristics of 15 different reading passages including ‘My Grandfather’, 
‘Rainbow Passage’ and ‘Arthur the Rat’. The phonetic characteristics were 
analysed including the number of syllables, consonant distribution, length of 
the passage and structural complexity (determined by the cluster of vowels 
and consonants). The majority of the passages provided a representative 
sample of the consonants and vowels. ‘My Grandfather’ and the ‘Rainbow 
Passage’ provide a varied sample that would be an appropriate sample for 
adults in normative studies.145 A criticism of ‘Arthur the Rat’ passage is that is 
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contains sections of direct speech which may encourage the reader to change 
their normal range which has the potential to affect the analysis.144   
Although considered to be an unnatural voice sample, sustained vowel 
recordings can be used for objective voice evaluation. This will be covered in 
the section 1.5.5.  The sustained vowel production (such as /a/) provides 
voice material that is from the vocal folds and not affected by articulation from 
the rest of the vocal tract.146 The mouth is more open using the vowel /a/ 
compared to other vowels and this helps to minimize vocal tract vibration.147 
Although Orlikoff 148 demonstrated that there was no change in the acoustic 
analysis when assessing different vowels. One protocol by Speyer et al. 149 
included /a/ at a comfortable pitch/loudness, recorded three times to evaluate 
variability of quality. During the sustained vowels it is important the mouth-to-
microphone distance is constant to maintain a high signal-to-noise ratio.139  
 
1.5.3 Perceptual rating of voice 
Perceptual rating of voice quality ideally requires an expert to listen and 
evaluate the voice. The assessor is referred to as a rater and is often a 
Speech and Language Therapist trained in using the assessment. The rater 
has to judge the extent to which the voice deviates from normality.   
The GRBAS scale is the most commonly used voice rating scale in the 
literature when comparing voice outcomes following an intervention. This 
scale provides a structure for the evaluator to assess the voice in a systematic 
way whilst a phonetically balanced passage is read out. The development of 
GRBAS scale was undertaken by the Committee of Phonatory Function Tests 
92 
 
of the Japan Society of Logopedics and Phoniatrics and first published by 
Hirano in 1981.150 
The scale comprises five different parameters; G = grade, R = roughness, B = 
breathiness, A= asthenia, S = strain. Grade is the overall degree of 
abnormality of voice. Roughness is the rattling sound which is mainly found 
when there are irregularities of vocal fold vibrations. Breathiness relates to the 
extent of air leakage through the glottis. This is a whispery voice which is 
heard when there is insufficient glottic closure such as that which occurs with 
vocal fold palsy. Asthenia means weakness or lack of strength in the voice. 
Finally, Strain relates to the hyperfunctional state of phonation of the voice. 
This is found in patients with spasmodic vocal conditions.   Each domain is 
rated 0 to 3 where 0 is normal, 1 represents a slight voice problem, 2 
moderate and 3, a severe dysphonia. The auditory-perceptual evaluation of 
dysphonia has been criticised on the basis of its reliability.151 An expert rater is 
required to provide consistent, reliable and reproducible assessments and 
therefore raises the issue of general applicability.104 The European 
Laryngological Society (ELS) guidelines on phonosurgery recommend 
GRBAS scale due to its reliability (inter and intraobserver reproducibility).96 
De brodt et al.104 assessed the test-retest reliability of the GRBAS scale by 
asking the same raters to rate two successive voice recordings more than two 
weeks apart. In the study, 23 raters assessed 12 different voices. The judges 
included professional Speech and Language Therapists and 
Otorhinolaryngologists with different levels of experience. There was no 
statistical inter or intra-rater differences between the raters despite their 
experience or profession.  
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There are aspects of the GRBAS that have been shown to be not as reliable. 
This includes Strain and Asthenia which have only been shown to have a low 
to fair intra- and inter-judge reliability.151 This in some centres a simplified 
GRBAS version is used omitting Strain and Asthenia, known as GRB.152 
A number of other scales have been described as an alternative to the 
GRBAS scale. These include the CAPE-V, Buffalo Voice Profile and Vocal 
Profile Analysis. The CAPE-V is the Consensus Auditory-Perceptual 
Evaluation of Voice and was developed by the American Speech Language 
Hearing Association. However, a study comparing three perceptual evaluation 
scales 153, GRBAS, Vocal Profile Analysis and Buffalo Vocal Profile, found 
that GRBAS was the most reliable with respect to the inter-rater, intra-rater 
and test-retest reliability.   
The advantages of perceptual evaluation scales are their ease of use. 
Although potentially time consuming, they are non-invasive and provide a 
workable basis for the speech therapist and clinician to reliable compare voice 
quality over time as well as the impact of treatment intervention.154,155 
 
1.5.4 Electroglottography 
Electroglottography (EGG) was first used in voice research by Fabre in 
1957.156 EGG is a simple electrical method of non-invasive examination of 
vocal fold phonatory vibration (figure 20).157 Electrically isolated ring 
electrodes are placed on the neck skin overlying either side of the thyroid 
cartilage (figure 21). A small electrical current is passed from one electrode to 
the other and resistance to current flow (impedance), which varies with the 
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extent of vocal cord and mucosal wave contact, can be measured. Therefore, 
impedance measurements can then be used to calculate relative vocal fold 
contact area throughout the vocal cycle. The admittance is a measure of how 
easily an electrical circuit will allow current to flow and is the inverse of 
impedance. The small electric current is not perceptible to the subject as it is 
high frequency (0.3-5MHz).158 
 
Figure 20: Electrolaryngograph (A: neck strap, B: ring electrodes, C: microprocessor, 
D: cable to microphone) 
 
 
Source: Image taken by author 
 
The EGG is able to monitor vocal fold contact, the rate and regularity of sound 
vibration during voice. However, the electric current from the EGG cannot be 
focused directly onto the vocal folds due to the surrounding tissues of the 
larynx.  Thus it has been suggested, by Fourcin 159, that  the term 
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‘electrolaryngograph’ be used as it represents the entire larynx. However EGG 
is still more widely accepted terminology in the literature. Fourcin also 
described the laryngograph waveform (Lx) created from the change in 
impedance.159 This waveform corresponds to the different stages of vocal fold 
cycle and is referred to as Lx, as illustrated in figure 22.  
 
Figure 21: Electrodes are placed on either side of thyroid cartilage 
 
Source: Image taken by author 
 
When vocal folds are closed, the impedance to current flow across the neck is 
reduced relative to when the vocal folds are apart. This causes a detectable 
signal change at the receiving electrode which can be converted into a 
waveform representing variations in impedance. The major advantage of this 
approach is the ability to analyze vocal fold activity without having to visualize 
them.  
The impedance of the tissues does vary and this can affect the electrical 
signal. Adipose tissue has high impedance whilst muscle and blood have low 
impedance.158 Other factors that may affect the electrical signal include 
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movement such as swallowing, breathing or articulation. However the EGG, 
such as Laryngograph®, has both a filter and gain control that can control the 
electrical signal. Thus, making it possible to filter out unwanted signals and 
focus on the impedance variation from the vibratory movement of the vocal 
folds. However if there is poor contact of the electrodes on the skin or thick 
soft tissues to the neck the electrical signal may not be detected.22   
 
Figure 22: Lx waveform and corresponding vocal fold cycle and contact  
 
Source: Figure created by author with Lx waveform from SpeechStudio
TM
 software 
 
In a normal Lx the closing and opening sequences should be regular. This is 
because normal vocal folds have similar mass, shape and stiffness. The steep 
rise in (i - ii on the curve in Figure 22) is due to the folds closing faster than 
they open (due to the ‘Bernoulli Effect’ as discussed previously in section 1.2). 
This is followed by the more gradual ‘opening phase’ (III-IV on the 
laryngograph curve). 
Following the work of Fabre156 the laryngograph was further developed by 
Fourcin 159 and much research was performed on the practical importance of 
vocal fold contact. Fourcin in 1971 159 described the laryngograph (Lx) 
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waveform and further experiments were performed on cadavers assessing the 
waveform and its relation to physical factors160.  Hampala et al. 161 created 
vocal fold vibration by blowing warm and humidified air trough the cadaver 
larynx. Thus it was possible to assess the relationship between the vocal fold 
contact area and the EGG signal. The peak of the Lx waveform in a normal 
voice is the main acoustic excitation of the vocal tract and this coincides with 
vocal fold closure. This is when there is maximum conductance and minimum 
impedance. The shape of Lx curve depends on the contact area of the vocal 
folds. Due to the complex nature of the vocal folds during the phonatory cycle, 
especially when the mucosal waveform is taken in to account, and the contact 
area not being fully understood there is still ongoing debate regarding the 
interpretation of Lx.162 The use of the laryngograph and stroboscopy 
synchronously 163 was developed as a technique to improve accuracy. It also 
allows improved assessment of the pathological voice which can be irregular 
and difficult to analyse.  
The EGG can be used to calculate different measurements of the vocal fold 
cycle collectively referred to as acoustic analysis and this will be covered in 
more detail in the section 1.5.5. The EGG has been shown to improve 
accuracy for some of these acoustic measurements.148 
 
1.5.5 Acoustic analysis 
Acoustic data provides non-invasive objective assessments of vocal function 
by measuring specific properties of the sound produced by the patient during 
voice or speech production. Acoustic analysis has been used to differentiate 
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normal from abnormal voice, help in diagnose voice pathology and evaluate 
the effectiveness of different treatments. Acoustic studies are typically 
performed using recorded or live voice.  
The most commonly used and simplest method of analysis is using voice 
samples recorded using a microphone.  Such recordings are accurate 
representations of what a voice sounds and contain the acoustic 
characteristics of the vocal tract and not just sound generated by the larynx. 
Following recording, the analogue signals are converted to a digital file in a 
process called digitization. The conversion of the frequency into a digital 
format is known as sampling and the digital conversion of the signal amplitude 
is known as quantization. The sampling rate or frequency rate is measured in 
Hertz (Hz) or cycles per second.  
Once the acoustic signal is converted into a digital format it can then be 
analysed using computer software. As explained previously, acoustic analysis 
is most commonly performed using recordings of sustained vowels. This 
makes the analysis easier as the sustained vowels are produced by the 
vibrating vocal folds whilst maintaining a relatively fixed position.  
One of the methods used to try and remove the effects of the vocal tract is 
inverse filtering approach. This can include a pneumotachograph mask to filter 
the sounds or by processing the speech pressure waveform from a 
microphone. The aim of this approach is to calculate the waveform produced 
by the glottis by cancelling out the other sounds from the vocal tract. The 
Linear Predictive Coding (LPC) is another speech analysis technique. This 
method again requires a vocal tract filter but also uses previous voice signals 
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to predict future values. LPC is used in most acoustic software to calculate 
frequencies.162 
The commonest acoustic parameter used is fundamental frequency.164 The 
fundamental frequency corresponds to the frequency of vibration of the vocal 
folds. Other measures include changes in frequency or amplitude. These 
changes are compared from vocal fold cycle-to-cycle and are known as 
perturbation measures.  
 
1.5.5.1 Acoustic analysis parameters 
Titze et al. defined perturbation as a minor disturbance or a temporary change 
from an expected behaviour.139 These perturbations are often small and go 
unnoticed without altering the qualitative appearance. Much research has 
been undertaken into the perturbation analysis of voice to help diagnose and 
assess voice disorders. Thus perturbation analysis is based on the idea that 
small changes in frequency and amplitude of the voice signal reflect an 
underlying cause. This premise forms the basis of acoustic analysis.  
There are many different factors that can influence acoustic measurement. 
These include sex, age and dialect but also the equipment and software 
programmes used. Certain measures like jitter and shimmer using one 
software programme cannot always be directly compared to another software 
programme. This is because of the different methods and algorithms used to 
calculate these measures. For example there may be differences in how one 
programme determines the period and amplitude of a voice signal compared 
to another.  
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One software programme frequently used is the Multi-Dimensional Voice 
Program (MDVP) which was developed by Kay PENTAX 2008.165 Praat is an 
open-source programme for the analysis of speech, developed at the 
University of Amsterdam.166 Maryn et al. 167 compared two software 
programmes, MDVP and Praat software. There was a statistically significant 
difference between the different programmes when assessing the frequency 
and amplitude perturbations. They concluded that it is important that acoustic 
analysis normative data is system-specific. Thus for these reasons it is difficult 
to have a normal range of data for the different acoustic parameters.   
 
1.5.5.2 Sustained vowel analysis  
The most common acoustic analysis measures used are fundamental 
frequency (Fx), jitter and shimmer.  Other measures are the noise ratios which 
include Harmonics to Noise Ratio (HNR), Normalized Noise Energy (NNE) 
and Signal-to-Noise Ratio (SNR). These measurements are performed on 
sustained vowels using computer software such as MDVP and Praat.  
For perturbation analysis (Jitter and Shimmer) a voice sample of sustained 
vowels is required.139 The voice recording (for example /a/) should be at a 
comfortable frequency and intensity. A stable portion of the voice should be 
included and any voice breaks excluded to calculate these data. The central 
portion of the sustained vowels is the most stable part avoiding the very start 
and end of vowel phonation. 
Sustained vowel recordings are used as the vocal folds are oscillating with 
less contamination from vibration of the rest of the vocal tract. The consonants 
in connected speech cause more vibration of the vocal tract and would affect 
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the results.168 Although there are concerns that analysis of a stable portion of 
a sustained vowel may not reflect the quality of overall speech. In a review of 
‘Measuring Voice Outcomes’ by Carding et al. 130 the limitations of the clinical 
application of these techniques were discussed. The published concerns are 
that the tests are only moderately reliable when tested on steady state vowel 
production rather than connected speech. The sustained vowels are usually /i/ 
(as in beet) or /a/ (as in card) and are produced at a comfortable volume and 
pitch 22 and therefore bear little relevance to the greater variability seen with 
connected speech. In addition, there are no fixed normal measures for many 
of these acoustic measures such as jitter and shimmer.  
The acoustic analysis can also be performed using the EGG. An advantage of 
analysis using the Lx waveform (from the EGG) is that it can more accurately 
assess the sustained vowels as it can directly monitor the vocal fold cycles. 
The SpeechstudioTM software used the Lx waveform to calculate Fx, Jitter and 
Contact Quotient (Qx) and the acoustic signal is used to measure the 
Shimmer, Relative Average Perturbation (RAP), Harmonics to Noise Ratio 
(HNR), Cepstral Peak Prominence (CPP) and Mean Speech Pressure Level 
(SPL). 
An example of sustained vowel analysis using SpeechstudioTM software is 
demonstrated in Figure 23. The blue waveform is the Sp (acoustic) signal and 
the green is the Lx (laryngograph) waveform. The stable mid-portion is used 
to improve accuracy. 
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Figure 23: Screenshot illustrating section of sustained vowels on SpeechStudio
TM
 
 
Source: Image created by author using SpeechStudio
TM 
software 
 
1.5.5.2.1 Fundamental frequency  
The frequency of a sound wave is the number of regular fluctuations which 
occur in a given time period. It is measured in Hz which is the number of 
cycles per second.  
The fundamental frequency (Fx) can be defined as the lowest frequency of a 
periodic waveform. Previous studies have used both acoustic and EGG 
measurements to examine the Fx. A more reliable method of calculating Fx is 
by using the EGG to derive it directly from the Lx waveform.148  
The Fundamental Frequency (Fx) can be calculated by measuring the interval 
between successive vocal fold closures on the Lx waveform.  
Fundamental frequency = 1/time to complete one vibratory cycle 
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The fundamental frequency varies with age and gender (see table 5). The 
frequency depends on: vibratory mass and tension of the vocal folds; as well 
as changes in the aperture of the glottal opening and the subglottic pressure. 
For example, Fx is found to be lower than average in conditions such as 
Reinke’s oedema – a collection of fluid in the superficial lamina propria 
normally due to smoking -  as a result of increased mass of the vocal fold 169. 
As a consequence, the sublgottic pressures have to be higher to overcome 
this increase mass of the vocal folds in order to generate sound. A higher than 
average Fx is found in scarring of the vocal folds and in glottic 
carcinoma.170,171 
Gonzalez et al. 165 assessed the reliability of acoustic parameters in 148 
healthy adults. The fundamental frequency was found to have high intra-
subject stability.  
 
Table 5: Average Fundamental Frequencies with age  
 Mean Fx (Hz) 
Age Females Males 
20-29 227 120 
30-39 214 112 
40-49 214 107 
50-59 214 118 
60-69 209 112 
79-80 206 132 
81-89 197 146 
 
Source: Aronson et al., Clinical Voice Disorders, fourth edition (2008)
21
 
 
The MDVP software includes the following outcomes regarding fundamental 
frequency: minimum Fx, maximum Fx, average Fx and Standard Deviation 
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(S.D) Fx. These measurements are performed directly from the Lx waveform. 
The MDVP takes the mean from four cycles as well as the minimum and 
maximum Fx.  
 
1.5.5.2.2 Jitter  
Perturbation of the waveform frequency is known as jitter. Jitter is calculated 
as a percentage. The equation of jitter percentage is the cycle to cycle 
frequency perturbation: 
            Jitter % = Average temporal perturbation        x100 
             Average vocal fold cycle duration  
Higher values of jitter indicate an increase in perturbation and this has been 
found in abnormal voice samples.171 However there are limitations to its use 
as an objective measure, for example Carding et al. 172 found the test-retest 
reliability of jitter to be only moderate.  
Some studies have found a difference in Jitter in males compared to 
females.173 Titze 174 theorised that males have larger vocalis muscle 
contraction compared to females which causes a medial bulge along the vocal 
fold surface. Thus a lower jitter reported in females was thought to be due to 
the shorter length of the vocal folds and the smaller muscle mass.175 jitter is 
also referred to as a measurement of vocal stability. An elevated jitter 
corresponds to a hoarse, harsh or rough voice quality. In a ‘normal’ voice the 
jitter is usually less than 1% frequency variability. The jitter factor is the mean 
difference between two consecutive vocal frequencies divided by the overall 
mean frequency of phonation. This proportion is then multiplied by 100. 
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The relative average perturbation (RAP) compares an average jitter over a 
three cycle period.  The RAP is calculated as the average absolute difference 
between a period and the average of its two neighbouring cycles, divided by 
the average period. Once multiplied by 100 then it is then called RAP%. The 
RAP measure attempts to reduce the effects of long term Fx changes, such 
as slowly rising or falling pitch. 
 
1.5.5.2.3 Shimmer  
In contrast to jitter, shimmer is the waveform cycle-to-cycle amplitude 
perturbation. It is normally expressed in decibels (dB).  It is measured on the 
peak amplitude of the acoustic wave with each cycle. Raised values of 
shimmer correspond with a higher degrees of perturbation and this has been 
shown to be linked with abnormal voice samples.171 Amplitude perturbation or 
vocal shimmer serves as an index of vocal stability and an excessive shimmer 
is associated with an increased perception of hoarseness.  
Shimmer is different to the average amplitude which is the basis for the sound 
pressure level (SPL). SPL is the local pressure deviation from the average 
atmospheric pressure caused by a sound wave and is in decibels.    
 
1.5.5.2.4 Cepstral Peak Prominence (CPP) 
The CPP is a measure of periodicity and has been shown to measure 
dysphonia and is calculated from the frequency of each component wave 
making up the signal.176 CPP is a measure of the degree of harmony within a 
voice and the more periodic the voice signal, the greater the harmony and 
thus the value of CPP.177 Shrivastav found that CPP was more consistent in 
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predicting breathiness than jitter or shimmer178. In a study by Heman-Ackah et 
al.179, 872 voice samples were analysed this included 92 dysphonic patients 
and 780 healthy volunteers. The mean CPP value was 4.77 (SD 0.97) 
compared to a CPP of 2.57 (SD 1.05) in 92 dysphonic voices. The difference 
between the normal and dysphonic voices was found to be statistically 
significant (P<0.05).  
 
1.5.5.2.5 Contact Quotient (Qx) 
The MDVP software also includes a measurement of when the vocal folds are 
in contact during the vocal fold cycle. The Qx is calculated as a percentage 
from the Lx on the EGG.  
Qx (%) = Lx closure width 70% down from positive peak 
     Time to complete one vibratory cycle 
There is a close relationship between the closed quotient value and the voice 
quality. When there is less vocal fold contact during a vocal fold cycle the 
voice is more breathy. Qx is expressed as a percentage and a Qx of 50% 
would indicate that the vocal folds are in contact for half the time period of the 
cycle. The MDVP with the SpeechstudioTM software produces the following 
data set for Qx: minimum Qx, maximum Qx, average Qx and S.D Qx. The 
programme includes contact during the cycle if it is at the upper 70% or more 
of the peak amplitude. This would cover all those stages of the cycle where 
there is some vocal fold contact. In patients with vocal cord paralysis, Choi et 
al. demonstrated that by performing thyroplasty the Fx and Qx were improved. 
This corresponded with a perceptual decrease in breathiness in the voice 
quality.180  
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1.5.5.2.6 Measurement of Noise Ratios 
Voice can be considered to have two main components. Firstly a well defined 
periodic signal of the vocal folds vibrating and secondly the random noise of 
vibration from the remaining vocal tract and turbulent air flow. The most 
common noise ratios include harmonics to noise ratio (HNR) and normalized 
noise energy (NNE).  
 
Harmonics to noise ratio (HNR) 
Yumoto et al. 181 , in 1982 proposed HNR, as an objective measure of the 
degree of hoarseness. HNR compares the level of desired signal to the level 
of background noise and is also termed the signal-to-noise ratio (SNR). HNR 
is calculated using a sustained vowel and assesses the relationship between 
the harmonics and the noise. The harmonics is the frequency of the vibrating 
vocal folds and is also known as the periodic part and the noise is the 
aperiodic part. The vowel /a/ provides the clearest sound from the vocal 
folds22. Voice, similar to speech, can be divided into two components: a well 
defined signal (harmonic) and random noise. The harmonic is from the vocal 
folds and/or vocal tract whilst the random noise can be turbulent airflow. An 
increased noise is due to turbulent airflow produced around the glottal 
opening during phonation and this may suggest a voice abnormality. In terms 
of the EGG the harmonics is the energy of the average Lx. It is measured in 
decibels (dB). The HNR has been found to be related to the perceptual 
variation in rough voices. Martin et al. 182 found that in 80 samples  analysed, 
the severity of rough voice was predicted successfully by HNR. The severity 
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of dysphonia has also been correlated with the HNR.183  The published 
evidence regarding the reliability of HNR is mixed. Leong 176 found the HNR 
measure to be the most variable in a group of 18 normal voices. However 
Wolfe et al. 184 assessed severity of dysphonia with different voice types, 
finding that HNR was the best prediction of severity. HNR correlated tightly 
with the basic perceptual elements of voice quality: grade, roughness and 
breathiness.184  
Normalized noise energy (NNE) was described by Kasuya and Ogawa 185 in 
1985. NNE measures primarily the turbulent noise caused by insufficient 
glottic closure during phonation. It does this by assessing the relative level of 
vocal noise to that of harmonics but only uses a small number of vocal 
periods. This can be altered by any pathology which impedes glottic closure, 
for example, vocal fold paralysis, vocal nodules or glottic carcinomas. In a 
study by Jotic et al.186 69 patients underwent treatment for Tis and T1a glottic 
carcinomas with either surgery or RT. Acoustic analysis was performed post 
operative and the NNE improved statistically significantly in patients at 6 
months and 12 months following treatment. In terms of voice outcomes there 
was no difference between the treatment arms at 12 months.186 
 
1.5.5.3 Connective speech acoustic analysis  
The analysis of connective speech has the advantages of being 
representative of normal conversations. The Speech Studio software 187 can 
assess both sustained vowels and connective speech. When assessing the 
connective speech it uses both the EGG waveform (Lx) and the acoustic or 
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speech signal (Sp) from the microphone. In analysis of connective speech it 
correlates the Sp with the vocal fold cycle. 
The availability of the Lx from the EGG reflects the vocal fold cycle. It can thus 
separate the cycle into closing, connecting and opening of the vocal folds.  
The connective speech analysis in the Speech Studio software with the 
LaryngographTM187 is known as quantitative analysis (QA). It provides a wide 
range of different analysis of connective speech including: frequency (Fx), 
amplitude (Ax), contact quotient (Qx) and different combinations of these. The 
Lx is used to calculate the frequency (Fx) measures and the contact 
measures (Qx). The acoustic signal (Sp) is used to measure the sound 
pressure level (dB).  
 
1.5.5.3.1 Frequency (Fx) 
The frequency of the vocal folds in connected speech can be illustrated in a 
histogram. The analysis is not standard as it is based on the period by period 
measurement of vocal fold frequencies with no smoothing. This distribution is 
called DFx.188 DFx1 is the probability distribution for the frequency of each 
vocal fold cycle during voiced speech. It is performed by splitting the 
frequency range into consecutive intervals and dividing the total number of 
vocal fold cycles falling in each interval by the total number of vocal fold 
cycles in the whole data sample.168 The frequency intervals are divided into 
3% frequency steps so that there are practical measurements that can be 
used clinically. DFx2 is the second order distribution. This is based on 
successive pairs of vocal fold cycles in a 3% frequency bin. When these are 
plotted together the closer the two traces, the better the pitch control. 
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Therefore DFx2 represents regular, periodic vocal fold cycles over at least two 
cycles. Figure 24 illustrates a histogram of DFx 1 and 2.  
 
Figure 24: DFx 1&2 (DFx1 in red) 
 
Source: Image created by author using SpeechStudio
TM 
software 
 
The CFx is an indicator of pitch irregularity which provides a numerical value 
for the degree of irregularity. The frequency of each vocal fold cycle is plotted 
against the frequency of the next cycle. When considering a `normal` voice 
most data points are within the core of the diagonal plot. When the irregularity 
from cycle to cycle increases so does the amount of scatter which is reflected 
in the numerical readout. Figure 25 illustrates an example of a scatter plot of 
CFx. 
The SpeechStudioTM programme using the Lx waveform allows the following 
measures to be recorded from connective speech regarding Fx: mean (DFx1 
& DFx2), mode (DFx1 & DFx2), median (DFx1 & DFx2), SD of Fx, coherence 
%, 80% and 90% Range Hz/Octaves, irregularity Score (CFx)%. 
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Figure 25: CFx scatter plot  
 
Source: Image created by author using SpeechStudio
TM 
software 
  
1.5.5.3.1.2 Contact quotient (Qx) 
The Lx is also used to measure the contact quotient (Qx). The degree of 
contact between vocal folds during the vocal fold cycle can be measured from 
the EGG waveform. The closed quotient has been used as an indicator of 
voice quality.168 The SpeechStudioTM uses the Lx to measure different 
aspects of Qx. These measurements include: mean, mode and median DQx1 
& DQx2, S.D (DQx1 & DQx2), coherence %, 80% and 90% Range % and 
irregularity score (CQx)%.  
A breathy voice leads to a decrease in the Qx value whereas a pressed voice 
causes the Qx values above normal. DQx1 is the probability distribution for 
the closed phase of each vocal fold cycle. The peak of the plot shows the 
most commonly occurring value (modal value). The DQx2 is the second 
distribution of the closed phase and is an indicator of its regularity. DQx2 
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includes the adjacent vocal cycles. The better the closed phase of the vocal 
fold cycle the more similar DQx2 will be to DQx1. DQx1 is in red to allow 
comparison. Figure 26 illustrates a histogram of DQx 1 and 2. 
 
Figure 26: DQx1 and DQx1&2 
 
Source: Image created by author using SpeechStudio
TM 
software 
 
Figure 27: CQx scatter plot 
 
Source: Image created by author using SpeechStudio
TM 
software 
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CQx is a graphical indicator of the irregularity of the Qx within the vocal fold 
cycle. In the scatter plot as irregularity increases so do the amount of scatter 
and the associated irregularity score (CQx). Figure 27 illustrates an example 
of a scatter plot of CQx. 
 
1.5.5.3.1.3 Amplitude (Ax) 
The Ax measurements are calculated from the acoustic signal from the 
microphone. The DAx1 is the probability distribution for the peak amplitude of 
the acoustic signal during each vocal fold cycle. The peak of the plot shows 
the most commonly occurring value (modal value).168 DAx2 is calculated 
similarly to DFx2 as explained in section 1.5.5.3.1. DAx2 is measured by 
assessing only regular periods and this is performed over at least two cycles. 
It therefore can be used as an indication of loudness regularity. The better the 
amplitude control the more similar DAx2 will be to DAx1. Using the 
SpeechStudioTM software the DAx1 is shown in red to allow comparison 
(Figure 28).  
CAx is another graphical indicator of loudness irregularity and provides 
numerical value for the irregularity. The peak amplitude during each vocal fold 
cycle is plotted against the peak amplitude during the next cycle (Figure 29). 
In a normal voice most data points are within the core of the diagonal plot. 
With increased irregularity so does the amount of scatter and hence the 
irregularity score.  
The SpeechStudioTM calculates from Ax the mean, mode and median of DAx1 
& DAx2 dB, the SD DAx1 & DAx2 dB, coherence %, 80% and 90% range dB 
and irregularity Score (CAx) %.  
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Figure 28: DAx1 and DAx1&2  
 
Source: Image created by author using SpeechStudio
TM 
software 
 
Figure 29: Amplitude Scatter graph (CAx)  
 
Source: Image created by author using SpeechStudio
TM 
software 
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1.5.5.3.1.4 Combined parameters 
The different parameters of Fx, Ax and Qx can be combined and analysed. 
The amplitude (Ax) can be plotted against the Fx, known as Ax1Fx1. Ax1Fx1 
is the first order relation between Ax and Fx. Every value of Fx is plotted 
against the corresponding value of Ax. It shows the range of the speaker’s 
voice with respect to Fx and Ax. A normal voice should use a suitable range of 
loudness values across its pitch range.  
Qx1Fx1 is the first order relation between Qx and Fx i.e every value of Fx is 
plotted against the corresponding value of Qx. It shows the range of the 
speaker’s voice with respect to Fx and Qx. A normal voice should use a 
suitable range of closed phase values across its pitch range. 
 
1.5.6 Videolaryngostroboscopy  
Stroboscopy or videolaryngostroboscopy is useful in clinical settings to aid 
with the diagnosis of voice disorders. Stroboscopy can be used to assess the 
quality of vocal fold vibration by allowing the vocal folds to appear as if they 
are moving slowly using a strobe light at the end of an endoscope. There is a 
misconception that the slowing down of the image is due to the phenomenon 
of Talbot’s law, that there is a persistence of an image on the human retina for 
0.2 seconds after exposure.189 In fact laryngeal stroboscopy creates an 
apparent slow-motion by sampling successive phases of the vocal fold cycle. 
It is ultimately subjective, relying on observer interpretation; however, it is 
often helpful when used in conjunction with other methods of voice 
assessment. 
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This technique has been used to assess the depth of the laryngeal tumour 
and help guide the extent of surgical resection. Manola et al. assessed 
patients with early glottic tumours with videolaryngostroboscopy using a 
300,700 and 1200 rigid optical endoscope.190 If the lesion showed no evidence 
of infiltration (normal wave form of the vocal fold on stroboscopy) then a sub-
epithelial partial cordectomy was performed. Thus preserving as much normal 
tissue as possible and having good voice quality post-operatively.  
There are other parameters that can be assessed using stroboscopy such as 
glottal closure, regularity of the vocal fold cycle, mucosal wave form and 
symmetry. The rate of glottis closure on stroboscopy has been found to be a 
reliable tool in assessing vocal fold movement.138 Unfortunately, this 
equipment is currently not used routinely in the otolaryngology department 
where this research was performed.  
  
1.5.7 Aerodynamics 
The vocal tract is an aerodynamic sound generator and resonator. Therefore 
variations in the flow of air through it can change both consonant and vowel 
articulations.162  
Maximum Phonation Time (MPT) is one of the more basic methods of 
measuring aerodynamics and is used frequently to assess phonatory 
mechanisms.191  It consists of sounding a prolonged vowel (/a/) for as long as 
possible after maximal inspiration, at a comfortable volume and pitch. There is 
variation with age and children (with smaller lung volume) will have shorter 
MPTs than adults.192 There is also a difference between younger and older 
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adults, with the latter having a lower MPT. This is thought to be due to a 
change in physiological function of the lungs and muscles as well as an 
increased frequency of existing co-morbidities. MPT varies with respect to the 
pitch and intensity of phonation.  
The Phonation Quotient (PQ) can help reduce these variables by including the 
vital capacity (VC) in the below equation.  
Average phonation airflow (PQ) = VC (ml)/MPT (s) 
The PQ therefore takes into account the speakers moveable air supply and 
reduces possible bias. The VC can be measured reliably using a spirometer. 
The PQ is therefore useful when assessing different ages because it takes 
into account the natural variation in VC.96 The average airflow can also be 
measured using pneumotachography. This equipment measures the airflow 
as one produces a voice over a prolonged period through a tube or a fine 
wire-mesh.162 During production of a sustained vowel most airway resistance 
is at the level of the glottis. Therefore airflow being a reflection of resistance, it 
can provide information regarding glottic function.  However there are 
considerable variations of averaged phonation airflow among normal subjects 
and this limits its diagnostic value.   
 
1.6 Health related quality of life 
In the past, the outcome of different treatments has concentrated on local 
control as a definition of successful treatment. However the health-related 
quality of life (HRQOL) is now a well-recognised method of assessing 
outcomes after any treatment. The British Association of Head and Neck 
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Oncologists (BAHNO) recommend that HRQOL should be documented and 
provides an important insight into the patient’s perspective.36 Over the past 
two decades, in the field of head and neck cancer, there has been an 
increase in the number of publications on HRQOL.95,118-120,123,193 The impact 
of head and neck cancer and its treatment can have such a profound 
detrimental effect on function and well-being that it is essential that the 
patient’s perspective is taken into account.  
Questionnaires are the commonest method of assessing HRQOL and there 
are many different questionnaires that are validated at assessing quality of life 
in head and neck patients.194 Ringash reviewed eight different disease 
specific, multi-dimensional quality of life instruments for patients with head 
and neck cancer. The questionnaires varied in their methodology, strengths 
and weaknesses with no adequate prospective comparison between the 
assessments.194 The commonest assessments used in head and neck 
oncology are the European Organization for Research and Treatment of 
Cancer (EORTC), Functional Assessment of Cancer Therapy – Head and 
Neck (FACT- H&N) and University of Washington Quality of Life (UW-QoL).   
The European Organization for Research and Treatment of Cancer (EORTC) 
developed an integrated system for assessment of the health related QoL of 
cancer patients.195 It was developed for head and neck cancer patients known 
as QoL Questionnaire – Head & Neck 35 (QLQ- H&N35).196 It is a 35 item 
questionnaire which includes relevant questions regarding the effects of RT, 
chemotherapy and surgery. It has been shown to be reliable and distinguish 
between different stages of head and neck cancer treatment.196    
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The Functional Assessment of Cancer Therapy – Head and Neck (FACT- 
H&N) was developed by Cella et al. 197 and consists of 27 questions in 4 
domains: physical, social/family, emotional and functional. It was specifically 
designed for head and neck cancer patients and has been translated into 37 
languages. This tool has been directly compared with the EORTC QLQ- 
H&N35 198 in 102 Head and Neck cancer patients. Both questionnaires 
demonstrated good internal consistency. The internal consistency is a 
measure of reliability and specifically is a measure of how well the items in a 
multi-item scale interrelate. However it was found that there were some 
differences in the QoL aspects it assessed. The FACT- H&N was found to 
have a more multidimensional view with a broader perspective, covering a 
variety of different areas compared to the EORTC QLQ- H&N35 which was 
more focused on physical and symptom aspects.  
The University of Washington Head and Neck cancer Questionnaire (UW-
QoL) has gone through several revisions since it was first published. Version 
4 (UW-QoLV4) is the latest of these updates with the addition of mood and 
anxiety to the domains.199 
A systematic review by Ojo et al. in 2012 200 assessed the head and neck 
cancer quality of life tools. They found that UW-QoL and EORTC QLQ-H&N35 
have been researched most since their development. Although this is partly 
due to the fact they have been used more widely for a longer period. The 
EORTC QLQ-H&N35 and UW-QoL were found to have criterion validity and 
internal consistency. Criterion validity refers to how well the scores of the test 
are compared to other similar instruments. The internal consistency relates to 
the reliability of the test and how consistent and reproducible it is.  
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The continual modifications of the questionnaire and the substantial number of 
published studies using UW-QoL are the reasons that many centres, like 
Aintree University Hospital NHS Foundation Trust, use this tool. There is also 
a local connection with the UW-QoL as Professor Simon Rogers (based at 
AUH) 199 lead in the development of version 4.  
The UW-QoLv4 version four includes 12 domains and the higher the score, 
the better the quality of life. The domains are: pain, appearance, activity, 
recreation, swallowing, chewing, speech, shoulder, taste, saliva, mood and 
anxiety.  The UW-QoLv4 version four also creates two composite scores: 
‘Physical Function’ and ‘Social Function’. 199 The Physical Function score is 
the average of the following six domain scores: chewing, swallowing, speech, 
taste, saliva and appearance. The Social Function is the average of the 
scores for anxiety, mood, pain, activity, recreation and shoulder function.  
There are also three global questions asked in the UW-QoLv4. The first 
question is how the patients feel relative to before they developed their 
cancer, the second about their health-related QoL and finally one about their 
overall QoL.   
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2. Aims and Objectives 
 
This research has three main aims: 
 
I. To describe acoustic parameters of ‘normal’ voice; 
 
 
II. To compare voice outcomes in patients treated with TLM with those 
treated with radiotherapy for T1a SCC of the glottis; 
 
 
III. To investigate longitudinal changes in voice quality in patients 
undergoing TLM for T1a SCC of the glottis; 
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3. Methods 
An application to study and record voices of patients with Head & Neck cancer 
at AUH was approved by the Liverpool Central North West Research Ethics 
Committee on 3rd August 2007. A substantial amendment was accepted by 
the ethics committee on 8th September 2008 (Reference 07/Q1505/46). This 
amendment included the use of three different questionnaires and also the 
recording and use of electrolaryngography. 
 
 
The three aims outlined above were addressed in three individual studies.  
3.1 Describing acoustic parameters of ‘normal’ voice  
3.1.1 Study design 
This study is a cross-sectional cohort study of the acoustic parameters of 
‘normal’ voice.  
3.1.2 Study population 
Adult subjects with no known voice disorders were recruited from NHS staff at 
the AUH between January 2009 and January 2010. Subjects were 
purposefully chosen to provide a range of ages and gender balance. Subjects 
were approached by the researcher within the Head & Neck department at 
AUH and invited to participate in the study. Participants were provided an 
explanation of the study and details of how the measurements will be 
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collected. Verbal consent was taken to complete a voice questionnaire (VHI-
10) and have their voices recorded.   
 
Inclusion criteria:  
 current non-smokers (or not smoked in the past five years);  
 no known voice disorders or difficulties;  
 score zero on the VHI-10 questionnaire;   
Exclusion criteria:  
 smokers (within the last five years) 
 previous neck or phono surgery  
 health issues that may affect the voice such as thyroid disease 
 
3.1.3 Materials and methods 
The same methodology was adopted for voice recording in all three studies.  
The voice recordings and associated electrolaryngography was undertaken in 
a designated sound proof booth in the Department of Otolaryngology – Head 
and Neck Surgery (ORL-HNS) at AUH. Audio readings were recorded by a 
headset SHURE® (Shure Distribution UK, Unit 2, The IO Centre, Lea Road, 
Waltham Abbey, Essex, EN9 1AS) microphone placed 10cm from the corner 
of the mouth. Concurrent with the sound recording, EGG readings were 
recorded using two gold-plated electrodes placed on the skin overlying each 
ala of the thyroid cartilage. The laryngograph® and microprocessor 
(Laryngograph Ltd, 78 Manor road, Wallington, Greater London, SM6 0AB) 
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equipment was used for the EGG recordings, connected to a Microsoft 
Windows® based desktop computer.   
Subjects were required to produce three separate prolonged vowel sounds 
(/a/) and then repeated for the vowel /i/ at a comfortable pitch and volume and 
for as long as felt comfortable. Following this, subjects read out a phonetically 
balanced passage, ‘The Grandfather Passage’ (Appendix 1). All audio 
readings were recorded as a digital file (waveform audio file format for 
Microsoft Windows®), assigned a study number (and therefore anonymised) 
and stored on a password-protected hospital network computer. The voice 
recordings were copied onto a CD format as waveform audio files suitable for 
playback using Microsoft Windows Media Player®. The recordings were rated 
by experienced raters in the Speech and Language Department in AUH, 
Liverpool and in the Freeman Hospital, Newcastle upon Tyne Hospitals NHS 
Foundation Trust, Newcastle. There were a total of three experienced raters 
(one in AUH and two in the Freeman Hospital) and the recordings were 
scored according to the GRBAS voice scale. The raters were blinded and 
were not aware of the patient or participant details or which treatment they 
may have had.  
Acoustic analysis of the recordings was performed using Speech StudioTM 
(Laryngograph® Ltd , 78 Manor Road, Wallington, Greater London, SM6 0AB, 
UK).  The Speech StudioTM software enabled analysis of the sustained vowels 
using the multi-dimensional voice program (MDVP) and Quantative Analysis 
(QA) for the connected speech passage. The MDVP was undertaken using 
the stable mid portion of the sustained vowel recording.  The QA was 
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undertaken on connected speech from the complete ‘Grandfather Passage’. 
The data capture was the same for all the three studies. 
 
3.1.4 Outcome measures 
1. Perceptual rating of voice with GRBAS scores  
2. Acoustic analysis 
a. for sustained vowels:  
-  The Fundamental Frequency, Fx (Hz) 
- Jitter (%) 
- Shimmer (dB) 
- Closed Quotient, Qx (%) 
- Relative Average Perturbation, RAP  (%) 
- Cepstral Peak Prominence, CPP 
- Normalized noise energy, NNE (dB) 
- Harmonics to Noise Ratio, HNR (dB) 
- Speech Pressure Level, SPL (dB) 
b. for connected speech: 
- Frequency, Fx (Hz) 
- Amplitude, Ax (dB) 
- Closed Quotient, Qx (%) 
- Combined parameters of amplitude and frequency, AxFx (%) 
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3.1.5 Data collection and analysis 
The resulting data were collated using Microsoft Office Excel® 2007. Baseline 
characteristics have been compared for males and females, using the Mann 
Whitney U test for age and the Fisher Exact test for smoking status. All data is 
presented with mean, standard deviation (SD), median and interquartile range 
(IQR), as the sample size is small and normal distribution cannot be assumed. 
Analysis of differences between men and women has been undertaken using 
the Mann Whitney U test. P values have also been adjusted for age using a 
proportional odds ordinal logistic model. Due to the small sample size, it was 
only possible to adjust for age and not other variables.   
 
 
3.2 Voice outcomes in patients treated with TLM with those 
treated with RT for T1a SCC of the glottis  
 
3.2.1 Study design   
A comparative cross-sectional cohort study was undertaken to investigate 
differences in voice quality of patients treated for early laryngeal cancer (T1a) 
with TLM or RT.  
 
3.2.2 Study population 
Patients were identified using the AUH Head & Neck database. All patients 
coded as having treatment for laryngeal carcinoma from January 2000 to 
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January 2013 were initially screened. Clinic letters and case notes were then 
reviewed (on the hospital computer system) to identify patients treated for 
T1aN0M0 laryngeal carcinoma. Letters were sent to the patients informing 
them about the research and inviting them to participate. This was followed up 
with a telephone call. The researcher and the consultant surgeons also 
approached patients in the Head & Neck clinic to participate in the study. 
 
Inclusion criteria:  
 A diagnosis of  T1aN0M0 laryngeal squamous cell carcinoma 
 Completion of treatment in excess of twelve months previously 
 TLM group only 
- TLM surgery performed at AUH 
 RT group only  
- Completed RT in Clatterbridge Cancer Centre NHS Foundation 
Trust 
- RT regimes varied depending on the bulk of the tumour. The 
typical schedule was either 50-52 Gy in 16 fractions or 53-55Gy 
in 20 fractions over three to four weeks  
Exclusion criteria: 
 Previous other voice altering surgery or existing condition 
 Signs of loco regional recurrence at last outpatient review  
 
Patients meeting the inclusion criteria were contacted with a letter inviting 
them to participate in the research. This letter outlined the proposed study and 
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informed the participant that they would be contacted by telephone to discuss 
whether they wanted to be involved (Appendix 5). The patient was then 
telephoned and a date arranged for them to attend AUH for the voice 
recording and data collection.  
 
3.2.3 Materials and methods 
Clinicopathological demographic data of the included participants were 
retrieved from case notes and participant interview prior the voice recordings. 
Data collected included: age, sex, smoking history (non-smoker/active/ex-
smoker), type of intervention, extent of surgical resection and any post-
treatment speech therapy. Measurements of voice and speech parameters 
were undertaken through simultaneous audio and electrolaryngograph 
readings as described in section 3.1.3. Following the recording the 
participants completed two self-reported questionnaires for voice (VHI-10 and 
VoiSS) and one to assess quality of life (UW-QoLv4).   
 
3.2.4 Outcome measures 
1. Self-reported voice questionnaires:  
- VHI-10(Appendix 2) 
-  VoiSS (Appendix 3) 
2. Self-reported QoL questionnaire:  
- UW-QoLv4 (Appendix 4) 
3. Perceptual rating of voice with GRBAS scores  
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4. Acoustic analysis for sustained vowel and connective speech as 
described in the section 3.1.4.  
 
3.2.5 Data collection and analysis 
The resulting data were collated using Microsoft Office Excel® 2007. Baseline 
characteristics have been compared for RT and TLM patients, using: Mann 
Whitney U test for age; Fisher Exact test for sex and co-morbidities; and  Chi-
squared test for smoking status and alcohol intake. All data is presented with 
mean, standard deviation (SD), median and interquartile range (IQR), as the 
sample size is small and normal distribution cannot be assumed. Analysis of 
differences between RT and TLM patients has been undertaken using the 
Mann Whitney U test. P values have also been adjusted for age using a 
proportional odds ordinal logistic model. Due to the small sample size, it was 
only possible to adjust for age and not other variables.   
 
 
3.3 Longitudinal changes in voice quality in patients 
undergoing TLM for T1a SCC of the glottis 
 
3.3.1 Study design 
A prospective longitudinal study design was used to investigate changes in 
voice quality and quality of life in patients treated with TLM for T1a glottis 
SCC. 
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3.3.2 Study population 
All patients undergoing TLM for T1a laryngeal squamous cell carcinoma were 
invited to join the study. Patients due to attend for TLM for T1aN0M0 laryngeal 
carcinoma were identified at the weekly multi-disciplinary team (MDT) meeting 
at AUH between August 2008 and August 2010. Patients were approached in 
clinic by the researcher or the operating surgeon to participate in the study 
prior their surgery.  
 
Inclusion criteria:  
 Diagnosis of T1aN0M0 laryngeal squamous cell carcinoma 
 MDT treatment decision for TLM at AUH 
Exclusion criteria: 
 Previous other voice altering surgery or existing condition 
 Previous RT  
Patients attending for their pre-operative assessments were approached and 
asked whether they would like to enrol in the study. If they expressed an initial 
interest they were given a patient information sheet (Appendix 5). Following a 
period of consideration, willing patients were then formally consented to enrol 
on the study (Appendix 5). 
 
3.3.3 Material and methods 
Patients undertook pre-operative voice recordings and then repeat voice 
recordings at least twelve months post-operatively. The same outcome 
measures were collected at each visit and the procedure for data collection 
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was standardised for all patients for each visit. Clinicopathological 
demographic data of the included participants were retrieved from case notes 
and participant interview prior the voice recordings. Data collected included: 
age, sex, smoking history (non-smoker/active/ex-smoker), type of intervention, 
extent of surgical resection and any post-treatment speech therapy.  
Measurements of voice and speech parameters were undertaken through 
simultaneous audio and electrolaryngograph readings as described in section 
3.1.3. Following the recording the participants completed two self-reported 
questionnaires for voice (VHI-10 and VoiSS) and one to assess quality of life 
(UW-QoLv4).   
 
3.3.4 Outcome measures 
1. Self-reported voice questionnaires:  
- VHI-10(Appendix 2) 
-  VoiSS (Appendix 3) 
2. Self-reported QoL questionnaire:  
- UW-QoLv4 (Appendix 4) 
3. Perceptual rating of voice with GRBAS scores  
4. Acoustic analysis for sustained vowel and connective speech as 
described in the section 3.1.4.  
 
3.3.5 Data collection and analysis 
The resulting data were collated using Microsoft Office Excel® 2007. The 
analyses only included patients where pre- and post TLM results were 
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available. Baseline characteristics have been compared for all pre-TLM 
patients compared with those where post-TLM data were available. Baseline 
characteristics were compared using: Mann Whitney U test for age; Fisher 
Exact test for sex and co-morbidities; and  Chi-squared test for smoking status 
and alcohol intake. In addition, a comparison of quality of life and voice 
outcome has been included for patients included and excluded from pre- and 
post- TLM using a Mann Whitney U test.  
 
All data is presented with mean, standard deviation (SD), median and 
interquartile range (IQR), as the sample size is small and normal distribution 
cannot be assumed. Analysis of differences between pre and post TLM 
results has been undertaken using the Wilcoxon test. P values have also been 
adjusted for age using a proportional odds ordinal logistic model. Due to the 
small sample size, it was only possible to adjust for age and not other 
variables.   
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4. Results 
4.1 Describing acoustic parameters of ‘normal’ voice 
Twenty adults with subjectively normal voices were recruited. All subjects 
invited to take part in the research consented to have their voice recorded and 
analysed. There were 10 males and 10 females. The age range varied from 
24 to 59 years, with average age of 40 years.  There were all NHS members 
of staff in AUH. They were all non-smokers and did not have any reported 
voice problems or had not undergone previous head and neck surgery or 
potentially voice altering surgery. All subjects were pre-screened and scored 
zero on the VHI-10 questionnaire. Summary of characteristics are presented 
in table 6. 
 
 
 
Table 6: Summary of characteristics for ‘normal’ voice 
 
Characteristic
 
Gender p-value
  
Male 
(n = 10) 
Female 
(n = 10) 
Age 
Mean (SD) 34 (9) 44 (12) 0.072
 a 
Median (IQR) 34 (28–37) 47 (34-51) 
Smoking Status 
Never 10 (100%) 10 (100%) 1.000
 b 
Smoker - - 
Ex-smoker - - 
a. Mann-Whitney U test 
b. Fisher’s exact test 
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4.1.1 Perceptual rating  
All 20 adults scored zero for each GRBAS domain as judged by a single 
blinded expert rater.  
 
4.1.2 Acoustic analysis  
4.1.2.1 Acoustic analysis on sustained vowels 
The full data set from the MDVP (Multi-Dimensional Voice Program) can be 
found in Appendix 6. The mean results have been calculated and are shown 
in Table 7. The mean results are expressed separately for males and females. 
Where there is a statistically significant difference between males and 
females, p<0.05, the p-value has been highlighted in bold font. There is a 
statistically significant difference in the minimum, maximum and average Fx 
(p=<0.05) between males and female, including when adjusting for age.  
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Table 7: Mean and range of acoustic analysis of sustained vowels for ‘normal’ voice 
 
Males /a/ Males /i/ Females /a/ Females /i/ p value a 
adjusted p value 
b
 
Mean  SD Median IQR Mean  SD Median IQR Mean  SD Median IQR Mean  SD Median IQR /a/ /i/ /a/ /i/ 
Minimum 
Fx (Hz) 
132.9 35.0 118.5 113.4, 148.6 124.0 38.6 124.3 104.4, 139.0 211.7 20.9 118.5 200.0, 229.0 210.8 30.7 218.0 195.4, 228.5 <0.001 <0.001 0.002 0.001 
Maximum 
Fx (Hz) 
195.7 165.8 130.7 125.9, 197.6 163.6 55.0 140.7 131.3, 185.5 227.2 19.4 130.7 216.7, 242.2 252.5 42.5 243.8 228.6, 259.7 0.004 0.002 0.005 0.009 
Average Fx 
(Hz) 
138.5 35.7 122.0 119.9, 154.7 148.5 41.8 130.5 125.6, 163.8 218.7 20.9 122.0 205.7, 235.8 233.9 28.3 232.1 214.8, 246.5 <0.001 0.001 0.001 0.005 
S.D. Fx (%) 2.8 4.9 1.3 1.0, 1.7 1.7 1.8 1.1 0.9, 1.4 1.2 0.6 1.3 0.9, 1.2 1.9 2.4 1.0 0.8, 1.6 0.159 0.698 0.143 0.350 
Minimum 
Qx (%) 
38.9 6.9 36.4 34.8, 41.2 36.9 11.7 40.2 34.5, 42.8 53.1 51.3 36.4 32.6, 46.5 39.6 12.0 39.5 29.1, 48.5 0.944 0.725 0.998 0.859 
Maximum 
Qx (%) 
51.8 11.4 48.1 43.4, 56.6 50.7 6.4 48.3 45.6, 54.7 65.3 50.4 48.1 45.7, 56.4 56.4 13.6 56.1 47.4, 60.4 0.597 0.324 0.522 0.880 
Average 
Qx (%) 
44.4 6.5 44.6 39.2, 48.4 46.2 7.2 44.8 42.8, 51.0 42.3 8.6 44.6 34.1, 49.0 49.1 13.0 45.7 42.0, 56.1 0.573 0.725 0.154 0.449 
S.D. Qx (%) 1.8 0.5 1.7 1.5, 2.1 1.5 0.5 1.5 1.2, 1.9 2.4 1.0 1.7 1.7, 2.7 3.5 3.4 1.7 1.3, 4.8 0.105 0.291 0.143 0.591 
Jitter First 
(%) 
0.7 0.5 0.5 0.4, 0.8 0.7 0.9 0.4 0.3, 0.7 0.8 0.7 0.5 0.4, 0.8 0.9 0.5 0.7 0.6, 1.1 0.418 0.048 0.531 0.105 
Jitter 
Second (%) 
0.4 0.4 0.3 0.2, 0.5 0.4 0.6 0.2 0.1, 0.4 0.5 0.4 0.3 0.2, 0.5 0.5 0.3 0.4 0.3, 0.7 0.672 0.045 0.611 0.098 
Shimmer + 
(%) 
4.7 1.9 4.4 3.3, 6.0 3.6 2.0 2.7 2.6, 4.1 3.2 1.3 4.4 2.3, 3.7 3.9 3.5 3.0 2.3, 3.7 0.067 0.833 0.074 0.883 
Shimmer – 
(%) 
-4.2 1.7 -4.4 -5.2, -3.1 -3.3 1.4 -2.9 -3.6, -2.4 -3.0 1.4 -4.4 -3.5, -1.9 -4.0 1.5 -3.8 -3.9, -3.2 0.078 0.139 0.102 0.031 
Jitter 
Factor (%) 
0.8 0.7 0.5 0.4, 0.8 0.7 0.9 0.4 0.3, 0.6 0.8 0.7 0.5 0.4, 0.8 0.9 0.5 0.7 0.6, 1.1 0.647 0.032 0.576 0.063 
RAP (%) 0.4 0.3 0.3 0.2, 0.5 0.4 0.6 0.2 0.1, 0.4 0.5 0.4 0.3 0.2, 0.5 0.6 0.3 0.4 0.3, 0.7 0.597 0.057 0.550 0.127 
Shimmer 
dB (dB) 
0.4 0.2 0.4 0.3, 0.5 0.3 0.2 0.2 0.2, 0.4 0.3 0.1 0.4 0.2, 0.3 0.3 0.3 0.3 0.2, 0.3 0.037 0.751 0.051 0.855 
NNE (dB) -18.9 5.4 -19.6 -22.8, -15.2 -22.3 5.5 -22.9 -25.7, -20.8 -23.7 3.6 -19.6 -26.0, -20.8 -20.6 4.3 -21.6 -22.6, -18.2 0.049 0.291 0.079 0.368 
CPP 4.3 1.4 4.3 3.4, 5.2 3.6 1.0 3.6 2.9, 4.3 5.7 1.4 4.3 5.1, 6.7 4.4 1.1 4.2 3.6, 4.9 0.041 0.149 0.069 0.391 
HNR (dB) 16.6 3.4 16.8 15.5, 18.9 19.5 3.5 20.5 18.1, 21.3 19.3 2.5 16.8 17.1, 21.2 19.0 3.1 19.8 17.6, 21.1 0.078 0.5732 0.137 0.851 
Mean SPL 
(dB) 
87.5 4.2 86.4 84.6, 89.8 85.0 3.8 84.8 81.9, 87.9 91.1 6.9 86.4 86.9, 97.4 87.4 5.7 86.6 84.4, 89.8 0.175 0.4179 0.551 0.845 
a. Mann Whitney U test; b. Age-adjusted Mann Whitney U test; IQR = interquartile range; SD=standard deviation 
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4.1.2.2 Acoustic analysis on connected speech  
4.1.2.2.1 Frequency (Fx) 
The results for the DFx1 and 2 using the connected speech passage are 
shown in Table 8. Data are presented separately for the groups of males and 
females and for the whole cohort.   
 
Table 8: Summary table of DFx1&2 connective speech for ‘normal’ subjects 
 
Mean 
DFx1 (Hz) 
Mean 
DFx2 (Hz) 
Coherence (%) CFx (%) 
Mean SD Median IQR Mean SD Median IQR 
Males 134.7 136.5 72.3 8.9 73.5 68.0, 79.9 3.6 2.1 3.1 1.9, 4.6 
Females 218.3 210.5 52.4 16.3 54.3 43.3, 60.2 12.2 10.0 11.4 3.7, 17.7 
Total 174.5 171.7 62.8 16.3 66.2 54.7, 74.4 7.7 8.2 3.4 2.4, 8.2 
IQR = interquartile range; SD=standard deviation; DFx=frequency; CFx=frequency irregularity 
 
Of note the mean DFx is statistically significantly higher in the females 
compared with the males (p=<0.001). The coherence is statistically 
significantly lower in the females than in the males (54.3 and 73.5 
respectively, p=0.004) and this is still statistically significant when adjusting for 
age (adjusted p=0.036). There is a statistically significantly higher pitch 
irregularity within the females (11.4 and 3.1 respectively, p=0.038), although 
this difference is non-statistically significant when adjusting for age (adjusted 
p=0.094).  
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4.1.2.2.2 Amplitude (Ax) 
The results for the DAx1 and 2 using the connected speech passage are 
shown in Table 9. Data are presented separately for the groups of males and 
females and for the whole cohort.   
 
Table 9: Summary table of DAx1&2 connective speech for ‘normal’ subjects 
 
Mean 
DAx1 (dB) 
Mean 
DAx2 (dB) 
Coherence (%) CAx (%) 
Mean SD Median IQR Mean SD Median IQR 
Males 85.2 85.7 71.9 5.8 72.9 68.8, 77.2 2.5 0.9 2.1 1.8, 2.9 
Females 87.0 88.2 64.9 17.6 60.3 57.1, 74.0 6.7 6.2 4.9 1.4 10.1 
Total 86.1 86.9 68.5 13.0 72.6 59.4, 77.0 4.5 4.7 2.3 1.7, 4.6 
IQR = interquartile range; SD=standard deviation; DAx=amplitude; CAx = amplitude irregularity 
 
No statistically significant difference between mean DAx (p=0.149), coherence 
(p=0.193) or loudness irregularity (p=0.290) is demonstrated between the 
groups of males and females. There is no statistically significant difference 
when adjusting for age in mean DAx (adjusted p=0.308), coherence (adjusted 
p=0.402) or loudness irregularity (adjusted p=0.867). 
 
 
4.1.2.2.3 Contact quotient (Qx)  
The results for the DQx1 and 2 using the connected speech passage are 
shown in Table 10. Data are presented separately for the groups of males and 
females and for the whole cohort.    
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Table 10: Summary table of DQx1&2 connective speech for ‘normal’ subjects 
 
Mean 
DQx1 (%) 
Mean 
DQx2 (%) 
Coherence (%) CQx (%) 
Mean SD Median IQR Mean SD Median IQR 
Males 44.8 45.3 48.2 6.3 47.9 43.3, 54.4 12.9 9.0 13.3 7.8, 15.4 
Females 43.4 43.3 23.4 13.7 22.8 17.1, 28.4 42.6 15.1 45.0 32.7, 52.4 
Total 44.2 44.3 36.4 18.3 36.1 25.3, 47.9 27.0 15.6 21.9 13.3, 41.4 
IQR = interquartile range; SD=standard deviation; DQx=contact quotient; CQX=pitch irregularity 
 
There is no statistically significant difference in contact quotient (DQx) for 
males and females (p=0.438), and there is no difference when adjusting for 
age (adjusted p=0.06). Coherence is statistically significantly higher in males 
(47.9 and 22.8 respectively, p=<0.001), and this statistically significant 
remains when adjusting for age (adjusted p=<0.001).  Contact irregularity is 
statistically significantly lower in males (13.3 and 45.0 respectively, p=<0.001), 
and this significance remains when adjusting for age (adjusted p=<0.001).   
 
4.1.2.2.4 Combined acoustic parameters 
The results for the AxFx1 and 2 using the connected speech passage are 
shown in Table 11.   
 
Table 11: Summary table of AxFx1&2 connective speech for ‘normal’ subjects 
 Mean SD Median IQR 
Males 82.5 9.0 86.0 80.5, 87.9 
Females 62.7 15.1 62.5 54.6, 71.0 
Total 73.1 15.6 77.4 60.0, 86.0 
IQR = interquartile range; SD=standard deviation 
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AxFx is statistically significantly higher in males compared with female (86.0 
and 62.5, p=0.002), and this significance remains when adjusting for age 
(adjusted p=0.010).   
 
 4.2 Voice outcomes in patients treated with TLM with those 
treated with RT for T1a SCC of the glottis  
4.2.1 Patient demographics 
There were 122 patients identified as having treatment for T1 glottic 
carcinoma on the Head & Neck database. Following review of the electronic 
case notes and clinic letters sixty patients were invited to take part in the 
study.Forty patients were recruited to this study, 20 who had completed RT 
and 20 who had completed TLM for T1aN0M0 glottic carcinoma more than 12 
months prior to inclusion in the study. One patient from the RT group was 
excluded from the study following recruitment as they had laryngeal surgery 
prior to undergoing RT for recurrent disease. There were four females and 35 
males, reflecting the relative sex bias seen with larynx cancer. There is a 
statistically significant difference in sex between the two groups, with a higher 
proportion of men in the TLM group (100% vs. 73.7%, p=0.020). The mean 
age is 72 years in the RT group compared with 62 years in the TLM group, 
although date of birth was unavailable for one patient in the TLM group and 
seven in the RT group. There is a statistically significant difference in age 
between the groups (p=0.049). The majority (30/39) of patients were previous 
smokers. There is a statistically significantly higher proportion of ex-smokers 
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in the TLM group compared with the RT group (85.0% vs. 47.4%, p=0.013). 
There is a statistically significantly higher proportion of patients with asthma or 
with COPD in the RT group compared with the TLM group (31.6% vs. 5.0%, 
p=0.044). There is no statistically significant difference in alcohol history or 
other comorbidities between the groups (Table 12). TLM and RT patients 
were routinely offered speech and language therapy following treatment. 
However none of the patients were undergoing speech and language therapy 
at the time of their voice recording.  
 
Table 12: Baseline demographics for RT and TLM patients 
Characteristic
 
Treatment  p-value
  
RT (n=19) TLM (n=20) 
Age 
Mean (SD) 72 (7) 62 (12) 
0.049
b
 
Median (IQR) 71 (65,78) 66 (59,68) 
Sex 
Male 14 (73.7%) 20 (100%) 
0.020
 c
 
Female 5 (26.3%) 0 (0%) 
Smoking Status 
Never 2 (10.5%) 1 (5.0%) 
0.013
d
 
Smoker 2 (10.5%) 0 (0%) 
Ex-smoker 9 (47.4%) 17 (85.0%) 
Unknown 6 (31.6%) 2 (10.0%) 
Alcohol history 
No alcohol 4 (21.1%) 1 (5.0%) 
0.770
 d
 
Within recommended limits 
(<14 units) 
4 (21.1%) 8 (40.0%) 
Above recommended limits 
(14 units or above) 
4 (21.1%) 5 (25.0%) 
Unknown 7 (36.8%) 6 (30.0%) 
Comorbidities 
Reflux disease 4 (21.1%) 6 (30.0%) 0.716
 c
 
Has asthma/COPD 6 (31.6%) 1 (5.0%) 0.044 
c
 
Ischaemic heart disease 3 (15.8%) 5 (25.0%) 0.695 
c
 
a. Mann-Whitney U test adjusted for baseline characteristics 
b. Mann-Whitney U test 
c. Fisher’s exact test 
d. Chi squared test 
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4.2.2 Subjective voice questionnaires 
The complete data set for subjective voice questionnaires for the RT and TLM 
patient groups can be found in Appendix 7.  
4.2.2.1 Voice Handicap Index – 10 
The VHI-10 results for TLM and RT are presented in Table 13. The total 
median score for the RT group is 4 (IQR 1,7) compared with 6 in the TLM 
group (IQR 0,7).  There is no statistical difference between the two groups 
with regards to Voice Handicap Index.  
 
Table 13: Voice handicap index–10 for RT and TLM patients 
 
 
Domain (range) 
RT (N=19) TLM (N=20) p value 
a
 Adjusted 
p value 
b
 
Mean  SD Median  IQR Mean  SD Median IQR 
Functional (0 - 20) 2.0 2.1 1 0,3 2.4 2.3 2 0,4 0.666 0.925 
Physical (0 - 12) 2.4 2.1 2 1,4 2.0 2.0 2 0,3 0.574 0.328 
Emotional (0 - 8) 0.6 1.0 0 0,1 0.5 0.8 0 0,1 0.567 0.350 
Total (0 - 40) 4.9 4.4 4 1,7 4.9 4.3 6 0,7 0.809 0.614 
a. Mann Whitney U test; b. Age-adjusted Mann Whitney U test; IQR = interquartile range; SD=standard deviation 
 
 
4.2.2.2 VoiSS 
The VoiSS questionnaire results for TLM and RT are shown in Table 14. The 
highest scores are recorded for the impairment domain whilst the emotional 
domain questions resulted in the lowest scores. The total median score for the 
RT group is 17 (IQR 8, 32) compared with 18 in the TLM group (IQR 9,28).  
There is no statistical difference between the two groups with regards to 
VoiSS scores.  
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Table 14: VoiSS questionnaire for RT and TLM patients 
 
 
Domain (range) 
RT (N=19) TLM (N=20) p value 
a
 Adjusted 
p value 
b
 
Mean  SD Median  IQR Mean  SD Median IQR 
Impairment (0-60) 14.2 10.9 13 5,23 11.4 8.8 11 4,18 0.396 0.187 
Emotional (0-32) 1.1 1.8 0 0,2 1.7 2.2 1 0,2 0.431 0.903 
Physical (0-28) 5.9 4.7 5 2,9 5.0 2.4 5 4,6 0.906 0.247 
Total (0-120) 21.2 15.6 17 8,32 18.0 10.8 18 9,28 0.715 0.255 
a. Mann Whitney U test; b. Age-adjusted Mann Whitney U test; IQR = interquartile range; SD=standard deviation 
*IQR – interquartile range 
4.2.3 QoL questionnaire: UW-QoLv4 
The health related QoL results are shown in Table 15.  The full data set can 
be found in Appendix 8. There is a statistically significantly higher score in the 
TLM compared with the RT group for appearance (p=0.003), recreation 
(p=0.048), chewing (p=0.015) and saliva (p=0.016), however these are not 
statistically significant when adjusted for age. The lowest mean scores are 
recorded for the RT group in the activity (76.3) and recreation (77.6) domains. 
Whilst for the TLM group the lowest mean scores are reported for the anxiety 
(85.8) and mood (88.8) domains.  
 
Table 15: Summary table for UW-QoLv4 domain scores for RT and TLM patients 
 
 
RT (N=19) TLM (n=20) p value 
a
 Adjusted 
p value 
b
 
Mean SD Median IQR Mean SD Median IQR 
Pain 92.1 20.5 100.0 100.0, 100.0 97.5 7.7 100.0 100.0 ,100.0 0.529 0.178 
Appearance 90.8 12.4 100.0 75.0, 100.0 100 0.0 100.0 100.0 ,100.0 0.003 0.996 
Activity 76.3 30.6 100.0 50.0, 100.0 92.5 16.4 100.0 100.0 ,100.0 0.055 0.075 
Recreation 77.6 26.2 75.0 62.5, 100.0 91.3 18.6 100.0 100.0 ,100.0 0.048 0.137 
Swallowing 95.3 11.2 100.0 100.0, 100.0 100 0.0 100.0 100.0 ,100.0 0.068 0.996 
Chewing 84.2 29.1 100.0 75.0, 100.0 100 0.0 100.0 100.0 ,100.0 0.015 0.996 
Speech 88.4 19.5 100.0 70.0, 100.0 95.3 11.2 100.0 100.0 ,100.0 0.236 0.341 
Shoulder 91.6 18.6 100.0 100.0, 100.0 95.0 16.7 100.0 100.0 ,100.0 0.370 0.291 
Taste 94.7 22.9 100.0 100.0, 100.0 98.5 6.7 100.0 100.0 ,100.0 0.941 0.760 
Saliva 84.2 30.6 100.0 85.0, 100.0 100 0.0 100.0 100.0 ,100.0 0.016 0.997 
Mood 92.1 14.6 100.0 87.5, 100.0 88.8 20.6 100.0 75.0 ,100.0 0.735 0.609 
Anxiety 86.3 23.4 100.0 70.0, 100.0 85.8 20.3 100.0 70.0 ,100.0 0.690 0.813 
a. Mann Whitney U test; b. Age-adjusted Mann Whitney U test; IQR = interquartile range; SD=standard deviation 
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The two composite scores, calculated from the UW-QoLv4, ‘Physical 
Function’ and ‘Social Function’ are shown in Table 16. The RT group have a 
statistically significantly lower median score compared to TLM in physical 
function (p=0.004) and this remains statistically significant when adjusted for 
age (adjusted p=0.036). There is no statistically significant difference for 
social function (adjusted p=0.114) 
 
Table 16: UW-QoLv4 composite quality of life scores of physical and social function for 
RT and TLM patients 
 
 
RT (N=19) TLM (N=20) 
p value 
a
 Adjusted 
p value 
b
 
Mean SD Median IQR Mean SD Median IQR 
Physical 
function 
89.6 12.9 95.0 83,100 99.0 2.1 100 100,100 0.004 0.036 
Social 
function 
86.0 14.7 89.1 70.6,100 91.8 9.6 93.3 89.8,100 0.297 0.114 
a. Mann Whitney U test; b. Age-adjusted Mann Whitney U test; IQR = interquartile range; SD=standard deviation 
 
 
The composite scores are illustrated in box-plots for physical function and 
social function in Figure 30 and 31. The box plot graphs demonstrate the 
worse score and the increased range in the physical and social function of the 
RT group.  
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Figure 30: Box plot of physical function for RT and TLM patients 
 
 
 
 
 
 
 
 
Fig
ure 
31:  
 
Box-plot of social function for RT and TLM patients 
 
The global questions of the UW-QoLv4 were completed for only eight out of 
20 patients from the TLM group due to an administrative error in the printing of 
the questionnaires, which was not possible to resolve at a later stage. The 
results for global questions are presented in Table 17. No statistically 
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significant difference in the global questions is demonstrated between the two 
groups.  
 
Table 17: Summary table for UW-QoLv4 global questions for RT and TLM patients 
 
RT (N=19) TLM (N=20) 
p value 
a
 Adjusted 
p value 
b
 
Mean SD Median IQR Mean SD Median IQR 
A. Health-related QOL 
compared to month 
before had cancer 
56.9 22.4 50.0 50.0, 50.0 68.8 25.9 50.0 50.0, 100.0 0.248 0.453 
B. Health-related QOL 
during the past 7 
days 
72.2 21.8 80.0 60.0, 80.0 70.0 18.5 70.0 60.0, 80.0 0.705 0.931 
C. Overall QOL 
during the past 7 
days 
75.6 22.3 80.0 60.0, 95.0 77.5 12.8 80.0 75.0, 80.0 0.953 0.538 
a. Mann Whitney U test; b. Age-adjusted Mann Whitney U test; IQR = interquartile range; SD=standard deviation 
 
In the final part of the UW-QoLv4 it asks participants to report which are the 
three most important domain issues over the past seven days. The most 
commonly selected domain issues across both groups are: speech (9/39); 
activity (8/39); recreation (6/39) and anxiety (6/39). 
 
4.2.4 Perceptual rating 
The full data set is presented in Appendix 9. Voice was rated by three expert 
raters for 14 of the 20 TLM patients and for 7 out of 19 RT patients. The 
remaining six TLM and 12 RT patients were rated by one expert rater.    
 
The mean for each GRBAS indicator is similar for the RT and TLM groups 
except for roughness where the mean GRBAS score is statistically 
significantly higher for RT compared with TLM group (1.46 vs. 0.85, adjusted 
p=0.001). There is no statistically significant difference between the combined 
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mean for the RT and TLM groups, 5.49 [95% CI 3.95, 7.04] vs. 5.12 [95% CI 
3.79, 6.44], adjusted p=0.254 (Table 18).  
 
Table 18: Combined mean GRBAS scores for RT and TLM patients 
 
Grade 
(0-3) 
Roughness (0-
3) 
Breathiness (0-
3) 
Asthenia 
(0-3) 
Strain 
(0-3) 
Total 
(0-15) 
RT (n=19) 1.72 1.46 0.98 0.49 0.86 5.49 
TLM (n=20) 1.50 0.85 1.13 0.65 1.02 5.12 
p value 
a
 0.424 0.004 0.909 0.383 0.461 0.682 
Adjusted p value 
b
 0.172 0.001 0.803 0.414 0.836 0.254 
a. Mann Whitney U test; b. Age-adjusted Mann Whitney U test 
 
4.2.5 Acoustic analysis  
4.2.5.1 Acoustic analysis on sustained vowels 
Analysis was undertaken on sustained /i/ and /a/ vowel sounds. A full data set 
is available in Appendix 10. It was not possible, for technical reasons, despite 
repeated attempts, to gain a waveform for /i/ and /a/ vowel sounds for two RT 
patients.  Similarly waveforms for /i/ and /a/ vowel sounds were not achievable 
for three patients in the TLM group. In two of the RT patients the neck tissue 
rigidity (due to fibrosis following RT) prevented the measurement of a constant 
Lx waveform signal. In addition a further two patients found the neck strap too 
tight and uncomfortable and therefore could not tolerate an optimal EGG. 
Thus the waveform measured in these two patients was inconsistent as the 
neck straps were too loose during the EGG recording. Finally, a further patient 
with a larger neck size due to excess adipose tissue made it difficult to gain an 
adequate EGG recording.   
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Table 19 presents mean values, 95% confidence intervals and p values for 
acoustic groups. The majority of acoustic parameters do not show any 
statistical difference between RT and TLM groups for either /i/ or /a/ vowel 
sounds. Without adjusting for age, only SD Fx for /a/ and HNR for /a/ show 
any statistically significant difference between groups. The only age-adjusted 
statistically significant differences are for average Fx for /a/, S.D. Fx /i/, and 
HNR for /a/.  
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Table 19: Acoustic analysis of both sustained vowels for RT and TLM patients 
  
 
RT /a/ RT /i/ TLM /a/ TLM /i/ P value
 a
 
Adjusted p 
value 
b
 
Mean SD Median IQR Mean SD Median IQR Mean SD Median IQR Mean SD Median IQR /a/ /i/ /a/ /i/ 
Minimum Fx (Hz) 119.2 49.3 118.4 55.2, 205.0 125.3 40.4 130.7 87.9, 151.4 146.2 35.4 149.2 134.7, 172.3 146.4 50.0 151.9 119.8, 179.0 0.052 0.186 0.057 0.133 
Maximum Fx (Hz) 430.1 433.4 217.9 112.3, 1335.1 265.4 236.2 169.8 139.6, 255.1 243.0 251.6 167.3 157.1, 196.8 267.0 279.5 197.7 166.1, 223.1 0.517 0.985 0.281 0.132 
Average Fx (Hz) 171.6 51.3 169.2 104.7, 305.9 164.2 43.7 158.1 137.4, 184.7 165.8 33.6 156.9 150.4, 185.8 186.0 38.1 182.5 162.3, 207.9 0.052 0.131 0.048 0.238 
S.D. Fx (%) 18.9 29.4 4.1 0.8, 85.4 12.8 23.4 2.5 1.2, 6.5 6.3 18.7 1.5 1.0, 2.1 8.0 19.5 1.1 0.8, 2.0 0.032 0.519 0.112 0.024 
Minimum Qx (%) 25.9 19.9 34.7 0.0, 46.4 28.8 18.6 34.3 14.9, 43.5 34.3 14.8 36.4 30.8, 41.7 34.8 18.2 35.9 25.5, 42.7 0.971 0.346 0.936 0.120 
Maximum Qx (%) 59.4 13.2 55.2 43.6, 88.2 54.8 10.0 53.5 50, 61.4 50.6 7.4 51.0 43.8, 54.9 55.3 14.2 51.8 46.7, 62.4 0.564 0.905 0.973 0.897 
Average Qx (%) 44.0 8.0 46.4 23.2, 55.1 45.0 9.4 46.8 40.6, 49.1 44.5 8.0 41.5 38.5, 48.4 45.3 9.8 43.3 39.0, 48.9 0.517 0.922 0.964 0.357 
S.D. Qx (%) 6.1 6.9 2.9 0.7, 23.9 5.4 5.8 2.9 1.9, 6.23 3.8 4.1 2.2 1.3, 5.2 3.8 5.2 1.7 1.1, 3.2 0.149 0.412 0.122 0.456 
Jitter First (%) 8.9 18.0 2.0 0.5, 67.7 8.0 14.0 1.4 0.6, 5.2 3.3 10.3 0.8 0.4, 1.3 5.3 11.5 0.7 0.4, 1.3 0.027 0.552 0.162 0.123 
Jitter Second (%) 7.1 14.1 1.2 0.3, 49.5 6.3 11.4 0.8 0.3, 3.1 3.1 11.0 0.5 0.2, 0.8 3.5 8.1 0.4 0.2, 0.8 0.041 0.418 0.164 0.671 
Shimmer + (%) 11.3 11.6 7.4 3.6, 46.4 6.1 6.5 4.3 2.34, 7.0 8.2 6.0 6.8 3.9, 10.7 5.7 5.9 4.2 3.0, 5.3 0.126 0.852 0.055 0.580 
Shimmer – (%) -9.9 10.2 -4.9 -34.1, -3.4 -8.2 8.8 -5.0 -7.4, -3.41 -6.7 5.7 -5.4 -8.0, -3.6 -5.4 3.1 -4.7 -7.5, -3.2 0.313 0.231 0.124 0.981 
Jitter Factor (%) 11.6 23.0 2.0 0.5, 80.6 10.1 18.2 1.4 0.6,   5.1 4.8 16.8 0.8 0.4, 1.3 5.7 13.2 0.7 0.4, 1.3 0.028 0.424 0.169 0.690 
RAP (%) 5.5 12.0 1.2 0.3, 46.4 4.2 7.6 0.9 0.3,   3.2 1.5 4.4 0.5 0.2, 0.8 4.1 9.6 0.4 0.2, 0.9 0.035 0.960 0.145 0.600 
Shimmer dB (dB) 1.1 1.2 0.6 0.3, 4.2 0.6 0.6 0.4 0.2,   0.9 0.7 0.6 0.6 0.4, 1.0 0.4 0.3 0.4 0.3, 0.5 0.120 0.298 0.051 0.660 
NNE (dB) -12.8 6.8 -14.9 -21.1, 0.8 -15.7 8.1 -17.3 -20.6,   -15.3 -18.2 7.0 -18.2 -22.8, -16.0 -17.0 8.0 -18.1 -21.9, -16.2 0.117 0.657 0.213 0.369 
CPP 3.4 1.0 3.6 1.1, 4.7 3.1 1.0 3.4 2.66,   3.6 4.4 1.4 4.3 3.7, 5.1 3.4 1.3 3.3 2.2, 3.7 0.517 0.399 0.591 0.955 
HNR (dB) 14.5 3.2 14.3 13.3, 16.2 16.2 5.5 17.7 14.9,    18.4 16.4 3.6 16.1 15.2, 18.7 18.2 2.5 18.1 16.4, 19.2 0.041 0.172 0.043 0.414 
Mean SPL (dB) 89.0 10.4 90.2 64.3, 107.7 88.2 6.9 88.2 84.9,    93.0 90.5 9.5 90.4 82.8, 96.1 88.5 9.3 90.7 82.5, 93.9 0.773 0.909 0.824 0.996 
a. Mann Whitney U test; b. Age-adjusted Mann Whitney U test; IQR = interquartile range; SD=standard deviation 
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4.2.5.2 Acoustic analysis of connected speech 
The acoustic analysis could only be performed on 17 RT patients and 17 TLM 
patients. The reasons for not obtaining an adequate EGG recording in all of 
the patients have been explained in section 4.2.5.1. 
 
4.2.5.2.1 Frequency (Fx) 
The mean Fx analysis on connective speech is statistically significantly higher 
in the TLM group, 161.2Hz and 164.4Hz compared to 131.1Hz and 137Hz 
(p=0.044, p=0.009) in the RT group (Table 20). This difference remains 
statistically significant when adjusted for age (adjusted p=0.001). Coherence 
is statistically significantly higher in the TLM group (48.6% vs. 36.0%, 
p=0.028, adjusted p=0.027).  Pitch irregularity is statistically significantly 
higher in the RT group (26.7% vs. 14.9%, p=0.004, adjusted p=0.013).   
 
Table 20: Summary table of DFx1&2 connective speech for RT and TLM patients 
 
Mean 
DFx1 (Hz) 
Mean 
DFx2 (Hz) 
Coherence (%) CFx (%) 
Mean SD Median IQR Mean SD Median IQR 
RT (n=17) 131.1 137.0 36.0 18.2 36.5 24.3, 46.4 26.7 14.3 25.8 15.9, 29.2 
TLM (n=17) 161.2 164.4 48.6 19.4 50.9 41.2, 60.3 14.9 19.0 7.7 4.0, 17.8 
p value
a
 0.044 0.009 0.028 0.004 
Adjusted p 
value
b
 
0.001 0.001 0.027 0.013 
a. Mann Whitney U test; b. Age-adjusted Mann Whitney U test; IQR = interquartile range; SD=standard deviation; DFx=frequency; 
CFx=frequency irregularity 
 
An example of DFx1&2 on connected speech in a RT and a TLM patient is 
presented in figure 32.  
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Figure 32: Example of DFx1&2 on connected speech in a RT and a TLM patient 
 
 
4.2.5.2.2 Amplitude (Ax) 
There is no statistically significant difference in mean amplitude between the 
two groups. Coherence is statistically significantly higher in the TLM group 
compared with the RT group when adjusted for age (p=0.076, adjusted 
p=0.006). CAx is statistically significantly higher in the RT group, (12.4% vs. 
6.3%, p=0.005, adjusted p=0.005, Table 21).  
 
Table 21 : Summary table of DAx1&2 connective speech for RT and TLM  
 
Mean 
DAx1 (dB) 
Mean 
DAx2 (dB) 
Coherence (%) CAx (%) 
Mean SD Median IQR Mean SD Median IQR 
RT (n=17) 83.9 85.1 41.6 16.0 43.2 30.8, 51.0 12.4 7.0 10.0 7.7, 16.1 
TLM (n=17) 84.8 85.8 50.2 10.8 52.5 42.8, 56.6 6.3 3.7 6.3 3.0, 8.1 
p value
a
 0.380 0.547 0.076 0.005 
Adjusted p 
value
b
 
0.162 0.128 0.006 0.004 
a. Mann Whitney U test; b. Age-adjusted Mann Whitney U test; IQR = interquartile range; SD=standard deviation; DAx=amplitude; 
CAx=amplitude irregularity 
 
An example of DAx1&2 on connected speech in a RT and a TLM patient is 
presented in figure 33.  
 
 
RT  TLM 
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Figure 33: Example of DAx1&2 on connected speech in a RT and a TLM patient 
  
 
4.2.5.2.3 Contact quotient (Qx) 
There is no statistically significant difference in mean contact quotient 
(p=0.368), coherence (p=0.236) or irregularity (p=0.125) between the two 
groups (Table 22).  
 
Table 22: Summary table of DQx1&2 connective speech for RT and TLM  
 
Mean DQx1 
(%) 
Mean 
DQx2 (%) 
Coherence (%) CQx (%) 
Mean SD Median IQR Mean SD Median IQR 
RT (n=17) 45.7 47.4 24.0 11.0 21.7 17.1, 30.8 43.7 17.4 42.4 32.7, 38.1 
TLM (n=17) 43.8 44.4 30.1 12.5 33.4 25.2, 36.1 34.5 21.0 26.7 21.3, 38.1 
p value
a
 0.286 0.134 0.130 0.085 
Adjusted p 
value
b
 
0.368 0.104 0.236 0.125 
a. Mann Whitney U test; b. Age-adjusted Mann Whitney U test; IQR = interquartile range; SD=standard deviation; DQx=contact 
quotient; CQx=contact quotient irregularity 
 
An example of CQx on connected speech in a RT and a TLM patient is 
presented in figure 34.  
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Figure 34: Example of CQx on connected speech in a RT and a TLM patient 
 
   
 
4.2.5.2.4 Combined acoustic parameters 
The combined parameters, including amplitude and frequency, are statistically 
significantly higher in the TLM group compared with the RT group (61.2% vs. 
47.2%, p=0.013, adjusted p=0.013, Table 23).  
 
Table 23: Summary table of AxFx1&2 connective speech for RT and TLM  
 
AxFx1&2 
Mean SD Median IQR 
RT (n=17) 47.2 18.6 47.2 39.0, 57.1 
TLM (n=17) 61.2 20.1 67.0 54.2, 72.9 
p value
a
 0.013 
Adjusted p value
b
 0.015 
a. Mann Whitney U test; b. Age-adjusted Mann Whitney U test; IQR = interquartile range; 
SD=standard deviation; DFx=frequency; CFx=frequency irregularity 
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4.3 Longitudinal changes in voice quality in patients 
undergoing TLM for T1a SCC of glottis 
4.3.1 Patient demographics 
Thirty-three patients were enrolled into this study and consented to voice 
recording and completion of voice (VHI-10, VoiSS) and QoL (UW-QoLv4) 
questionnaires prior to and twelve months after surgery. All patients 
approached agreed to take part in the study. All patients recruited underwent 
surgery between December 2008 and August 2010. Four patients were 
subsequently excluded from the study: two patients had tumours which were 
upstaged from T1a to T2 at time of the resection; one patient initially 
scheduled for TLM opted instead for RT; following resection one patient was 
diagnosed with a spindle cell carcinoma and post-operative RT was advised 
following MDT discussion. Consequently 29 patients met the inclusion criteria: 
26 males and three females.  Patient demographic information is included in 
Table 24. Patients were routinely offered speech and language therapy as 
part of the MDT. There were no patients undergoing speech and language 
therapy at their follow up voice recording.    
 
Follow up data collection was performed between 12 and 24 months post 
TLM.  Patients with a complete pre and post TLM dataset were included in the 
analysis.  In total only 17 (58.6%) patients attended for follow up study 
assessments (Figure 35). There were different reasons for the patients not 
attending for follow up data collection. Two patients developed a primary lung 
carcinoma one as a synchronous primary and one as metastases and were 
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unable to return for a follow-up recording due to ill health. One patient 
underwent vocal cord medialisation surgery rendering them ineligible. One 
patient lived in the Midlands and opted for local oncological follow-up. In 
addition, eight patients either declined to attend or did not respond to 
invitations for a post TLM data recordings.  
 
Table 24: Baseline demographics for prospective TLM patients 
Characteristic
 
Treatment p-value
 
Pre- TLM 
(n=29) 
Post-TLM 
(N=17) 
Age 
Mean (SD) 61.7 (9.3) 60 (7.0) 
0.766
b
 
Median (IQR) 60.4 (56.2, 67.8) 59.2 (57.3, 62.0) 
Sex 
Male 26 (89.7%) 16 (94.1%) 
1.000
c
 
Female 3 (10.3%) 1 (5.9%) 
Smoking Status 
Never 4 (13.8%) 3 (17.6%) 
0.074
d
 Smoker 5 (17.2%) 7 (41.2%) 
Ex-smoker 20 (69.0%) 7 (41.2%) 
Alcohol history 
No alcohol 0 (0%) 0 (0%) 
0.694
d
 
Within recommended limits 
(<14 units) 
14 (48.3%) 8 (47%) 
Above recommended limits 
(14 units or above) 
7 (24.1%) 5 (29.4%) 
Unknown 8 (27.6%) 4 (23.5%) 
Comorbidities 
Reflux disease 17 (58.6%) 10 (58.8%) 0.989
d
 
Has asthma/COPD 2 (6.9%) 0 (0%) 0.524
c
 
Ischaemic heart disease 3 (10.3%) 1 (5.9%) 1.000
c
 
a. Mann Whitney U test adjusted for baseline characteristics 
b. Mann Whitney U test 
c. Fisher’s exact test 
d. Chi squared test 
 
A full dataset for all 29 patients has been included in Appendices 11 to 
14.There was no statistically significant difference in quality of life or voice 
outcomes between the 17 included patients and the 12 excluded patients 
(Appendix 15). 
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Figure 35: Study flow chart: outline of patient follow up 
 
 
 
4.3.2 Subjective voice questionnaires  
The complete data set for subjective voice questionnaires for pre- and post-
TLM patients can be found in Appendix 11.  
 
4.3.2.1 VHI-10 
There is no statistically significant difference in median scores for functional, 
physical and emotional outcomes pre and post TLM (Table 25).  
33 patients 
enrolled 
4 patients 
excluded 
2 patients staged 
T2 
2 patients for RT 
(including 1 for 
spindle cell 
carcinoma) 
29 patients met 
inclusion criteria 
and pre-TLM 
data recorded 
12 patient not 
followed up  
2 patients 
developed lung 
carcinoma 
1 patient had 
injection 
laryngoplasty 
9 patients declined follow 
up/not responded/moved 
out of area 
17 patients 
recorded at 12 
months post 
TLM 
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Table 25: Voice handicap index–10 pre and post TLM  
 
 
Domain (range) 
Pre-TLM (N=17) Post-TLM (N=17) 
p value 
a
 
Adjusted 
p value 
b
 
Mean SD Median IQR Mean SD Median IQR 
Functional (0 - 20) 6.4 4.2 5 3,9 6.8 5.1 6 2,11 0.708 0.687 
Physical (0 - 12) 6.1 2.6 6 4,7 4.6 3.5 5 2,7 0.480 0.413 
Emotional (0 - 8) 2.1 2.2 2 1, 2 2.0 2.3 1 0,3 0.497 0.498 
Total (0 - 40) 14.5 8.0 13 11, 18 13.4 10.5 12 5,20 0.842 0.843 
a. Wilcoxon test; b. Age-adjusted Wilcoxon test; IQR = interquartile range; SD=standard deviation 
 
4.3.2.2 VoiSS 
There is no statistically significant difference in median scores for impairment, 
emotional and physical in the pre- and post- TLM groups (Table 26).  
 
Table 26: VoiSS questionnaire for pre-TLM and TLM patients 
Domain (range) 
Pre-TLM (N=17) Post-TLM (N=17) 
p value 
a
 
Adjusted 
p value 
b
 
Mean SD Median IQR Mean SD Median IQR 
Impairment (0-60) 29.2 10.5 31.0 21.0,32.0 25.1 14.0 25.0 13.5,40.0 0.897 0.942 
Emotional (0-32) 4.9 5.0 4.0 3.0,5.0 5.7 6.3 2.5 0,11.3 0.594 0.770 
Physical (0-28) 7.2 3.2 7.0 6.0, 9.0 7.3 3.8 6.0 5.0,9.3 0.786 0.757 
Total (0-120) 41.3 15.5 43.0 
29.0 
,49.0 
38.1 21.7 32.5 19.5, 58.5 0.892 0.987 
a. Wilcoxon test; b. Age-adjusted Wilcoxon test; IQR = interquartile range; SD=standard deviation 
 
 
4.3.3 QoL questionnaire: UW-QoLv4 
Table 27 depicts the UW-QoLv4 results of the pre- and post-TLM patients. 
The full data set can be found in Appendix 12. The lowest mean scores in the 
pre-TLM group are anxiety (66.5), followed by speech (75.3) and mood (79.4). 
The post-TLM the mean anxiety, speech and mood scores have improved 
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(80.0, 85.9 and 83.8 respectively). There is no statistically significant 
difference in the UW-QOLv4 domain scores in patients pre- and post- TLM.  
 
Table 27: Summary table UW-QoLv4 domain scores for pre- and post-TLM patients 
 
Pre-TLM (N=17) Post-TLM (N=17) 
p value 
a
 
Adjusted 
p value 
b
 Mean SD Median IQR Mean SD Median IQR 
Pain 83.8 17.5 75 75, 100 95.6 13.2 100 75, 100 0.13 0.142 
Appearance 97.1 8.3 100 100, 100 97.1 12.1 100 100, 100 0.900 0.879 
Activity 95.6 13.2 100 100, 100 80.9 22.6 100 100, 100 0.238 0.163 
Recreation 89.7 15.5 100 75, 100 86.8 17.9 100 75, 100 0.893 0.721 
Swallowing 98.2 7.3 100 100, 100 94.7 11.8 100 100, 100 0.301 0.259 
Chewing 100.0 0.0 100 100, 100 97.1 12.1 100 100, 100 0.997 0.996 
Speech 75.3 25.8 70 70, 100 85.9 15.4 100 70, 100 0.078 0.042 
Shoulder 90.0 23.7 100 100, 100 82.4 31.9 100 100, 100 0.360 0.314 
Taste 98.2 7.3 100 100, 100 92.9 13.1 100 100, 100 0.805 0.365 
Saliva 95.9 17.0 100 100, 100 92.4 18.9 100 100, 100 0.507 0.30 
Mood 79.4 20.2 75 75, 100 83.8 24.9 100 75, 100 0.371 0.393 
Anxiety 66.5 20.0 70 70, 70 80.0 19.7 70 70, 100 0.146 0.237 
a. Wilcoxon test; b. Age-adjusted Wilcoxon test; IQR = interquartile range; SD=standard deviation 
 
The composite scores show that there is no statistically significant difference 
in physical (p=0.424) or social (p=0.755) function pre and post TLM (Table 
28).  
 
Table 28: UW-QoLv4 composite scores of physical and social function for pre- and 
post-TLM patients 
 
Pre-TLM (N=17) Post-TLM (N=17) 
p value 
a
 
Adjusted p 
value 
b
 
Mean SD Median IQR Mean SD Median IQR 
Physical 
function 
94.1 5.3 95.0 90,100 93.3 9.3 95.0 90.0,100 0.365 0.424 
Social 
function 
84.2 11.3 86.7 82.5,90.8 84.9 15.3 90.8 82.5,91.7 0.535 0.755 
a. Wilcoxon test; b. Age-adjusted Wilcoxon test; IQR = interquartile range; SD=standard deviation 
 
The composite scores are illustrated in box-plots for physical function and 
social function in Figure 36 and 37.  
 
158 
 
Figure 36: Box plot of physical function for pre- and post-TLM patients 
 
 
Figure 37: Box plot of social function for pre- and post-TLM patients 
 
 
The global questions of the UW-QoLv4 were only completed by a small 
number of patients in the pre-operative group. The sample size is too small to 
allow a direct comparison of pre- and post-TLM responses.  
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4.3.4 Perceptual rating 
The full data set is presented in Appendix 13. Voice was rated by one expert 
rater for all patients. The expert was unable to rate one pre-operative voice 
due to poor quality recording. This patient has been excluded from the 
GRBAS analysis.  
There is no statistically significant difference in mean score for ‘G’,’R’,’B’ and 
‘S’ indicators between pre and post TLM patients.  Asthenia was statistically 
significantly lower in post-TLM patients (0.97 vs. 0.94, p=0.018, adjusted 
p=0.015, Table 29).  
 
Table 29: Combined mean GRBAS scores for pre- and post-TLM patients 
 
Grade 
(0-3) 
Roughness (0-
3) 
Breathiness (0-
3) 
Asthenia 
(0-3) 
Strain 
(0-3) 
Total 
(0-15) 
Pre TLM (n=16) 1.82 1.41 1.28 0.97 1.17 6.66 
Post TLM (n=16) 1.81 1.38 1.31 0.94 1.00 6.44 
p value 
a
 0.648 0.416 0.058 0.018 0.345 0.572 
Adjusted p value 
b
 0.759 0.439 0.112 0.015 0.295 0.606 
a. Wilcoxon test; b. Age-adjusted Wilcoxon test 
 
 
4.3.5 Acoustic analysis  
4.3.5.1 Acoustic analysis on sustained vowels 
Analysis was undertaken on sustained /i/ and /a/ vowel sounds. The full data 
set is available in Appendix 14. Table 30 presents mean values, 95% 
confidence intervals and p values for acoustic analysis of sustained vowels 
(/a/ and /i/) for pre- and post- TLM patients. There is no statistically significant 
difference in the mean values for pre and post TLM in any of the indicators. 
This included either of the sustained vowels (/i/ or /a/).  
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There was acoustic data missing on five of the follow-up patients despite 
repeated attempts. In one patient it was not possible to gain an Lx waveform 
on pre or post TLM. This was due to the neck size and excess adipose tissue 
preventing good conduction between the electrodes. In the four patients with 
no acoustic data post TLM this was due to a technical error with the 
Laryngograph. It was not noted until after the recordings had been performed 
that the acoustic data had not been captured.  
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Table 30: Acoustic analysis of both sustained vowels for pre- and post-TLM patients 
 
Pre-TLM  /a/ (n=12) Pre-TLM  /i/ (n=12) Post-TLM /a/ (n=12) Post-TLM /i/ (n=12) P value
 a
 
Adjusted p 
value 
b
 
Mean SD Median IQR Mean SD Median IQR Mean SD Median IQR Mean SD Median IQR /a/ /i/ /a/ /i/ 
Minimum 
Fx (Hz) 
134.4 41.9 143.4 127.0, 156.7 140.7 43.8 149.6 131.9, 169.7 125.5 50.8 142.0 72.8, 159.4 146.0 59.9 151.9 113.7, 175.7 0.921 0.791 0.751 0.836 
Maximum 
Fx (Hz) 
244.1 221.6 168.7 155.7, 182.5 209.4 134.5 175.9 162.7, 192.0 314.2 340.9 188.0 172.6, 241.6 274.1 274.5 199.9 172.4, 227.6 0.042 0.617 0.054 0.602 
Average Fx 
(Hz) 
166.0 41.3 160.2 148.1, 168.4 167.7 26.8 167.1 150.5, 188.6 181.0 50.7 169.5 155.5, 185.9 195.5 65.2 174.9 161.8, 202.1 0.072 0.375 0.062 0.445 
S.D. Fx (%) 11.4 25.7 1.3 1.1, 2.5 6.2 12.3 1.4 1.1, 1.8 18.5 34.1 2.0 1.7, 11.4 12.4 25.1 1.7 1.2, 5.0 0.159 0.661 0.131 0.733 
Minimum 
Qx (%) 
25.1 13.5 30.8 20.8, 34.7 33.1 14.9 36.5 30.1, 40.7 20.5 14.6 23.7 10.7, 27.7 26.4 18.4 31.7 13.7, 35.5 0.170 0.276 0.269 0.348 
Maximum 
Qx (%) 
44.4 13.9 42.7 39.6, 45.0 50.6 11.8 46.6 42.9, 56.2 49.5 20.5 43.7 34.6, 57.5 50.7 17.8 45.4 37.2, 65.2 0.903 0.419 0.869 0.598 
Average Qx 
(%) 
34.8 6.3 36.7 32.6, 37.9 41.5 6.3 39.7 36.8, 44.2 34.8 8.0 35.8 31.4, 40.1 37.6 9.3 36.4 32.5, 41.5 0.334 0.121 0.500 0.213 
S.D. Qx (%) 3.7 4.6 1.9 1.4, 3.4 3.4 4.2 1.4 0.9, 3.7 7.2 9.7 2.6 1.5, 7.8 6.9 11.5 1.4 1.0, 4.4 0.508 0.280 0.520 0.754 
Jitter First 
(%) 
7.9 18.7 0.8 0.5, 2.8 5.5 11.6 0.8 0.5, 1.6 13.3 25.6 1.8 0.7, 9.4 14.7 29.9 1.9 0.9, 5.0 0.257 0.288 0.264 0.331 
Jitter 
Second (%) 
6.4 14.1 0.5 0.3, 1.7 3.5 7.7 0.4 0.3, 1.0 9.9 19.6 1.2 0.4, 5.1 8.7 17.6 1.2 0.5, 2.9 0.304 0.304 0.307 0.341 
Shimmer + 
(%) 
13.8 21.0 7.3 5.9, 11.9 7.2 6.7 4.2 3.3, 7.1 12.5 10.7 10.0 6.8, 12.5 7.9 8.7 6.1 3.0, 8.8 0.686 0.966 0.695 0.979 
Shimmer – 
(%) 
-13.3 17.5 -8.3 -12.9, -6.2 -8.4 7.5 -5.4 -9.8, -4.0 -12.7 10.5 -9.3 -13.8, -6.8 -7.6 8.0 -5.2 -7.4, -3.7 0.745 0.746 0.690 0.901 
Jitter 
Factor (%) 
9.9 21.8 0.8 0.5, 2.8 5.6 12.0 0.7 0.5, 1.6 16.2 32.3 1.8 0.7, 8.7 14.4 29.9 1.9 0.9, 4.5 0.328 0.288 0.336 0.322 
RAP (%) 4.8 11.8 0.5 0.3, 1.7 3.6 7.7 0.4 0.3, 1.0 7.5 13.4 1.2 0.4, 6.5 9.6 18.6 1.2 0.5, 3.9 0.297 0.251 0.308 0.299 
Shimmer 
dB (dB) 
1.3 2.3 0.7 0.5, 1.2 0.7 0.7 0.4 0.3, 0.7 1.2 1.1 0.9 0.6, 1.1 0.7 0.8 0.5 0.3, 0.8 0.745 0.837 0.762 0.826 
NNE (dB) -14.0 6.9 -16.2 -17.5, -12.4 -16.0 8.4 -19.0 -21.0, -10.6 -13.1 9.1 -16.7 -18.8, -5.5 -16.7 10.4 -19.9 -22.1, -11.9 0.973 0.744 0.849 0.804 
CPP 3.1 1.0 3.3 2.4, 3.7 2.8 1.5 2.5 2.1, 3.0 3.0 1.6 3.0 1.8, 3.7 2.7 1.6 2.4 1.8, 3.9 0.670 0.725 0.605 0.687 
HNR (dB) 12.7 10.1 15.2 13.6, 16.7 17.4 4.6 18.4 15.2, 20.9 12.5 6.7 14.3 9.5, 16.9 16.9 9.1 19.6 16.3, 21.8 0.408 0.674 0.320 0.707 
Mean SPL 
(dB) 
89.4 7.1 89.6 84.7, 95.6 87.1 4.4 87.7 83.9, 89.7 84.5 9.1 84.8 78.8, 91.7 82.6 10.5 82.4 77.6, 89.9 0.037 0.148 0.071 0.238 
a. Wilcoxon test; b. Age-adjusted Wilcoxon test; IQR = interquartile range; SD=standard deviation 
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4.3.5.2 Acoustic analysis of connected speech 
4.3.5.2.1 Frequency (Fx) 
The mean DFx is statistically significantly higher in the post TLM group 
(p=0.001, adjusted 0.001, Table 31). There is no statistically significant 
difference in the coherence (p=0.098, adjusted p=0.140) or irregularity 
(p=0.320, adjusted p=0.370) when comparing pre and post TLM.  
 
Table 31: Summary table of DFx1&2 connective speech for pre- and post-TLM patients 
 
Mean 
DFx1 (Hz) 
Mean 
DFx2 
(Hz) 
Coherence (%) CFx (%) 
Mean SD Median IQR Mean SD Median IQR 
Pre-TLM 
(n=12) 
154.4 150.3 41.0 14.9 42.6 32.6, 50.8 20.4 19.0 12.1 7.4, 23.5 
Post-TLM 
(n=12) 
197.3 185.1 28.8 24.5 22.1 11.3, 46.7 35.9 30.5 32.8 12.8, 49.6 
p value
a
 0.001 0.002 0.098 0.320 
Adjusted p 
value
b
 
0.001 0.004 0.140 0.370 
a. Wilcoxon test; b. Age-adjusted Wilcoxon test; IQR = interquartile range; SD=standard deviation; DFx=frequency; CFx=frequency 
irregularity 
 
An example of DFx1&2 on connected speech on a patient pre and post TLM 
is presented in figure 38.  
 
Figure 38: Example of DFx1&2 on connected speech in a pre and post TLM patient 
Pre TLM Post TLM 
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4.3.4.2.2 Amplitude (Ax) 
There is no statistically significant difference in the mean DAx (p=0.121), 
coherence (p=0.472) or irregularity of amplitude (p=0.184) when comparing 
pre and post TLM (Table 32).  
 
Table 32: Summary table of DAx1&2 connective speech for pre- and post-TLM patients 
 
Mean 
DAx1 (dB) 
Mean 
DAx2 
(dB) 
Coherence (%) CAx (%) 
Mean SD Median IQR Mean SD Median IQR 
Pre-TLM 
(n=12) 
84.9 86.1 48.7 15.8 47.9 39.5, 54.6 8.0 6.5 6.5 4.1, 9.6 
Post-TLM 
(n=12) 
79.8 80.7 42.5 22.8 45.0 24.8, 56.3 12.6 14.1 7.1 2.5, 14.8 
p value
a
 0.113 0.088 0.481 0.805 
Adjusted p 
value
b
 
0.195 0.165 0.479 0.905 
a. Wilcoxon test; b. Age-adjusted Wilcoxon test; IQR = interquartile range; SD=standard deviation; DAx=amplitude; CAx=amplitude 
irregularity 
 
An example of DAx1&2 on connected speech on a patient pre and post TLM 
is presented in figure 39.  
 
Figure 39: Example of DAx1&2 on connected speech in a pre and post TLM patient 
 
 
 
Pre TLM Post TLM 
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4.3.5.2.3 Contact quotient (Qx) 
There is no statistically significant difference in the mean DQx (p=0.654, 
adjusted p=0.904), coherence (p=0.231, adjusted p=0.293) or irregularity of 
the contact quotient (p=0.312, adjusted p=0.400) when comparing pre and 
post TLM (Table 33).  
 
Table 33: Summary table of DQx1&2 connective speech for pre- and post-TLM patients 
 
Mean 
DQx1 (%) 
Mean 
DQx2 (%) 
Coherence (%) CQx (%) 
Mean SD Median IQR Mean SD Median IQR 
Pre-TLM 
(n=12) 
38.3 38.5 25.3 8.6 28.7 20.1, 31.1 39.5 15.4 33.0 28.1, 46.0 
Post-TLM 
(n=12) 
39.9 38.5 19.9 14.9 17.1 10.5, 28.7 50.7 28.0 50.4 32.3, 64.4 
p value
a
 0.908 0.654 0.231 0.312 
Adjusted 
p value
b
 
0.678 0.904 0.293 0.400 
a. Wilcoxon test; b. Age-adjusted Wilcoxon test; IQR = interquartile range; SD=standard deviation; DQx=contact quotient; CQx=contact 
quotient irregularity 
 
An example of CQx on connected speech on a patient pre and post TLM is 
presented in figure 40.  
 
Figure 40: Example of CQx on connected speech in a pre and post TLM patient 
 
 
Pre TLM 
Post TLM 
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4.3.4.2.4 Combined acoustic parameters 
The combined parameters demonstrate amplitude (Ax) and frequency (Fx) 
distribution. There is no statistically significant difference in the combined 
parameters pre and post TLM (p=0.098, adjusted p=0.134, Table 34). 
 
Table 34: Summary table of AxFx1&2 connective speech for pre- and post-TLM patients 
 
AxFx1&2 
Mean SD Median IQR 
Pre-TLM 
(n=12) 
54.2 16.8 60.5 45.5, 65.3 
Post-TLM (n=12) 39.2 26.8 37.9 20.0, 60.5 
p value
a
 0.098 
Adjusted p value
b
 0.134 
a. Wilcoxon test; b. Age-adjusted Wilcoxon test; IQR = interquartile range; SD=standard deviation; 
DFx=frequency; CFx=frequency irregularity 
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5. Discussion 
There were three parts to this research: to describe acoustic parameters of 
‘normal’ voice; to compare voice outcomes in patients treated with TLM with 
those treated with radiotherapy for T1a SCC of the glottis; and to investigate 
longitudinal changes in voice quality in patients undergoing TLM for T1a SCC 
of the glottis. 
 
5.1 Acoustic parameters of a ‘normal’ voice 
The aim of the study of ‘normal’ voice was to develop a range of acoustic 
parameters for the ‘normal’ voice. Defining the acoustic parameters of ‘normal’ 
voice in a healthy group of subjects is an important initial part of this research. 
To date, there are no standardised values for the acoustic parameters of 
‘normal’ voice. This is due to the number of different potential variables 
(including age, sex, social history and environment) which influence voice 
characteristics. These variables and possible combinations make it difficult to 
define normal acoustic parameters. It also means that research groups have 
to be standardised to allow comparison. In addition to these variables, 
different software packages use slightly different methodology to calculate 
acoustic parameters and so published data cannot always be directly 
compared.  
In order to define the acoustic parameters of ‘normal’ voice, only subjects who 
scored zero on the standardised patient reported voice outcome 
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questionnaire, VHI-10, and on assessment of their voice recording using the 
GRBAS score were included.  
 
5.1.1 Acoustic analysis of sustained vowels in ‘normal’ subjects 
The electroglottographic (EGG) analysis of sustained vowels demonstrated 
the inherent variability of the subjectively ‘normal’ adult voice in males and 
females. The data confirms the variability between male and female voices as 
well as the influence of the different recorded vowel sounds used for the 
analysis. In terms of the fundamental frequency (Fx), the female subjects 
have a statistically significantly higher mean value for both vowel sounds 
recorded. Mean Fx is 218.7Hz for /a/ and 233.9Hz for /i/ in females and 
average Fx in males is 138.5Hz for /a/ and 148.5Hz for /i/.The difference in Fx 
between males and females is statistically significant, (adjusted p=0.001 for 
/a/, adjusted p=0.005 for /i/). This is consistent with the published literature on 
the subject, described in section 1.2.2, and is primarily due to the anatomical 
differences of the vocal cords between the sexes. The male vocal folds are 
thicker and larger compared to females. Izadi et al. 201 assessed 200 healthy 
adult voices (100 males and 100 females). The Fx was greater in females 
(170-240 Hz) compared to males (107-140Hz) and the difference was 
statistically significant (p<0.05). Studies of Fx of voice in ‘normal’ subjects 
comparing the sustained vowels /i/ and /a/ found that Fx of /i/ was higher than 
Fx of /a/, in line with the findings of this research.201-203  Robb et al. in a study 
of 30 adults (15 females and 15 males) found average Fx in females 220 Hz 
/a/ and 236 Hz /i/ compared to 124 Hz /a/ and 136Hz /i/ in males.203 This 
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higher mean Fx of /i/ is explained by the intrinsic higher pitch of vowel sound 
/i/ compared with the vowel /a/, which in turn is dictated by sex differences in 
laryngeal anatomy.  
Contact quotient (Qx) is a measurement of the vocal fold contact during the 
vocal fold cycle. The mean Qx in males is 44.4% /a/ and 46.2% /i/ compared 
to females 42.3% /a/ and 49.1% /i/. These values show that around 45% of 
the time the vocal folds are in contact for the period of the vocal fold cycle. No 
statistically significant difference in mean Qx between males and females is 
identified (p=0.573 /a/, p=0.725 /i/). The literature on the difference in contact 
quotient between males and females is mixed, with some studies suggesting 
that males have a higher contact quotient and others stating there is no 
difference.  Awan et al. 204 assessed difference in contact quotient between 25 
males and 25 females with ‘normal’ voice.  The authors found a statistically 
significantly higher mean Qx using EGG in males than females (0.44% vs 
0.37%), although p values were not presented, i.e. males have a longer vocal 
fold contact time. Faria et al. 205 assessed contact quotient in 20 male and 20 
female Portuguese-speakers without voice-related complaints. The authors 
found no statistically significant difference in Qx, or contact time, between 
males and females (0.447vs. 0.443, p=0.835).  
Jitter is a measurement of variation of the frequency from one vocal fold cycle 
to another. The mean jitter factor is 0.8% and 0.7% for males for /a/ and /i/ 
respectively, and 0.8% and 0.9% for females for /a/ and /i/ respectively. There 
is no statistically significant difference in jitter factor for /a/ between males and 
females, however there is a statistically significant difference in /i/ (p=0.032), 
although this difference is no longer statistically significant once adjusted for 
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age (p=0.063). The literature on the difference in jitter between males and 
females is mixed, with some studies suggesting that males have a higher jitter 
and others stating there is no difference.  Felippe et al. in a study of 40 
‘normal’ voices (20 males and 20 females) reported no statistically significant 
difference in average jitter for /a/ between females and males (0.6% vs. 0.5% 
respectively), although no p values were presented.206  Faria et al. assessed 
jitter in 20 male and 20 female Portuguese-speakers without voice-related 
complaints.205 The authors also found no statistically significant difference in 
jitter factor between males and females (1.34% vs. 1.60%, p=0.285). Orlikoff 
173 compared 10 ‘normal’ males and 10 females. The mean jitter was 
calculated as an average of eight different sustained vowels. Mean EGG jitter 
was statistically significantly higher in males compared with females (0.046ms 
vs. 0.037ms, p=<0.0001).  
The RAP (relative average perturbation) provides an average of the jitter 
across three vocal fold cycles. RAP is 0.4% and 0.4% for males for /a/ and /i/ 
respectively, and 0.5% and 0.6% for females for /a/ and /i/ respectively. There 
is no statistically significant difference in RAP for /a/ or /i/ between males and 
females (adjusted p=0.550 for /a/, adjusted p=0.127 for /i/). There is limited 
evidence base surrounding differences in RAP between sexes. Faria et al. 
assessed RAP in 20 male and 20 female Portuguese-speakers without voice-
related complaints.205 The authors found no statistically significant difference 
in RAP between males and females (0.1 vs. 0.1, p=0.05). 
Shimmer is the variation in amplitude from one vocal fold cycle to another. 
Mean shimmer dB is 0.4dB and 0.3dB for males for /a/ and /i/ respectively, 
and 0.4dB and 0.3dB for females for /a/ and /i/ respectively. There is no 
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statistically significant difference in mean shimmer dB for /i/ between males 
and females, however there is a statistically significant difference in /a/ 
(p=0.037), although this difference is no longer statistically significant once 
adjusted for age (p=0.051). The mean shimmer dB is less than 0.5 in both 
sexes and vowels, which is similar to other published studies report the mean 
shimmer of ‘normal’ voice. Felippe et al. reported an average  shimmer of 
0.23dB for /a/ in males and 0.22dB females. 206 There was no statistically 
significant difference between the males and females, although no p values 
were presented. Orlikoff compared 10 ‘normal’ males and 10 females. 173 The 
mean shimmer was calculated as an average of eight different sustained 
vowels. There was no statistically significant difference in mean shimmer 
using EGG recordings between males and females (0.34dB vs. 0.27dB 
respectively, p=0.47).  
NNE, normalized noise energy, measures turbulent noise caused by 
insufficient glottic closure during phonation. NNE is -18.9dB and -22.3dB for 
males for /a/ and /i/ respectively, and -23.7dB and -20.6dB for females for /a/ 
and /i/ respectively. There is no statistically significant difference in NNE for /i/ 
between males and females, however there is a statistically significant 
difference in /a/ (p=0.041), although this difference is no longer statistically 
significant once adjusted for age (p=0.069). I was unable to find any English 
language papers but two studies, one in Spanish and one in Chinese, found 
statistically significant differences in NNE across the sexes207,208. 
CPP, cepstral peak prominence, is a measure of the degree of harmony within 
a voice and predicts breathiness of voice. CPP is 4.3 and 3.6 for males for /a/ 
and /i/ respectively, and 5.7 and 4.4 for females for /a/ and /i/ respectively. 
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There is no statistically significant difference in CPP for /i/ between males and 
females, however there is a statistically significant difference in /a/ (p=0.041), 
although this difference is no longer statistically significant once adjusted for 
age (p=0.069). These values are similar to values presented in study of 780 
‘normal’ voice samples conducted by Shrivastav, where mean CPP was found 
to be 4.8.178 This study did not differentiate CPP by sex.  
HNR, harmonics to noise ratio, is an objective measure of hoarseness. HNR 
is 16.6dB and 19.5dB for males for /a/ and /i/ respectively, and 19.3dB and 
19.0dB for females for /a/ and /i/ respectively. There is no statistically 
significant difference in HNR for /a/ or /i/ between males and females 
(adjusted p=0.137 for /a/, adjusted p=0.851 for /i/). There is limited evidence 
base surrounding differences in HNR between sexes. In a study of Turkish 
speakers (44 women and 39 men) there was no gender effect in HNR, 
p=0.097 for /i/ and p=0.280 for /a/ .209   
SPL, sound pressure level, is the local pressure deviation from the average 
atmospheric pressure caused by a sound wave. Mean SPL is 87.5dB and 
85.0dB for males for /a/ and /i/ respectively, and 91.1dB and 87.4dB for 
females for /a/ and /i/ respectively. There is no statistically significant 
difference in SPL for /a/ or /i/ between males and females (adjusted p=0.551 
for /a/, adjusted p=0.845 for /i/). There is limited evidence base surrounding 
differences in SPL between sexes. Wang et al. assessed voice in 45 
Taiwanese females and 45 Taiwanese males. 210 There is no statistically 
significant difference in mean SPL between males and females (77.5dB 
vs.77.8dB), although no p value was provided.  
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In summary, frequency was statistically significantly different between males 
and females, resulting in females having a subjectively higher pitched voices. 
All other parameters were not statistically significantly different, when adjusted 
for age. There is variation in the literature relating to these other parameters. 
Our data adds to the current evidence base.  
 
5.1.2 Acoustic analysis of connected speech in ‘normal’ subjects 
The analysis of connected speech in the ‘normal’ subjects also demonstrated 
an increase in Fx in females. Mean Fx is statistically significantly higher in 
females than males (218.3Hz and 210.5Hz in females vs. 134.7Hz and 
136.5Hz in men, p=<0.001). As described above, females are known to have 
higher voice frequency than males, primarily due to the anatomical differences 
of the vocal cords between the sexes. The distribution of frequency was also 
calculated, known as DFx1 and a second order distribution, DFx2, was based 
on successive pairs of vocal fold cycles. Irregularity is calculated by 
measuring the difference between DFx1 and DFx2. In contrast, coherence is 
calculated by measuring the similarity between DFx1 and DFx2.  
Coherence of frequency is statistically significantly lower in females than in 
males (54.3% and 73.5% respectively, p=0.004) and this is still statistically 
significant when adjusting for age (p=0.036). There is a statistically 
significantly higher pitch irregularity in females compared with males (11.4% 
and 3.1% respectively, p=0.038), although this difference is not statistically 
significant when adjusting for age (p=0.094). These values are similar to those 
presented in the published literature from other patients with ‘normal’ voices. 
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Kazi et al. used a control group of 31 ‘normal’ subjects when comparing 
speech outcomes from laryngectomy patients.211 In the ‘normal’ group the 
CFx irregularity was 11.5% in males and 7.7% in females, although no p 
values were presented. In contrast to data presented in this thesis, Moon et al.  
performed acoustic analysis on 202 healthy volunteers, 87 males and 115 
females.212 The subjects were native Korean speakers aged 20 to 69 years of 
age. The mean CFx was 29.32% (+/- SD 16.39) in males and 23.83 (+/- SD 
17.64) in females and this difference was statistically significant (p<0.05).    
Amplitude (Ax) is an indication of loudness of voice. There is no statistically 
significant difference between mean amplitude (p=0.149), coherence 
(p=0.193) or loudness irregularity (p=0.290) between males and females. 
There was no statistically significant difference when adjusting for age in 
mean amplitude (p=0.308), coherence (p=0.402) or loudness irregularity 
(p=0.867). In contrast to my results, Moon et al. assessed voice in 202 healthy 
Korean speakers. The authors found the mean CAx to be higher in men and 
this was statistically significant (p<0.05).212 In patients aged 30 to 49, the CAx 
was 10.5% in males and 9.1% females, and for those aged 50 to 69, the CAx 
was 10.9% in males and 6.5% for females. This study illustrates the 
differences in CAx by age, and hence why it is was important to adjust for it in 
the analysis.  
Contact quotient (Qx) is the degree of contact between vocal folds during the 
vocal fold cycle. A breathy voice leads to a decrease in the Qx value whereas 
a pressed voice causes the Qx values above ‘normal’. There is no statistically 
significant difference in mean Qx for males and females (adjusted p=0.060). 
Coherence is statistically significantly higher in males (47.9% and 22.8% 
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respectively, p=<0.001), and this statistically significant remains when 
adjusting for age (p=<0.001). Contact irregularity is statistically significantly 
lower in males (13.3% and 45.0% respectively, p=<0.001), and this 
statistically significant remains when adjusting for age (p=<0.001).  As 
described above in the section on sustained vowels there have been reported 
gender differences in the Qx. Awan et al. 204 found a greater mean contact 
quotient in men compared to women in 50 ‘normal’ subjects. The authors 
found a statistically significantly higher mean Qx in males than females 
(0.44% vs 0.37%), although p values were not presented. I could not find any 
published evidence to support a gender difference in irregularity or coherence.  
In summary, fundamental frequency is statistically significantly different 
between males and females, with females having a perceived higher pitch of 
voice. This corresponded with the published data. Amplitude and CQx were 
not statistically significantly different, when adjusted for age. There is variation 
in the literature on these other parameters and this data adds to the current 
evidence base. There is limited published data on coherence and irregularity 
of the laryngograph waveform (Lx) on ‘normal’ voice. 
 
5.1.3 Study limitations 
An inevitable criticism of the ‘normal’ voice dataset is the size of the cohort. 
There are only 20 subjects and therefore, taking into account the high number 
of variables discussed above, such a small cohort will not be fully 
representative of the adult population, as a whole. Despite these limitations 
the acoustic analysis data on ‘normal’ subjects does provide a large number 
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of parameters for each subject for both sustained vowels and connective 
speech.  
 
5.1.3.1 Differences between groups 
Although it is possible to compare this ‘normal’ cohort of participants with 
patients with T1a carcinoma of the larynx included in the other two studies, 
there are differences in these populations which make the comparison less 
robust. The age, gender, smoking history and comorbidities are substantially 
different between these groups of individuals. Ideally, in order to compare with 
the T1a patients, the ‘normal’ cohort would be matched by these factors. 
Another possibility would be to account for these variables in the statistical 
analyses. However, given the small number of patients and the large number 
of variables, it was only possible to adjust for age.  
As the data were assumed to be non-parametric, the adjustment required was 
a proportional odds ordinal logistic model. Due to the small sample size, it was 
not possible to adjust for any other variable. In particular, there were only five 
females in this study, and so it was not possible to adjust for sex.  
 
5.1.3.2 Statistical concerns 
As this study is exploratory in nature, no primary outcome was identified and 
no sample size calculation was undertaken. A large number of statistical tests 
have been performed on the data, and this leads to a risk of statistical error, in 
176 
 
particular a type II error or having a false negative result. Therefore it is 
important to read the results of the statistical analysis with some caution.  
 
5.2 Voice outcomes in patients treated with TLM with those 
treated with RT for T1a SCC of the glottis 
The voice of 20 patients who had TLM were compared to 19 patients who had 
RT for T1a of the larynx. All patients recruited were at least one year post 
treatment. When comparing demographic data of the TLM group compared 
with the RT group, the TLM group are statistically significantly younger (mean 
age 62yrs vs. 71yrs, p=0.049 in the TLM and RT groups respectively); there is 
a higher proportion of males in the TLM group (100% vs 73.7%, p=0.020); and 
there is a statistically significantly higher proportion of smokers and ex-
smokers in the TLM group (57.9% vs. 85.0%, p=0.013). There is a statistically 
significantly higher proportion of patients with asthma and COPD in the RT 
group compared with the TLM group (15.8% vs. 5.0%, p=0.044). There is no 
statistically significant difference in the number of patients with reflux disease 
or ischaemic heart disease.  
 
5.2.1 Self-reported questionnaire TLM and RT 
There is no statistically significant difference between median scores in VHI-
10 for RT or TLM groups (4 vs. 6 respectively p=0.809, adjusted p=0.614). 
The maximum score for the VHI-10 questionnaire is 40, with the highest score 
for patients with perceived poor voice. As the median scores are only 4 and 6 
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for the two groups, both groups of patients report good outcomes in the 
questionnaire.  
Several studies have been published which used both the full VHI and the 
VHI-10 to assess voice outcomes in early glottic carcinoma treated with 
different modalities. There is no consistency in outcome between the studies 
with most finding no statistically significant difference in VHI between patients 
undergoing TLM and RT, although there are studies which found a statistically 
significantly worse outcome for patients undergoing both TLM and RT. Cohen 
et al. performed a systematic review and meta-analysis in 2006 to compare 
VHI scores in patients with T1a carcinomas undergoing TLM and RT.93  Six 
studies were included, which involved 208 TLM and 91 RT patients. There 
was no statistically significant difference in VHI score for TLM or RT patients 
(12.9 95% CI 10.4, 15.4 vs. 18.5 95% CI 15.1 to 22.0 respectively, p=0.2). 
One study included in the meta-analysis provided data on the post-operative 
scores post TLM depending on the type of cordectomy. There was no 
statistically significant difference between VHI scores in patients who had a 
type I or II cordectomy compared patients who had a type III cordectomy (6.2 
vs. 16.5, p=0.15). A more recent meta-analysis by Du et al, assessed VHI 
scores for TLM and RT for T1a carcinoma in five studies (n=125 RT, n=160 
TLM).213 Only two of the papers included in Du’s meta-analysis were also 
included in the study by Cohen. The included studies were homogenous 
(I2=0%, p=0.41). Du found no statistically significant difference in VHI between 
TLM and RT (mean difference -2.19, 95% CI -5.75 to 1.37, p=0.23).  Kerr et 
al. assessed voice outcomes in 83 patients post TLM and 49 patients post RT 
treated for early glottic carcinomas in three centres in Canada using the VHI-
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10 questionnaire, and was not included in either meta-analysis.214 The range 
of median VHI-10 scores at three time intervals over a 12 month post 
treatment period were 9.5-12.0 in the TLM patients and 3.5-8.0 in the RT 
patients. The scores were worse in the TLM group, although these values 
were only statistically significant at some time intervals (p=0.01-0.08). 
However this study also included T1b and T2 glottic tumours which are likely 
to have worse voice outcomes.  
Greulich et al performed a meta-analysis on voice outcomes comparing RT 
and TLM for T1 glottic carcinoma in 2015.215 In total eight retrospective cohort 
studies were included and described the outcomes of 362 patients. Six 
studies showed no difference in the VHI between treatment arms and two 
studies that favoured RT over surgery. However the meta-analysis revealed 
no significant difference in post treatment VHI between RT and TLM (mean 
difference, -5.52; 95% confidence interval, -11.40, 0.36; heterogeneity I (2) = 
61%, P = .01).215    
The total median VoiSS score for the RT group is 17 compared with 18 in the 
TLM group.  There is no statistical difference between the two groups with 
regards to VoiSS scores (adjusted p=0.255). The maximum score for the 
VoiSS questionnaire is 120, with the highest score for patients with perceived 
poor voice. As the median scores are only 17 and 18 for the two groups, both 
groups of patients report good outcomes in the questionnaire. Two studies 
have been published which used both the VoiSS questionnaire to assess 
voice outcomes in early glottic carcinoma treated with different modalities. 
Robertson et al. assesses voice outcomes in 43 patients post TLM and 26 
patients post RT treated for T1 carcinoma of the larynx using VoiSS 
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questionnaire216 . They did not identify a difference in median VoiSS scores 
between TLM and RT groups (20.5, range 2-62 vs. 15.0, range 0-93 
respectively, p=0.331). This study includes both T1a and T1b tumours and 
has not provided analysis by sub-type. Therefore VoiSS outcomes may be 
worse than results produced by this research. Loughran et al.  assessed voice 
outcomes in 23 patients post TLM and 30 patients post RT treated for T1a 
carcinoma of the larynx using VoiSS questionnaire 106. The authors found no 
statistically significant difference in mean VoiSS score between the TLM and 
the RT groups (27.5 vs. 20.4 respectively, p=0.35).   
The quality of life questionnaire (UW-QoL version 4) demonstrated a 
statistically significantly higher score in the TLM compared with the RT group 
for appearance (p=0.003), recreation (p=0.048), chewing (p=0.015) and saliva 
(p=0.016), however these are not statistically significant when adjusted for 
age.  The radiotherapy group have a statistically significantly lower median 
score compared to TLM in physical function (p=0.004) and this remains 
statistically significant when adjusted for age (p=0.036). There is no 
statistically significant difference for social function (p=0.441) 
This may correspond with a greater number of co-morbidities in RT cohort, 
although it is not possible to say what the cause for the poorer quality of life 
rating in the RT compared with the TLM group. There is likely to be selection 
bias when deciding which treatment a patient should have, as patients with 
more co-morbidities may not be suitable for general anaesthetic and therefore 
require RT rather than TLM. As described previously, this was part of the 
difficulty with the EaStER trial in randomisation patients into treatment groups, 
as only fitter patients received TLM.  One study was identified which assesses 
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quality of life in patients treated with TLM or RT for early glottic cancer. 
Robertson et al. assesses quality of life in 43 TLM patients and 26 RT patients 
treated for T1 carcinoma of the larynx using UW-QoL v4 questionnaire .The 
UW-QoL median score was 100 for both TLM and RT groups, p=0.586.216. 
These results are similar to those seen in this study. 
In summary, I found no statistically significant difference in VHI-10, VoiSS or 
UW-QoLv4 scores when comparing TLM and RT. There is variation in the 
published data, and this study adds to the evidence base.  
 
5.2.2 Perceptual rating of voice comparing TLM and radiotherapy 
Perceptual rating of voice was undertaken using GRBAS voice ratings. The 
mean for each GRBAS indicator is similar for the RT and TLM groups except 
for roughness where the mean GRBAS score is statistically significantly 
higher for RT compared with TLM group (1.46 vs. 0.85, p=0.004, adjusted 
p=0.001). There is no statistically significant difference between the combined 
mean for the RT and TLM groups, 5.49 [95% CI 3.95, 7.04] vs. 5.12 [95% CI 
3.79, 6.44], p=0.254, adjusted p=0.254. These results are similar to previous 
studies. Loughran et al. assessed voice outcomes using GRBAS in 18 
patients in both TLM and RT treatment groups. This study demonstrated 
higher GRBAS scores in the TLM group compared to the RT group although 
this was not statistically significant (p=0.287) 106.  Vilaseca et al. has shown 
that with a more extensive resection of the tumour with TLM the voice 
outcomes are worse108. In this study, 42 patients were treated for T1 glottic 
carcinoma with TLM. The extent of the TLM resection varied from type I to V 
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cordectomy. In the 16 patients with extended cordectomy (types IV and V) 
there was a statistically significantly higher score in all GRBAS domains 
compared with type I-III cordectomy, with breathiness having the highest 
mean score across the domains.  Mendelsohn et al. assessed GRBAS scores 
in 11 patients with T1 or T2 glottic carcinoma treated with TLM.111 The authors 
demonstrated a more breathy voice in the period immediately following TLM 
(up to four months post-operatively) compared with pre-operatively (mean ‘B’ 
2.50 vs. 0.75 respectively, p=0.003). However, the delayed post-operative 
rating of voice, after six month, improved and was statistically significantly 
higher than the result from up to four months post-operative (mean ‘B’ 1.17 vs. 
2.50, p=0.005) The reason for the improvement in breathiness with time post-
TLM is due to the healing of the resected tissue with fibrosis which fills in the 
defect and improves vocal fold contact. Kono et al. 217 compared voice 
outcomes of 27 RT patients with 37 TLM patients at 12 months post 
treatment. There GRBAS scores of roughness, asthenia and strain were 
similar in both groups. However the grade (0.9 for RT vs 1.28 for TLM 
p=0.049) and breathiness (0.61 for RT vs 0.7 for TLM, p=0.31) were worse in 
the TLM group.  
In summary, this study showed no statistically significant difference in the 
perceptual rating of voice between TLM and RT, except for roughness where 
the mean score is statistically significantly higher for RT compared with TLM 
group. Published data shows a more breathy voice with an extended 
cordectomy. This study is generally limited to type I to III cordectomy, which 
may account for better voice outcomes. Published data also often includes 
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T1b and T2 tumours, which this study excludes, and may further account for 
the better voice outcomes demonstrated by the presented data.  
5.2.3 Acoustic analysis comparing TLM and radiotherapy 
5.2.3.1 Acoustic analysis of sustained vowels in TLM and RT  
Average Fx is 171.6Hz and 164.2Hz for RT for /a/ and /i/ respectively, and 
165.8Hz and 186.0Hz for TLM for /a/ and /i/ respectively. There is no 
statistically significant difference in /i/ between RT and TLM, however there is 
a statistically significant difference in /a/ when adjusted for age (p=0.052, 
adjusted p=0.048). There is a significant difference in the baseline 
characteristics of the two groups with respect to gender (RT 26% females and 
TLM 0% females, p=0.020). This may account for the difference in the Fx 
between the groups. Compared to the control males the average Fx is higher 
in both of these groups. This is particularly relevant in the TLM group where 
all patients are men (average Fx 171.6Hz and 164.2Hz for /a/ and /i/ 
respectively for TLM and   average Fx 138.5Hz and 148.5Hz for /a/ and /i/ 
respectively for ‘normal’ males). This increase in Fx for patients post treatment 
for TLM and RT is in line with current literature on the subject. The theories on 
the increase in Fx in patients post TLM is the scarring (fibrosis) following the 
TLM which raises the tension of the vocal folds. Du et al. undertook a meta-
analysis assessing Fx in sustained vowels for TLM and RT for T1a carcinoma 
in four studies (n=69 RT, n=114 TLM).213 The included studies were 
homogenous (I2=0%, p=0.85). Du et al. found that frequency was statistically 
significantly higher in post TLM patients, compared with RT (mean difference -
11.00, 95% CI -12.60 to -9.40, p<0.0001). Two other studies were not 
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included in the meta-analysis. Vilaseca et al. analysed 42 patients post TLM 
including 35 T1a carcinomas 108. Compared to a control group the post TLM 
patients had an increase in Fx. The Fx for TLM in type I-III cordectomies were 
statistically significantly higher than the control group, 168.2+/-35.7Hz for /a/ 
and 165.5+/-43.5Hz for /i/ in the TLM group, compared to 119.7+/-19.8Hz for 
/a/ and 127.4+/-36.7Hz for /i/ in the control group (p=<0.001). Rovirosa et al. 
assessed voice outcomes in 18 patients that underwent RT for the treatment 
of T1 carcinoma of the larynx compared with 31 ‘normal’ subjects.218 In 
contrast to the other published papers, this study identified an increase in 
mean Fx in the RT group (149.7Hz in control group vs. 182.4Hz in RT group, 
p=0.034).  
Contact quotient (Qx) is a measurement of the vocal fold contact during the 
vocal fold cycle. Average Qx is 44.0% and 45.0% for RT for /a/ and /i/ 
respectively, and 44.5% and 45.3% for TLM for /a/ and /i/ respectively. There 
is no statistically significant difference in /a/ or /i/ between RT and TLM. I was 
unable to find any published studies including contact quotient in patients post 
TLM or RT on sustained vowels.  
Jitter is a measurement of variation of the frequency from one vocal fold cycle 
to another. Jitter factor is 11.6% and 10.1% for RT for /a/ and /i/ respectively, 
and 4.8% and 5.7% for TLM for /a/ and /i/ respectively. There is no statistically 
significant difference in /a/ or /i/ between RT and TLM groups. Both figures are 
substantially higher than jitter factor in ‘normal’ males (0.8% and 0.7% for /a/ 
and /i/). Other published studies have found a higher jitter post RT and TLM. 
Rovirosa et al. 218 assessed the voice of 18 patients post-RT for T1 laryngeal 
carcinoma to 31 ‘normal’ subjects. In sustained vowel analysis they found the 
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jitter was statistically significantly higher in those patients that were post RT 
(RT 3.5% vs. ‘normal’ 1.5%, p=0.0001). Du et al. undertook a meta-analysis 
assessing jitter in sustained vowels for TLM and RT for T1a carcinoma in 
three studies (n=54 RT, n=60 TLM).213 The included studies were 
homogenous (I2=0%, p=0.80). Du found that there was no statistically 
significant difference in jitter post-TLM compared with post RT (mean 
difference -0.03, 95% CI -0.30 to 0.23, p=0.8). One additional study, not 
included in the meta-analysis assessed voice in 15 patients post RT and 18 
patients post TLM for mid-cord glottic T1a carcinomas94. The authors found 
no statistically significant difference in jitter between RT and TLM groups 
(1.00% vs. 0.45%, p=0.06).  
The RAP (relative average perturbation) provides an average of the jitter 
across three vocal fold cycles. RAP is 5.5% and 4.2% for RT for /a/ and /i/ 
respectively, and 1.5% and 4.1% for TLM for /a/ and /i/ respectively. There is 
no statistically significant difference in /a/ or /i/ between RT and TLM. The 
RAP is substantially higher for both RT and TLM compared with values for 
‘normal’ voice. I was unable to find any published studies including RAP in 
patients post TLM or RT. Niedzielska et al. assessed voice outcomes in 45 
men with T1 (n=24) and T2 (n=21) glottic carcinomas post RT.219 Mean RAP 
was statistically significantly lower after treatment (5.33% before vs. 1.47% 
after, p<0.001). RAP was statistically significantly higher post treatment 
compared with the control (1.47% before vs. 0.61% after, p<0.05).  
Shimmer is variation in amplitude from one vocal fold cycle to another. Mean 
shimmer dB is 1.1dB and 0.6dB for RT for /a/ and /i/ respectively, and 0.7dB 
and 0.4dB for TLM for /a/ and /i/ respectively. There is no statistically 
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significant difference in /a/ or /i/ between RT and TLM. These values are 
similar to those presented for ‘normal’ voice. The literature on shimmer post 
RT or TLM is mixed. Rovirosa et al. 218 assessed the voice of 18 patients post-
RT for T1 laryngeal carcinoma to 31 ‘normal’ subjects. In sustained vowel 
analysis they found a statistically significantly higher shimmer in those 
patients that were post RT compared with the ‘normal’ subjects (RT 2.26% vs. 
‘normal’ 1.24%, p= 0.024). Du et al. undertook a meta-analysis assessing 
shimmer in sustained vowels for TLM and RT for T1a carcinoma in three 
studies (n=54 RT, n=48 TLM).213 The included studies were homogenous 
(I2=16%, p=0.30). Du found that there was no statistically significant difference 
in shimmer post-TLM compared with post RT (mean difference 0.19, 95% CI -
0.04 to 0.43, p=1).   
NNE, normalized noise energy, measures turbulent noise caused by 
insufficient glottic closure during phonation. Mean NNE is -12.8dB and -
15.7dB for RT for /a/ and /i/ respectively, and -18.2dB and -18.1dB for TLM for 
/a/ and /i/ respectively. There is no statistically significant difference in /a/ or /i/ 
between RT and TLM. Kazi et al. assessed voice outcomes on 17 T1 and 
seven T2 patients, post RT compared with 25 ‘normal’ subjects.220 There was 
no statistically significant difference in NNE post RT compared with ‘normal’ 
subjects (-14.9dB vs. -19.7dB respectively, p=0.09). 
CPP, cepstral peak prominence, is a measure of the degree of harmony within 
a voice and predicts breathiness of voice. Mean CPP is 3.4 and 3.1 for RT for 
/a/ and /i/ respectively, and 4.4 and 3.4 for TLM for /a/ and /i/ respectively. 
There is no statistically significant difference in /a/ or /i/ between RT and TLM. 
The mean CPP in the ‘normal’ subjects is 4.3 for /a/ and 3.6 for /i/ in the 
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males. The CPP appears to be similar for ‘normal’ subjects compared with 
post treatment patients. Stone et al. assessed voice outcomes in 14 patients 
treated with TLM for early glottic carcinoma.221 The voice recordings were 
taken post TLM and mean time following surgery was 3.7 years. The mean 
CPP for sustained vowel /a/ was 5.9 (SD 2.8). There were no studies that 
compared CPP post TLM and RT.  
 
HNR, harmonics to noise ratio, is an objective measure of hoarseness. Mean 
HNR is 14.5dB and 16.2dB for RT for /a/ and /i/ respectively, and 16.6dB and 
18.2dB for TLM for /a/ and /i/ respectively. There is no statistically significant 
difference in /i/ between RT and TLM. There is a statistically significant 
difference between /a/ (p=0.041). Rovirosa et al. 218 assessed the voice of 18 
patients post-RT for T1 laryngeal carcinoma to 31 ‘normal’ subjects. In 
sustained vowel analysis they found no statistically significant difference in 
HNR in those patients that were post RT compared with the ‘normal’ subjects 
(RT 4.21 vs. ‘normal’ 3.63, p=0.520). Tamura et al. assessed voice in 22 
patients post TLM and eight patients post RT. There was no statistically 
significant difference in HNR between TLM and RT groups (15.8% vs. 15.2%, 
p=0.58). 110 
SPL, sound pressure level, is the local pressure deviation from the average 
atmospheric pressure caused by a sound wave. Mean SPL is 89.0dB and 
88.2dB for RT for /a/ and /i/ respectively, and 90.5dB and 88.5dB for TLM for 
/a/ and /i/ respectively. There is no statistically significant difference in /a/ or /i/ 
between RT and TLM. Jotic et al. assessed voice outcomes in 69 patients 
treated for Tis and T1 glottic carcinoma with TLM (n=19), RT (n=15) and 
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laryngofissure (n=35). Analysis was conducted using phonetogram, different 
to EGG used in this study. The SPL at six to 12 months following treatment 
was 30.1dB for TLM and 29.4dB for RT (p<0.05).    
In summary the acoustic analysis on sustained vowels demonstrated a 
statistically significant difference in average Fx for /a/ when adjusted for age. 
The average Fx for RT and TLM is higher compared to the Fx in the control 
group. The literature does suggest that an increase in Fx post TLM and RT is 
expected. The HNR is statistically significantly higher in TLM compared with 
RT for /a/. Published literature found no statistically significant difference in 
HNR between the groups and so this result adds to the limited evidence base. 
The other values from in MDVP (Multi-Dimensional Voice Programme) show 
no statistically significant difference between RT and TLM. This demonstrates 
that there are similar objective voice outcomes from either treatment.  
 
5.2.3.2 Acoustic analysis of connected speech in TLM and RT 
In the acoustic analysis on the connective speech, the mean Fx is also higher 
in the TLM group compared to RT, 161.2Hz and 164.4Hz compared to 
131.1Hz and 137Hz (p=0.044, p=0.009) in the RT group. This difference 
remains statistically significant when adjusted for age (p=0.001). This concurs 
with the discussion on the Fx in the sustained vowels and the expected 
elevation of Fx post treatment due to scarring of the vocal folds. Coherence of 
frequency is statistically significantly higher in the TLM group compared with 
the RT group (48.6% vs. 36.0%, p=0.028, adjusted p=0.027).  Pitch 
irregularity is statistically significantly higher in the RT group than the TLM 
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group (26.7% vs. 14.9%, p=0.004, adjusted p=0.013).  Therefore the RT voice 
is deeper and more irregular than the post TLM voice.  
 
There are very few studies in the literature that have used EGG and 
connected speech analysis to assess this group of patients. Kazi et al. 
compared the voice of 25 T1 and T2 glottic carcinoma patients who had RT 
compared to a ‘normal’ cohort (n=25).220 The CFx was statistically significantly 
worse (11.3% vs 36.7%, p=0.001) in the RT group at 12 months post 
treatment compared to the control. The study did not conduct any analysis to 
account for difference in tumour size, and did not present results for T1 
compared with T2 tumours.  
There is no statistically significant difference in mean amplitude between the 
two groups. Coherence is statistically significantly higher in the TLM group 
compared with the RT group when adjusted for age (p=0.076, adjusted 
p=0.006). CAx is statistically significantly higher in the RT group, (12.4% vs. 
6.3%, p=0.005, adjusted p=0.005). I was unable to find any published 
literature considering amplitude in connected speech comparing TLM and RT.  
 
There is no statistically significant difference in mean contact quotient 
(p=0.368), coherence (p=0.236) or irregularity (p=0.125) between the TLM 
and RT. The mean CQx is 43.7% and 34.5% for RT and TLM respectively and 
this is higher than the mean CQx in ‘normal’ males (12.9%). This increase in 
CQx has previously been described by Fourcin, who suggests that dysphonic 
patients with a breathy voice have a higher irregularity of contact quotient.188  
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In summary there is a higher Fx in connected speech in TLM and RT 
compared to the control. The TLM Fx is also statistically significantly higher 
than the RT Fx. This corresponds with the published literature on increase in 
Fx in post treatment patients. TLM can potentially cause more scarring and 
thus a greater post treatment Fx. In terms of the DQx analysis it might be 
hypothesised that TLM would create a gap in the glottis affecting this 
measurement. However the mean DQx are similar in TLM, RT and ‘normal’ 
subjects.  
 
5.2.4 Study limitations 
5.2.4.1 Differences between groups 
There were statistically significant differences in age, sex, smoking status and 
co-morbidities between TLM and RT groups. This partly due to a selection 
bias, as patients with multiple co-morbidities may not be suitable for surgery. 
The EaStER (Early Stage Glottic Cancer Endoscopic Excision versus RT) 
trial, discussed in the introduction, outlines the difficulty in conducting a 
randomised controlled trial in this area. The aim of the EaStER study was to 
evaluate the outcome of patients treated with TLM or standard RT. An 
investigation into the reasons for the difficulties in recruitment found many 
issues79. One of the issues identified was surrounding the selection bias, 
where patients were not suitable for surgery.  
Despite the differences in baseline characteristics, it was only possible to 
adjust for age. As the data was assumed to be non-parametric, the 
adjustment required was a proportional odds ordinal logistic model. Due to the 
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small sample size, it was not possible to adjust for any other variable. In 
particular, there were only five females in this study, and so it was not 
possible to adjust for sex.  
 
5.2.4.2 Statistical concerns 
As this study is exploratory in nature, no primary outcome was identified and 
no sample size calculation was undertaken. A large number of statistical tests 
have been performed on the data, and this leads to a risk of statistical error, in 
particular a type II error or having a false negative result. Therefore it is 
important to interpret the results of the statistical analysis with some caution.  
 
5.2.4.3 Missing data 
Although the UW-QoLv4 was completed by all patients the global questions 
were not completed by everyone. This was an administration error in the 
printing of the questionnaires and some patients did not receive the question 
to be completed. This was not identified until a later stage. It was decided to 
collect data at a single time point in order that the data could be compared 
directly for each patient and therefore patients were not asked to re-attend for 
a complete data recollection.   
 The perceptual rating was performed by three blinded expert raters. These 
were speech and language therapist in two separate departments. At the 
outset, two raters were identified to conduct the GRBAS scores on the 39 
voice recordings. However, the lead contact for these raters moved out of the 
UK during the study and therefore another local expert rater was used to 
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complete the dataset. Inter-rater reliability was not completed due to there 
being only one rater who completed all the GRBAS scores. Ideally another 
rater should have been used to repeat the GRBAS scores and allow for inter-
rater reliability to be assessed. The reasons another rater was not found was 
due to time limitations and the focus of this research being on different 
aspects of data analysis. The subjective outcomes and acoustic analysis were 
prioritised in this research.  
 
Another study limitation was the failure to gain a complete data set of the 
acoustic analysis. There is missing data for two of the RT patients and three 
of the TLM patients. The reasons for the two RT patients were due to the 
rigidity of neck tissue and in the TLM patients due to the size of the neck and 
the discomfort of wearing the neck straps for the EGG. Multiple attempts were 
made to gain EGG readings but it was found not to be possible.  
The extent of the surgical resection was not documented by the operating 
surgeons and therefore has not been included in the analysis. Locally the 
surgeons would select TLM over RT for smaller and mid vocal cord tumours.  
The typical cordectomy chosen would be a type I-III. A tumour requiring a 
larger resection would normally be recommended RT due to the impact on 
perceived voice outcomes. However, as this has not been documented, it is 
not possible to confirm the cordectomy type. Similarly different RT regimes 
have been used in the past, depending on the clinical oncologists’ treatment 
plan. As RT is performed in an oncology centre in a different NHS Trust, it has 
not been possible to identify the RT regime for each patient.  
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5.3 Longitudinal changes in voice quality in patients 
undergoing TLM for T1a SCC of glottis 
 
5.3.1 Self-reported questionnaires pre and post TLM  
The VHI-10 demonstrated no statistically significant change comparing the pre 
and post-TLM. The mean total pre-TLM is 14.5 and 13.4 post TLM (adjusted 
p=0.843). In a longitudinal study by Mendelsohn et al. 111 a small number of 
cases  TLM (n=11) were followed up post TLM. The full VHI survey was used 
to record pre-operative and two post-operative TLM scores, (less than four 
months and more than six months from surgery). The mean VHI score was 
40.9 pre-op and initially worsened to 43.8 (p=0.003) before improving in the 
delayed VHI to 23.7 (p=0.037). The higher score found in this study is due to 
the authors using the full VHI survey, rather than the shortened VHI-10 
survey. The healing process and the closure of any phonatory gap were the 
reasons given for the initially worsening of voice and then improvement.  
The VoiSS questionnaire also does not show any statistically significant 
difference between the pre and post TLM scores for the different domains. 
The total mean pre-TLM is 41.3 and post TLM 38.1 (adjusted p=0.987). I was 
unable to find any published evidence including VoiSS to compare voice 
outcomes pre and post TLM. Loughran et al. and Robertson et al. both include 
VoiSS data post TLM and this is included in the discussion of RT compared 
with TLM.106,216  
There is no statistically significant difference between the UW-QoL4 scores for 
any of the domains when comparing QoL pre and post TLM. There were high 
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scores, throughout the domains, indicating a good pre and post TLM QoL. 
The composite scores show that there is no statistically significant difference 
in physical (p=0.424) or social (p=0.755) function pre and post TLM. This is 
consistent with the published literature regarding early glottic carcinomas.  
Stoeckli et al. assessed QoL in 91 patients treated with TLM and RT for T1 
and T2 carcinoma of the larynx.120 The study uses different QoL 
questionnaires (EORTC, QLQ-H&N35) however it demonstrates a good level 
of QoL for these patients. This study does not provide longitudinal data pre 
and post treatment.  
 
 5.3.2 Perceptual rating of voice pre and post TLM  
There is no statistically significant difference in mean perceptual rating by an 
expert rater (6.66 pre vs. 6.44 post, adjusted p=0.606). There is no statistically 
significant difference in mean scores across any of the domains, except 
asthenia, which is statistically significantly worse pre TLM compared with post 
(0.97 pre vs. 0.94 post, adjusted 0.015). Vilaseca et al. reviewed the voice of 
42 patients post TLM and compared with 21 control subjects 108. No pre TLM 
data was available. The authors found worse GRBAS scores for all domains 
in post TLM compared with the control (p<0.05). However, this study 
compared patient post TLM with those with ‘normal’ voice, and therefore this 
level of dysphonia would be expected in this cohort.  In a longitudinal study by 
Mendelsohn et al. 111 a small number of TLM cases  (n=11) were followed up 
post TLM for T1 and T2 glottic carcinoma. The GRBAS was measured pre-
operatively, initial post TLM (up to four months) and more than six months. 
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The mean breathiness showed a statistically significant worsening score in the 
initial post operatively rating (mean breathiness 0.75 to 2.50, p=0.003). 
However the voice recovered in the delayed post-operative rating of 
breathiness (1.17, p=0.005). This demonstrates the recovery of voice post 
TLM after six months. In my study, all patients were followed up for post TLM 
recordings at least 12 months post treatment. Therefore it is expected that 
patients’ voice would have had time to recover by this point.  
 
5.3.3 Acoustic analysis comparing pre and post TLM 
5.3.3.1 Acoustic analysis of sustained vowels on pre and post TLM 
There is no statistically significant difference in any of the acoustic parameters 
for pre and post TLM voice recordings. This is consistent with the findings 
from the perceptual ratings of voice, as described above. I was unable to find 
any published literature considering the acoustic parameters pre and post 
TLM. Therefore this shows the value of this study as it is an under-researched 
area. The reasons for the lack of studies including pre and post TLM data is 
likely to be due to the difficulty in identifying and following up patients for a 
considerable time period.  
 
5.3.3.2 Acoustic analysis of connected speech on pre and post TLM 
The mean DFx is statistically significantly higher in the post TLM group 
(p=0.001, adjusted 0.001). This is in contrast of the results of the Fx on 
sustained vowels. The connected speech analysis is performed on a longer 
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and more varied passage. Therefore analysis of connective speech is more 
likely to identify a statistically significant difference in Fx compared to 
sustained vowel analysis. There is no statistically significant difference in the 
coherence of frequency (p=0.098, adjusted p=0.140) or pitch irregularity 
(p=0.320, adjusted p=0.370) when comparing pre and post TLM.  
 
There is no statistically significant difference in the mean DAx (p=0.121), 
coherence (p=0.472) or irregularity of amplitude (p=0.184) when comparing 
pre and post TLM.  
 
There is no statistically significant difference in the mean DQx (p=0.654, 
adjusted p=0.904), coherence (p=0.231, adjusted p=0.293) or irregularity of 
the contact quotient (p=0.312, adjusted p=0.400) when comparing pre and 
post TLM. I was unable to find any published literature considering the 
acoustic analysis on connective speech pre and post TLM.  
 
5.3.4 Study limitations 
5.3.4.1 Lost to follow up 
There were 29 patients included in the initial pre-operative data collection but 
12 patients were not followed up. The reasons for loss to follow up are 
described in section 4.3.1. There is no statistically significant difference in 
quality of life or voice outcomes between the 17 included patients and the 12 
excluded patients (Appendix 15). 
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Despite the differences in baseline characteristics, it was only possible to 
adjust for age. As the data was assumed to be non-parametric, the 
adjustment required was a proportional odds ordinal logistic model. Due to the 
small sample size, it was not possible to adjust for any other variable. In 
particular, there were only five females in this study, and so it was not 
possible to adjust for sex.  
 
5.3.4.2 Statistical concerns 
As this study is exploratory in nature, no primary outcome was identified and 
no sample size calculation was undertaken. A large number of statistical tests 
have been performed on the data, and this leads to a risk of statistical error, in 
particular a type II error or having a false negative result. Therefore it is 
important to interpret the results of the statistical analysis with some caution.  
 
5.3.4.3 Missing data 
Although there were 29 patients enrolled into this study only 17 were able to 
be recorded post TLM. The explanation for the 12 patients not being followed 
up has been described in section 4.3. It was not possible to undertake any 
analysis using all 29 patients enrolled, accounting for the missing data. This is 
as there are too many baseline characteristics and outcome variables to 
account for.  
Although the UW-QoLv4 was completed by all patients the global questions 
were not completed by everyone. This was an administration error as 
previously discussed. Due to the limited completed global questions of the 
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UW-QoLv4 and the small sample size, there were insufficient data to allow a 
direct comparison of pre- and post-TLM responses.  
Voice was rated by one expert rater for all patients. The expert was unable to 
rate one pre-operative voice due to poor quality recording. This patient has 
been excluded from the GRBAS analysis. Only one rater performed the 
GRBAS scores. Ideally another rater should have been used to repeat the 
GRBAS scores and allow for inter-rater reliability to be assessed. The reasons 
another rater was not found was due to time limitations and the focus of this 
research being on different aspects of data analysis. The subjective outcomes 
and acoustic analysis were prioritised in this research. 
 
Another study limitation was the failure to gain a complete data set of the 
acoustic analysis. Out of the 17 patients with follow up data included in the 
study there was missing acoustic analysis reading in five of these cases. This 
was despite multiple attempts made to gain EGG readings but it was found 
not to be possible. In one patient it was not possible to gain an Lx waveform 
on pre or post TLM. This was due to the neck size and excess adipose tissue 
preventing good conduction between the electrodes. In the four patients with 
no acoustic data post TLM this was due to a technical error with the 
Laryngograph. It was not noted until after the recordings had been performed 
that the acoustic data had not been captured.  
The extent of the surgical resection was not documented by the operating 
surgeons and therefore has not been included in the analysis. Locally the 
surgeons would select TLM over RT for smaller and mid vocal cord tumours.  
The typical cordectomy chosen would be a type I-III. A tumour requiring a 
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larger resection would normally be recommended RT due to the impact on 
perceived voice outcomes. However, as this has not been documented, it is 
not possible to confirm the cordectomy type.  
 
5.4 Clinical implications 
Only minor differences in subjective and objective voice outcomes between 
the groups were identified in the study comparing TLM and RT. This is useful 
information that clinicians can share with their patients as it may guide both a 
clinician’s and patient’s decision regarding which treatment to opt for. Due to 
the subjective voice questionnaire results, it may also reassure patients that 
they are unlikely to notice a great change in their voice post treatment. 
Although there are larger studies in the published literature, this is the first 
from the local area and therefore is the most applicable to the local patient 
population. In addition, the number of published studies and patients included 
is limited and so this adds additional data to a limited evidence base. There is 
a cost benefit to the National Health Service in TLM as described in the 
introduction and this series helps to back up the clinical case for TLM.  
In the longitudinal study there are minimal differences in subjective and 
objective voice outcomes pre and post TLM. Again, this is reassuring for the 
patient and clinician and important information to help them chose their 
treatment option. This is the first study of voice outcomes pre and post TLM 
for early glottic tumours undertaken at AUH. This is important information 
locally to guide the local Head and Neck MDT in its decision making process.  
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Voice outcome measures are important when undertaking any voice altering 
surgery. This, unfortunately, is not always routine practice in the UK. As 
discussed in the introduction there are a plethora of voice outcome measures. 
Some measures are more suited to research as opposed to clinical settings 
due to time constraints and the need for specific equipment. In practice, I 
would suggest that the VHI-10 is routinely used. The VHI-10 provides a quick 
subjective assessment that is both reliable and validated. It is commonly used 
in published studies and therefore comparisons can easily be made. 
Documentation of the perceptual rating of voice by an expert rater using the 
GRBAS scale is another valuable measure that can be used in clinical 
practice. To an expert rater, GRBAS is also validated and reliable. However 
this is more resource and time intensive and is used more commonly by 
speech and language therapists than by physicians in medical settings.  
 
5.5 Future areas of research 
To improve research into voice outcomes a standardised measurement of 
voice should be introduced to improve the ability to compare outcomes of 
studies. Currently researchers use a variety of questionnaires, acoustic 
parameters and computer programs to measure voice outcomes. An 
important aspect of future research would be to identify the optimal tools to be 
used. In terms of the objective measures of voice there is a gap in the 
knowledge base describing the parameters of ‘normal’ voice. This would 
require evaluating a large cohort of participants with ‘normal’ voice of varying 
age, gender, co-morbidities and social history.     
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Advances in technology are likely to change the way we manage patients with 
laryngeal carcinoma. For example the improvement in endoscopy, NBI and 
transoral robotic surgery to identify the extent of the tumour and aid excision 
may influence the treatment plan.  It is important with any new techniques that 
as well as local control, voice outcomes are reported and can be compared to 
the current techniques.  
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6. Conclusion 
The treatment of T1a laryngeal carcinoma with either TLM or RT has been 
shown to have comparable good local control. There are advantages and 
disadvantages of both treatments, however TLM is often preferred by patient 
and clinician as it is a day case procedure, can provide histological clearance 
and leaves the option to use RT or further surgery in the future. However the 
voice outcomes of both procedures have been debated and results in the 
published literature are mixed. It is challenging to conduct a study to directly 
compare voice outcomes of TLM and RT as there are a number of other 
factors that impact voice, including: patient factors such as age, sex, co-
morbidities such as reflux disease, smoking history; tumour factors such as 
size and position; and treatment factors such as type of cordectomy 
performed and RT regime. The EaStER trial outlines the difficulty in 
conducting an RCT in this area.79 These variables mean that comparison of 
published data in this area is difficult, as underlying factors may influence the 
results. 
In this comparison of voice quality following RT or TLM of T1a laryngeal 
carcinomas, I found little difference between the treatment groups. This was 
consistent throughout the different methods of assessing voice quality, both 
subjective and objective. In addition, QoL was found to be very good in both 
treatment groups. These data show that with either treatment option, there are 
good voice and QoL outcomes at a year post treatment.  
In the comparison of voice quality pre and post TLM of T1a laryngeal 
carcinomas, I found little difference pre and one year post-treatment. This was 
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consistent throughout the different methods of assessing voice quality, both 
subjective and objective. In addition, QoL was found to be very good pre and 
post treatment. These data show that patients can be reassured that voice 
and QoL is not likely to be statistically significantly different a year following 
TLM treatment for T1a laryngeal carcinomas.  
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8. Appendices 
Appendix 1: The ‘Grandfather passage’  
(A phonetically balanced passage) 
 
My Grandfather 
You wished to know all about my grandfather. 
 
Well, he is nearly ninety-three years old; he dresses himself in an ancient 
black frock coat, usually minus several buttons; yet he still thinks as swiftly as 
ever.  
 
A long, flowing beard clings to his chin, giving those who observe him a 
pronounced feeling of utmost respect. When he speaks, his voice is just a bit 
cracked and quivers a trifle.  
 
Twice each day he plays skilfully and with zest upon our small organ. Except 
in the winter when the ooze or snow or ice prevents, he slowly takes a short 
walk in the open air each day. We have often urged him to walk more and 
smoke less, but he always answers “Banana oil!” 
 
Grandfather likes to be modern in his language. 
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Appendix 2: VHI-10 questionnaire 
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Appendix 3: VoiSS questionnaire 
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Appendix 4: UW-QoLv4 Questionnaire  
(University of Washington Quality of Life version 4 Questionnaire) 
This questionnaire asks about your health and quality of life over the past 
seven days.  Please answer all of the questions by ticking one box for each 
question. 
 
1. Pain.  (Tick one box:  ) 
  I have no pain. 
  There is mild pain not needing medication. 
  I have moderate pain - requires regular medication (e.g. 
paracetamol). 
  I have severe pain controlled only by prescription 
medicine (e.g. morphine). 
  I have severe pain, not controlled by medication. 
 
2. Appearance.  (Tick one box:  ) 
  There is no change in my appearance. 
  The change in my appearance is minor. 
  My appearance bothers me but I remain active. 
  I feel significantly disfigured and limit my activities due to 
my appearance. 
  I cannot be with people due to my appearance. 
 
3. Activity.  (Tick one box:  ) 
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  I am as active as I have ever been. 
  There are times when I can't keep up my old pace, but 
not often. 
  I am often tired and have slowed down my activities 
although I still get out. 
  I don't go out because I don't have the strength. 
  I am usually in bed or chair and don't leave home. 
 
4. Recreation.  (Tick one box:  ) 
  There are no limitations to recreation at home or away 
from home. 
  There are a few things I can't do but I still get out and 
enjoy life. 
  There are many times when I wish I could get out more, 
but I'm not up to it. 
  There are severe limitations to what I can do, mostly I stay 
at home and watch TV. 
  I can't do anything enjoyable. 
 
5. Swallowing.  (Tick one box:  ) 
  I can swallow as well as ever. 
  I cannot swallow certain solid foods. 
  I can only swallow liquid food. 
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  I cannot swallow because it "goes down the wrong way" 
and chokes me. 
 
6. Chewing.  (Tick one box:  ) 
  I can chew as well as ever. 
  I can eat soft solids but cannot chew some foods. 
  I cannot even chew soft solids. 
7.  Speech.  (Tick one box:  ) 
  My speech is the same as always. 
  I have difficulty saying some words but I can be 
understood over the phone. 
  Only my family and friends can understand me. 
  I cannot be understood. 
 
8. Shoulder.  (Tick one box:  ) 
  I have no problem with my shoulder. 
  My shoulder is stiff but it has not affected my activity or 
strength. 
  Pain or weakness in my shoulder has caused me to 
change my work / hobbies. 
  I cannot work or do my hobbies due to problems with my 
shoulder. 
 
9. Taste.  (Tick one box:  )  
223 
 
  I can taste food normally. 
  I can taste most foods normally. 
  I can taste some foods. 
  I cannot taste any foods. 
 
10. Saliva.  (Tick one box:  ) 
  My saliva is of normal consistency. 
  I have less saliva than normal, but it is enough.   
  I have too little saliva.   
  I have no saliva. 
 
11. Mood.  (Tick one box:  ) 
  My mood is excellent and unaffected by my cancer. 
  My mood is generally good and only occasionally affected 
by my cancer. 
  I am neither in a good mood nor depressed about my 
cancer. 
  I am somewhat depressed about my cancer. 
  I am extremely depressed about my cancer. 
 
12. Anxiety.  (Tick one box:  ) 
  I am not anxious about my cancer. 
  I am a little anxious about my cancer. 
  I am anxious about my cancer. 
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  I am very anxious about my cancer. 
 
 
Which issues have been the most important to you during the 
past 7 days?   
Tick  up to 3 boxes. 
 
   Pain  Swallowing
  Taste 
   Appearance  Chewing
  Saliva 
   Activity  Speech
  Mood 
   Recreation  Shoulder
  Anxiety 
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GENERAL QUESTIONS 
 
Compared to the month before you developed cancer, how 
would you rate your health-related quality of life? (Tick one box: 
 ) 
 
  Much better 
  Somewhat better 
  About the same   
  Somewhat worse   
  Much worse 
 
In general, would you say your health-related quality of life 
during the past 7 days has been:  (Tick one box:  ) 
 
  Outstanding 
  Very good 
  Good   
  Fair   
  Poor 
  Very poor 
 
Overall quality of life includes not only physical and mental 
health, but also many other factors, such as family, friends, 
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spirituality, or personal leisure activities that are important to 
your enjoyment of life.  Considering everything in your life that 
contributes to your personal well-being, rate your overall quality 
of life during the past 7 days.  (Tick one box:  ) 
 
  Outstanding 
  Very good 
  Good   
  Fair   
  Poor 
  Very poor 
 
 
Please describe any other issues (medical or nonmedical) that are important 
to your quality of life and have not been adequately addressed by our 
questions (you may attach additional sheets if needed). 
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Appendix 5: Consent form and information sheet 
 
                                                                
 
  
  
Analysis of voice characteristics of ENT patients 
 
We are inviting you to take part in a research study.  Before you decide, it is important 
to understand why the research is being done and what it will involve.  This 
information sheet provides you with an outline of the study so that you can think about 
whether you want to take part, and discuss it with others if you wish. 
 
You may be currently experiencing a change in your voice. The investigation or 
treatment you will be undergoing may also affect your voice. The degree of voice 
change varies according to what condition you have and the type of treatment or 
investigation you will be having, however we do not know this in as much detail as we 
would like to. 
 
 
WHAT IS THE PURPOSE OF THIS STUDY? 
We aim to analyse voice recordings from ENT patients to assess the degree of voice change 
that the condition itself and treatment may cause 
 
 
Professor Terry Jones 
Department of Head and Neck 
Surgery 
University Hospital Aintree 
Lower Lane 
Liverpool L9 7AL 
Tel 0151-525-5980 
Fax 0151-529-5263 
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WHY HAVE I BEEN CHOSEN? 
You have been chosen because you have a condition which has caused voice change or you 
will be undergoing an investigation or treatment which can cause a change in your voice.  
 
 
DO I HAVE TO TAKE PART? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time and without giving a reason. A decision to 
withdraw or not to take part will not affect the standard of care you receive. 
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
You will not notice any difference in your treatment. We will record your voice speaking a 
phrase and three prolonged “aah” sounds. This will be done prior to your procedure and then1 
week, 3 weeks and 6 weeks after your procedure. It will take only 10 minutes of your time and 
will be done at University Hospital Aintree in the ENT department. You will not undergo any 
procedures other than those normally applied. 
 
WHAT ARE THE SIDE EFFECTS OF ANY TREATMENT RECEIVED WHEN TAKING PART? 
As no extra procedures will be performed, there will be no side-effects. 
 
WHAT HAPPENS IF I WANT TO STOP BEING INVOLVED IN THIS STUDY? 
If you do not want to continue being in this study, you may simply contact any of the members 
of the research team and you will be removed from the study. You may do this at any time.  
 
WHAT ARE THE POSSIBLE DISADVANTAGES OR RISKS OF TAKING PART? 
There are no major disadvantages from taking part over and above those from routine normal 
care.  
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WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? 
The only benefit is the knowledge that you are helping to improve information given to 
patients in the future. 
 
WILL MY TAKING PART IN THIS STUDY BE KEPT CONFIDENTIAL? 
Information collected about you during the course of the research will be kept strictly 
confidential. The data we have recorded will be kept securely and safely on a computer with 
in the hospital 
 
WHAT HAPPENS WHEN THE RESEARCH STOPS? 
The data will be kept on the computer for analysis with access to the recordings limited to the 
research team only. 
 
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY? 
Once it has all been completed we will present the results at an international meeting 
attended by doctors from around the world interested in voice. After this, we will publish the 
results in an appropriate scientific journal.  If you wish, we will make sure you receive your 
own copy of the results and paper as soon as we have them. 
 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
The study is being organised and funded by the Department of ENT and Head and Neck 
surgery at University Hospital Aintree. 
 
WHO HAS REVIEWED THE STUDY? 
This study has been reviewed by the Local Research Ethics Committee covering the hospital 
in which you are treated. 
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WHAT IF I HAVE OTHER CONCERNS? 
If you have any concerns or questions, you may contact the doctor listed below for advice at 
their University Hospital Aintree number 0151-525-5980 or on the number shown at the top of 
the page: 
 
Professor Terry Jones 
 
If you have any complaints about the way the investigator has carried out the study, you may 
contact: local complaints procedure officer at Aintree Hospitals NHS Trust. 
 
You may also wish to contact Cancer BACUP, an independent advisory group. 
3 Bath place, Rivington Street, London EC2A 3DR.  Freephone: 0800 800 1234 
www.cancerbacup.org 
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Centre Number: 
Study Number: 
Patient Identification Number for this trial: 
CONSENT FORM 
Analysis of voice characteristics of ENT patients 
Name of Researcher: Mr Terry Jones                                                               Please initial box 
                         
1. I confirm that I have read and understand the information sheet dated 27/03/05 
(version 3) for the above study and have had the opportunity to ask questions.  
  
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected.  
   
3. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from [company name] or from regulatory authorities where it is 
relevant to my taking part in research.  I give permission for these individuals to have access 
to my records.          
 
4. I agree to take part in the above study.       
________________________ ________________ ________________ 
Name of Patient Date Signature 
 
_________________________ ________________ ________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
_________________________ ________________ ________________ 
 
Researcher Date Signature 
 
                                                        Copies:1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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Appendix 6: Complete data set: for sustained vowels for ‘normal’ voice  
Table 35: ‘Normal’ males sustained vowel /i/ (complete data set) 
Control age 
Duration 
(ms) 
Minimum 
Fx (Hz) 
Maximum 
Fx (Hz) 
Average 
Fx (Hz) 
S.D. 
Fx 
(%) 
Minimum 
Qx (%) 
Maximum 
Qx (%) 
Average 
Qx (%) 
S.D. 
Qx 
(%) 
Jitter 
First 
(%) 
Jitter 
Second 
(%) 
Shimmer 
+ (%) 
Shimmer 
– (%) 
Jitter 
Factor 
(%) 
RAP 
(%) 
Shimmer 
dB (dB) 
NNE 
(dB) 
CPP 
HNR 
(dB) 
Mean 
SPL 
(dB) 
male1 27 10905.5 124.25 135.17 130.51 1.09 40.16 45.9 43.2 1.12 0.27 0.14 1.66 -1.69 0.27 0.14 0.14 
-
30.98 3.64 24.03 84.75 
male 2 34 5141.4 200.28 209.9 204.77 0.86 43.58 53.84 48.76 1.79 0.4 0.2 1.7 -2.32 0.4 0.2 0.15 
-
26.05 4.59 20.48 86.01 
male 3 37 11802.3 165.34 183.48 174.76 1.42 41.93 53.26 48.52 2.12 1.41 0.88 6.78 -6.16 1.41 0.88 0.59 
-
14.52 2.06 12.8 81.69 
male 4 35 17337.1 125.42 133.65 129.42 1.16 50 55.64 53.21 0.81 0.19 0.1 2.57 -3.07 0.19 0.1 0.22 
-
22.42 4.69 18.41 89.78 
male 5 28 4852 97.46 103.95 100.18 1.02 40.64 48.12 44.81 1.46 0.33 0.16 3.82 -3.24 0.33 0.16 0.33 
-
23.98 3.07 21.5 80.04 
male 6 37 26915.7 146.75 159.18 152.84 1.4 50.46 59.61 56.28 1.4 0.42 0.25 2.63 -2.23 0.42 0.25 0.23 
-
21.25 5.16 18.62 90.82 
male 7 30 13729.1 111.38 119.17 114.99 0.87 34.26 42.96 38.92 1.3 0.27 0.14 2.67 -2.64 0.27 0.14 0.24 
-
25.41 3.86 21.11 80.8 
male 8 24 13806.8 64.28 187.61 125.82 6.96 16.5 42.97 33.24 2.03 3.13 1.97 7.92 -5.34 3.15 1.96 0.75 
-
11.46 2.75 14.75 82.11 
male 9 50 8343.6 75.18 298.32 239.19 2.05 15.02 61.29 55.93 1.91 0.7 0.41 4.42 -2.47 0.66 0.53 0.38 
-
20.38 4.01 21.19 85.58 
male 10 24 12530.4 122.57 128.89 125.4 0.72 39.06 45.38 42.31 0.76 0.23 0.11 2.53 -3.9 0.23 0.11 0.23 
-
26.35 2.65 23.65 83.67 
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Table 36: ‘Normal’ male sustained vowel /a/ (complete data set) 
 
Control age 
Duration 
(ms) 
Minim
um Fx 
(Hz) 
Maxim
um Fx 
(Hz) 
Avera
ge Fx 
(Hz) 
S.D. 
Fx (%) 
Minim
um Qx 
(%) 
Maxim
um Qx 
(%) 
Avera
ge Qx 
(%) 
S.D. 
Qx (%) 
Jitter 
First 
(%) 
Jitter 
Secon
d (%) 
Shim
mer + 
(%) 
Shim
mer – 
(%) 
Jitter 
Factor 
(%) 
RAP 
(%) 
Shimmer 
dB (dB) 
NNE 
(dB) 
CPP 
HNR 
(dB) 
Mean 
SPL 
(dB) 
male1 27 5998.1 119.8 130.66 124.24 1.6 34.1 41.4 38.46 1.54 0.46 0.27 3.69 -2.54 0.46 0.27 0.36 -23.31 4.29 19.8 85.29 
male 2 34 323.7.2 200 209.95 205.16 0.82 36.36 45.56 40.55 1.7 0.4 0.24 3.05 -1.41 0.4 0.24 0.27 -27.32 6.54 21.23 93.16 
male 3 37 16980.9 179.34 199.72 188.23 0.99 49.39 59.03 52.69 1.83 0.39 0.23 4.37 -4.71 0.39 0.23 0.38 -15.66 3.75 16.24 86.37 
male 4 35 7892.3 119.28 131.44 122.02 1.03 42.63 54.26 50.09 1.85 0.29 0.16 2.34 -2.28 0.29 0.16 0.22 -23.38 6.33 18.41 95.69 
male 5 28 5562 94.43 105.95 101.42 1.73 39.49 48.07 44.55 1.28 1.85 1.12 5.56 -5.59 1.84 1.12 0.5 -8.69 2.42 9.38 83.85 
male 6 37 23494.2 112.1 123.67 119.14 1.29 52.55 59.85 56.3 1.51 0.28 0.13 3.52 -3.86 0.28 0.13 0.31 -19.6 4.91 16.82 90.12 
male 7 30 9448 110.18 116.13 113 0.81 35.41 43.57 38.96 1.63 0.34 0.19 2.76 -3.71 0.34 0.19 0.24 -22.35 5.44 17.72 82.76 
male 8 24 6925.9 115.72 128.33 120.61 1.24 35.82 43.18 39.4 1.3 0.68 0.39 8.22 -6.32 0.68 0.39 0.75 -12.88 3.21 12.53 83.19 
male 9 50 2937.9 177.3 195.54 184.55 1.81 29.88 42.52 35.99 2.67 0.89 0.52 6.97 -4.41 0.89 0.52 0.6 -20.21 2.74 19.38 87.21 
male 10 24 10160 118.49 683.06 124.85 17.55 33 80 45.09 2.38 1.28 1.39 6.46 -6.83 2.22 0.64 0.58 -14.83 3.66 14.71 85.82 
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Table 37: ‘Normal’ female sustained vowel /i/ (complete data set) 
 
 
Control age 
Duratio
n (ms) 
Minim
um Fx 
(Hz) 
Maximum 
Fx (Hz) 
Average 
Fx (Hz) 
S.D. 
Fx 
(%) 
Minimu
m Qx 
(%) 
Maximum 
Qx (%) 
Average 
Qx (%) 
S.D. Qx 
(%) 
Jitter 
First 
(%) 
Jitter 
Second 
(%) 
Shimme
r + (%) 
Shimme
r – (%) 
Jitter 
Factor 
(%) 
RAP 
(%) 
Shim
mer 
dB 
(dB) 
NNE 
(dB) 
CPP 
HNR 
(dB) 
Mean 
SPL 
(dB) 
female 1 24 6302.9 205.25 214.36 209.59 0.65 38.15 44.73 41.67 1 0.42 0.24 2.51 -3.93 0.42 0.24 0.22 -23.82 4.27 21.65 84.63 
female 2 51 8595.6 229.3 285.06 236.63 1.05 39.28 51.47 47.66 1.29 1.1 0.67 13.71 -7.72 1.1 0.67 1.14 -17.17 3.42 13.73 79.65 
female 3 41 8440.6 213.4 224.11 218.96 0.82 49.29 58.66 55.17 1.67 0.44 0.27 2.26 -3.06 0.44 0.27 0.2 -21.65 4.19 20.37 85.78 
female 4 32 1469.9 187.19 244.2 213.44 2.62 26.02 58.66 39.99 11.59 1.62 0.95 3.99 -4.68 1.62 0.95 0.35 -12.05 4.09 14.71 89.3 
female 5 32 10391.9 225.93 242.07 233.07 1.16 24.28 35.82 28.95 1.75 1 0.65 3.77 -3.81 1 0.65 0.32 -21.61 3 19.67 84.31 
female 6 50 1892.5 222.61 243.48 231.19 1.75 46.26 70 58.89 5.26 0.67 0.38 3.42 -3.78 0.67 0.38 0.3 -22.86 4.22 21.32 87.45 
female 7 59 2149.8 143.12 352.6 296.54 8.5 23.71 53.57 43.67 3.58 2 1.09 2.13 -2.82 1.91 1.28 0.18 -19.78 5.16 17.48 
100.0
1 
female 8 49 888.3 192.08 201.97 196.43 0.88 57.31 83.95 75.79 6.46 0.56 0.32 2.69 -3.47 0.56 0.32 0.23 -21.93 3.41 17.76 81.69 
female 9 59 3074.8 246.42 260.82 252.91 0.8 39.68 46.03 43.17 1.2 0.7 0.41 1.53 -2.53 0.7 0.41 0.13 -27.97 6.28 23.57 89.92 
female 10 45 8149.1 242.42 256.34 249.78 0.93 52.38 60.93 56.47 1.43 0.69 0.44 3.4 -3.73 0.69 0.44 0.3 -17.65 5.97 19.99 91.1 
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Table 38: ‘Normal’ female sustained vowels /a/ (complete data set)
Control age 
Duration 
(ms) 
Minimum 
Fx (Hz) 
Maximum 
Fx (Hz) 
Average 
Fx (Hz) 
S.D. 
Fx 
(%) 
Minimum 
Qx (%) 
Maximum 
Qx (%) 
Average 
Qx (%) 
S.D. 
Qx 
(%) 
Jitter 
First (%) 
Jitter 
Second 
(%) 
Shimmer 
+ (%) 
Shimmer 
– (%) 
Jitter 
Factor 
(%) 
RAP 
(%) 
Shimmer 
dB (dB) 
NNE 
(dB) 
CPP 
HNR 
(dB) 
Mean 
SPL 
(dB) 
female 1 24 3445.6 196.73 207.51 202.54 0.85 196.73 207.51 33.18 2.62 0.54 0.31 3.61 -3.55 0.54 0.31 0.33 -24.64 5.65 19.55 86.83 
female 2 51 4248.4 229.99 242.54 235.45 0.81 36.76 45.58 40.59 1.55 0.82 0.51 6.29 -6.24 0.82 0.51 0.54 -21.69 4.04 16.42 82.25 
female 3 41 6414.8 212.58 223.06 218 0.81 43.83 54.66 48.98 1.93 0.41 0.23 3.77 -3.19 0.41 0.23 0.33 -18.63 5.53 15.84 89.17 
female 4 32 612.4 172.95 215.14 188.25 2.9 32.18 46.06 37 2.59 2.46 1.54 2.15 -1.79 2.49 1.51 0.19 -25.25 7.01 19.69 101.35 
female 5 32 2543.5 225.88 241.37 235.9 0.88 26.08 38.23 32.85 2.89 0.39 0.22 2.46 -2.91 0.39 0.23 0.22 -26.52 3.54 22.99 84.4 
female 6 50 1992.8 209.73 221.43 215.16 1.09 20.54 43.42 33.02 4.92 0.65 0.41 3.87 -3.89 0.65 0.41 0.33 -18.47 5.6 16.99 88.87 
female 7 59 2927.1 230.94 243.42 238.5 0.9 44.77 52.23 48.88 1.24 0.6 0.22 2.78 -1.89 0.36 0.22 0.24 -26.06 7.45 21.73 100.44 
female 8 49 271.3 186.74 191.35 186.74 1.22 47.12 56.97 51.23 2.35 0.5 0.27 3.54 -3.45 0.5 0.27 0.31 -20.46 5.09 17.4 87.22 
female 9 59 75588.9 214.08 230.04 220.6 1.42 33.8 48.61 40.8 2.71 1.56 0.96 2.28 -1.92 1.56 0.96 0.2 -29.17 5.15 20.45 91.26 
female 
10 
45 9677.1 237.19 255.68 245.77 1.18 49.23 60 56.57 1.68 0.37 0.21 1.55 -1.66 0.37 0.21 0.14 -25.83 7.71 21.48 99.51 
236 
 
Appendix 7: Complete data set: voice questionnaires for RT 
and TLM patients 
 
Table 39: VHI-10 for RT patients (complete data set) 
Patients 
Functional 
(VHI-10 F) 
(max=20) 
Physical 
(VHI-10 P) 
(max=12) 
Emotional 
(VHI-10 E) 
(max=8) 
Total 
(max=40) 
1 1 0 0 1 
2 2 4 0 6 
3 3 5 1 9 
4 4 3 0 7 
5 4 3 2 9 
6 7 6 2 15 
7 2 2 1 5 
8 0 1 0 1 
9 1 4 2 7 
10 6 1 0 7 
11 3 1 0 4 
12 0 4 0 4 
13 0 1 0 1 
14 0 2 0 2 
15 1 0 1 2 
16 0 1 0 1 
17 0 0 0 0 
18 1 0 0 0 
19 3 7 3 13 
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Table 40: VHI-10 for TLM patients (complete data set) 
Patients 
Functional 
(VHI-10 F) 
(max=20) 
Physical 
(VHI-10 P) 
(max=12) 
Emotional 
(VHI-10 E) 
(max=8) 
Total 
(max=40) 
1 1 0 0 1 
2 2 4 0 6 
3 3 5 1 9 
4 4 3 0 7 
5 4 3 2 9 
6 7 6 2 15 
7 2 2 1 5 
8 0 1 0 1 
9 1 4 2 7 
10 6 1 0 7 
11 3 1 0 4 
12 0 4 0 4 
13 1 4 2 7 
14 0 1 0 1 
15 0 2 0 2 
16 1 0 1 2 
17 0 1 0 1 
18 1 0 0 1 
19 2 4 0 6 
20 3 5 1 9 
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Table 41: VoiSS for RT patients (complete data set) 
 
 
 
  
Patients 
Impairment 
(max=60) 
Emotional 
(max=32) 
Physical 
(max=28) 
Total  
(max=120) 
1 12 1 3 16 
2 16 0 11 27 
3 26 2 7 35 
4 18 0 5 23 
5 26 5 14 45 
6 40 3 16 59 
7 13 0 1 14 
8 5 0 1 6 
9 24 6 9 39 
10 6 0 11 17 
11 3 0 1 4 
12 14 0 6 20 
13 2 0 4 6 
14 7 0 4 11 
15 3 1 0 4 
16 8 0 8 16 
17 - - - - 
 18 4 0 3 7 
 19 29 2 2 33 
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Table 42: VoiSS for TLM patients (complete data set) 
 
Patients 
Impairment 
(max=60) 
Emotional 
(max=32) 
Physical 
(max=28) 
Total  
(max=120) 
1 0 2 2 4 
2 25 2 6 33 
3 15 3 6 24 
4 21 1 10 32 
5 2 0 7 9 
6 6 0 4 10 
7 1 7 4 12 
8 0 0 0 0 
9 13 4 10 27 
10 17 2 4 23 
11 24 6 4 34 
12 4 0 3 7 
13 19 5 5 29 
14 18 0 4 22 
15 10 0 7 17 
16 12 1 5 18 
17 10 0 6 16 
18 25 0 5 30 
19 5 0 4 9 
20 0 0 3 3 
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Appendix 8: Complete data set: UW-QoLv4 questionnaire for RT and TLM patients 
 
Table 43: UW-QoLv4 for RT patients (complete data set) 
QOL - 
Questionnaire 
(UW-QOL v4) 
Pain Appearance Activity Recreation  Swallowing Chewing Speech Shoulder Taste Saliva Mood  Anxiety Total (1200) 
1 100 100 100 100 100 100 100 100 100 100 100 100 1200 
2 25 100 75 75 100 100 100 30 100 100 100 100 1005 
3 100 100 50 75 100 100 100 100 100 100 100 100 1125 
4 100 75 100 75 70 50 70 100 100 70 100 100 1010 
5 75 100 50 50 70 100 100 70 100 30 100 100 945 
6 100 100 25 25 70 50 30 70 0 100 50 100 720 
7 100 75 100 100 100 100 70 100 100 100 100 100 1145 
8 100 100 75 75 100 100 100 100 100 100 100 70 1120 
9 50 75 50 75 100 100 70 100 100 100 75 30 925 
10 100 75 100 100 100 100 100 100 100 100 100 70 1145 
11 100 75 100 100 100 100 100 100 100 100 100 100 1175 
12 100 75 0 50 100 50 100 70 100 30 75 100 850 
13 100 100 100 100 100 100 100 100 100 100 100 100 1200 
14 100 100 100 100 100 100 70 100 100 100 75 70 1115 
15 100 100 50 25 100 0 100 100 100 0 100 70 845 
16 100 100 100 100 100 100 100 100 100 100 100 100 1200 
17 100 100 100 100 100 100 100 100 100 100 100 100 1200 
18 100 75 100 100 100 100 100 100 100 100 100 100 1175 
19 100 100 75 50 100 50 70 100 100 70 75 30 920 
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Table 44: UW-QoLv4 for TLM patients (complete data set) 
QOL - 
Questionnaire 
(UW-QOL v4) 
Pain Appearance Activity Recreation  Swallowing Chewing Speech Shoulder Taste Saliva Mood  Anxiety Total (1200) 
1 100 100 50 50 100 100 100 100 100 100 50 70 1020 
2 100 100 100 100 100 100 70 100 100 100 100 100 1170 
3 75 100 100 100 100 100 100 100 100 100 100 70 1145 
4 100 100 100 100 100 100 100 100 100 100 100 100 1200 
5 100 100 100 100 100 100 100 100 100 100 100 100 1200 
6 100 100 100 100 100 100 100 100 100 100 100 100 1200 
7 100 100 100 100 100 100 100 100 100 100 25 25 1050 
8 100 100 100 100 100 100 100 100 100 100 100 100 1200 
9 100 100 100 100 100 100 100 30 100 100 100 70 1100 
10 100 100 75 100 100 100 100 100 100 100 100 100 1175 
11 100 100 100 100 100 100 70 100 100 100 75 70 1115 
12 100 100 100 100 100 100 100 70 100 100 100 100 1170 
13 100 100 100 50 100 100 70 100 100 100 100 100 1120 
14 100 100 100 100 100 100 100 100 100 100 100 100 1200 
15 100 100 50 50 100 100 100 100 70 100 75 70 1015 
16 75 100 100 100 100 100 100 100 100 100 75 70 1120 
17 100 100 100 100 100 100 100 100 100 100 100 100 1200 
18 100 100 100 100 100 100   100 100 100 75 70 1045 
19 100 100 75 75 100 100 100 100 100 100 100 100 1150 
20 100 100 100 100 100 100 100 100 100 100 100 100 1200 
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Table 45: UW-QoLv4 domain scores for RT patients (complete data set) 
 N 0 25 30 50 70 75 100 Mean SE 
% Best 
Score 
Pain 19 0 1  1  1 16 92.1 4.7 78.9 
Appearance 19 0 0  0  7 12 90.8 12.4 63.2 
Activity 19 1 1  4  3 10 76.3 7.0 52.6 
Recreation 19 0 2  3  5 9 77.6 6.0 47.4 
Swallowing 19 0  0  3  16 95.3 2.6 84.2 
Chewing 19 1  0 5 0  14 84.2 6.7 73.7 
Speech 19 0  1  5  13 88.4 4.5 68.4 
Shoulder 19 0  1  3  15 91.6 4.3 78.9 
Taste 19 1  0  0  18 94.7 5.3 94.7 
Saliva 19 1  2  2  16 84.2 7.0 73.7 
Mood 19 0 0  1  4 14 92.1 3.3 73.7 
Anxiety 19 0  2  4  13 86.3 5.4 68.4 
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Table 46: UW-QoLv4 domain scores for TLM patients (complete data set) 
 
N 0 25 30 50 70 75 100 Mean SE 
% Best 
Score 
Pain 20 0 0  0  2 18 97.5 1.7 95.0 
Appearance 20 0 0  0  0 20 100 0 100 
Activity 20 0 0  2  2 16 92.5 3.7 80.0 
Recreation 20 0 0  3  1 16 91.3 4.2 80.0 
Swallowing 20 0  0  0  100 100 0 100 
Chewing 20 0  0 0 0  100 100 0 100 
Speech 20 0  0  2  13 95.3 2.5 80.0 
Shoulder 20 0  1  1  18 95.0 3.7 90.0 
Taste 20 0  0  1  19 98.5 1.5 95.0 
Saliva 20 0  0  0  20 100 0 100 
Mood 20 0 1  1  4 14 88.8 4.6 70.0 
Anxiety 20 0  1  7  12 85.8 4.5 60.0 
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Table 47: UW-QoLv4 rank within past 7 days for RT patients (complete data set) 
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1 0 0 0 0 0 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 0 0 0 0 0 0 
3 0 0 0 0 0 0 0 0 0 0 0 0 
4 0 0 0 0 0 0 0 0 0 0 0 0 
5 0 0 0 0 0 0 0 0 0 1 0 0 
6 0 0 1 1 0 0 0 0 0 0 0 1 
7 1 1 1 1 1 1 0 0 1 1 1 1 
8 0 0 0 0 0 0 0 0 0 0 0 0 
9 0 1 0 0 1 0 1 0 0 0 0 0 
10 0 0 0 0 0 0 0 0 0 0 0 0 
11 0 0 0 0 0 0 0 0 0 0 0 0 
12 0 0 0 0 0 0 0 0 0 0 0 0 
13 0 0 0 0 0 0 0 0 0 0 0 0 
14 0 0 0 0 0 0 0 0 0 0 1 1 
15 0 0 0 0 0 1 0 0 1 1 1 0 
16 0 0 0 0 0 0 0 0 0 0 0 0 
17 0 0 0 0 0 0 0 0 0 0 0 0 
18 0 0 0 0 0 0 0 0 0 0 0 0 
19 0 1 1 0 0 0 1 0 0 0 0 0 
Total 1 3 3 2 2 2 2 0 2 3 3 3 
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Table 48: UW-QoLv4 rank within past 7 days for TLM patients (complete data set) 
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1 0 1 0 0 0 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 1 0 0 0 0 0 
3 1 0 0 0 0 0 1 0 0 1 0 0 
4 1 0 1 0 0 0 1 0 0 0 0 0 
5 0 0 0 1 0 0 1 0 0 0 1 0 
6 0 0 0 0 0 0 0 0 0 0 0 0 
7 0 0 0 0 0 0 0 0 0 0 0 0 
8 0 0 0 0 0 0 0 0 0 0 0 0 
9 0 0 0 0 0 0 0 0 0 0 0 1 
10 0 0 0 0 0 0 0 0 0 0 0 1 
11 0 0 1 1 0 0 1 0 0 0 0 0 
12 0 0 0 0 0 0 0 0 0 0 0 0 
13 0 0 0 0 0 0 1 0 0 0 0 0 
14 0 0 1 0 0 0 1 0 0 0 0 0 
15 1 0 1 1 0 0 0 0 0 0 0 0 
16 0 0 0 0 0 0 0 0 0 0 0 1 
17 0 0 0 0 0 0 0 0 0 0 0 0 
18 0 0 0 0 0 0 0 0 0 0 0 0 
19 0 1 1 1 0 0 0 0 0 0 0 0 
20 0 0 0 0 0 0 0 0 0 0 0 0 
Total 3 2 5 4 0 0 7 0 0 1 1 3 
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Table 49: UW-QoLv4 global question scores for RT patients (complete data set) 
 How would you rate 
your health-related 
QOL? 
Your Health-
related QOL is? 
Overall QOL? 
1 50 80 80 
2 25 60 60 
3 75 60 40 
4 100 80 100 
5 25 80 80 
6 50 20 20 
7 50 80 100 
8 50 80 80 
9 50 60 80 
10 50 100 100 
11 50 60 60 
12 50 60 60 
13 50 40 60 
14 50 60 80 
15 50 100 80 
16 50 80 80 
17 100 100 100 
18 100 100 100 
19 -  - - 
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Table 50: UW-QoLv4 global question scores for TLM patients (complete data set) 
 
How would you rate 
your health-related 
QOL? 
Your Health-
related QOL is? 
Overall QOL? 
1 - - - 
2 - - - 
3 - - - 
4 - - - 
5 - - - 
6 - - - 
7  -  -  - 
8  -  -  - 
9  -  -  - 
10  -  -  - 
11  - -   - 
12 100 80 80 
13 50 40 80 
14 -  -   - 
15 100 80 80 
16 50 60 60 
17 50 80 80 
18 50 60 60 
19 50 60 80 
20 100 100 100 
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Table 51: UW-QoLv4 global questions for RT patients (complete data set) 
 
  
 
N 0 20 25 40 50 60 75 80 100 Mean SE 
% Best 
Scores 
A. Health-related QOL 
compared to month 
before had cancer 
19 0  2  13  1  3 56.9 5.1 15.8 
B. Health-related QOL 
during the past 7 days 
19 0 1  1  7  6 4 72.2 5.0 21.1 
C. Overall QOL during 
the past 7 days 
19 0 1  1  4  8 5 75.6 5.1 26.3 
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 Table 52: UW-QoLv4 global questions for TLM patients (complete data set) 
 
 
  
 N 0 20 25 40 50 60 75 80 100 Mean SE 
% Best 
Scores 
A. Health-related QOL 
compared to month 
before had cancer 
8 0  0  5  0  3 68.8 9.1 37.5 
B. Health-related QOL 
during the past 7 days 
8 0 0  1  3  3 1 70.0 6.5 12.5 
C. Overall QOL during 
the past 7 days 
8 0 0  0  2  5 1 77.5 4.5 12.5 
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Table 53: UW-QoLv4 domain issue seen as most important in past seven days for RT 
and TLM patients (complete data set) 
 
N 
Number of RT 
patients 
choosing 
domain 
Number of 
TLM 
patients 
choosing 
domain 
Total number 
of patients 
choosing 
domain 
Rank order 
Pain 39 1 3 4 =6 
Appearance 39 3 2 5 5 
Activity 39 3 5 8 2 
Recreation 39 2 4 6 =3 
Swallowing 39 2 0 2 =9 
Chewing 39 2 0 2 =9 
Speech 39 2 7 9 1 
Shoulder 39 0 0 0 12 
Taste 39 2 0 2 =9 
Saliva 39 3 1 4 =6 
Mood 39 3 1 4 =6 
Anxiety 39 3 3 6 =3 
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Appendix 9: Complete data set: perception rating for RT and 
TLM patients  
Table 54: GRBAS scores for RT patients (complete data set) 
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1 1 1 0 0 0 1 1 0 0 0 1 1 0 0 0 
2 3 3 2 0 2 3 3 2 0 2 2 2 1 0 0 
3 3 3 1 1 3 3 3 1 1 2 3 3 2 1 1 
4 3 2 2 2 2 3 2 2 2 2 2 2 1 1 2 
5 3 1 2 1 2 3 2 2 1 2 1 1 0 0 0 
6 3 2 3 2 3 3 2 3 2 3 3 2 2 2 3 
7 2 2 1 1 2 2 1 1 1 2 2 2 1 1 1 
8 - - - - - - - - - - 1 1 1 0 0 
9 - - - - - - - - - - 2 2 1 0 1 
10 - - - - - - - - - - 2 2 1 1 1 
11 - - - - - - - - - - 2 1 2 1 1 
12 - - - - - - - - - - 2 2 1 0 0 
13 - - - - - - - - - - 0 0 0 0 0 
14 - - - - - - - - - - 1 1 0 0 0 
15 - - - - - - - - - - 1 1 0 0 0 
16 - - - - - - - - - - 1 1 0 0 0 
17 - - - - - - - - - - 1 1 1 0 0 
18 - - - - - - - - - - 1 1 1 0 0 
19 - - - - - - - - - - 2 1 1 1 2 
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Table 55: GRBAS scores for TLM patients (complete data set) 
 
 
Rater 1 scores Rater 2 scores Rater 3 scores 
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1 1 1 0 0 1 1 1 0 0 1 2 2 2 0 2 
2 2 1 2 2 1 2 0 2 2 1 2 2 2 2 2 
3 2 0 0 1 2 2 0 0 2 2 2 1 2 1 2 
4 1 1 0 0 1 1 1 0 0 1 2 1 2 1 2 
5 2 1 1 0 2 2 1 1 1 2 2 0 2 0 1 
6 0 0 0 0 0 0 0 0 0 0 2 1 2 0 1 
7 1 1 1 0 1 1 1 1 0 1 1 1 1 0 0 
8 2 1 0 0 2 2 1 0 0 2 2 2 1 0 1 
9 1 0 1 1 0 1 0 1 1 0 2 2 2 0 1 
10 1 1 0 0 0 1 1 0 1 0 2 0 2 0 0 
11 2 0 2 1 2 2 0 2 1 2 2 1 2 1 2 
12 1 0 1 0 1 1 0 1 0 1 1 1 0 0 0 
13 3 0 3 2 3 3 0 2 2 3 3 3 3 2 3 
14 1 1 0 0 0 1 1 0 0 0 1 1 0 0 0 
15 - - - - - - - - - - 1 1 1 1 1 
16 - - - - - - - - - - 0 0 0 0 0 
17 - - - - - - - - - - 1 1 1 1 0 
18 - - - - - - - - - - 3 2 3 2 2 
19 - - - - - - - - - - 2 1 2 1 1 
20 - - - - - - - - - - 1 1 1 0 0 
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Appendix 10: Complete data set: sustained vowels for RT and TLM patients  
Table 56: Sustained vowel /i/ for RT patients (complete data set) 
 Duration (ms) 
Minimum 
Fx (Hz) 
Maximum 
Fx (Hz) 
Average 
Fx (Hz) 
S.D. 
Fx 
(%) 
Minimum 
Qx (%) 
Maximum 
Qx (%) 
Average 
Qx (%) 
S.D. 
Qx 
(%) 
Jitter 
First 
(%) 
Jitter 
Second 
(%) 
Shimmer 
+ (%) 
Shimmer 
– (%) 
Jitter 
Factor 
(%) 
RAP 
(%) 
Shimmer 
dB (dB) 
NNE 
(dB) 
CPP 
HNR 
(dB) 
Mean 
SPL 
(dB) 
1 1612.0 116.5 129.5 123.7 2.0 50.0 58.5 55.1 1.8 0.5 0.3 3.0 -3.3 0.5 0.3 0.3 -22.9 4.0 18.4 94.8 
2 248.0 87.6 91.2 89.8 1.0 38.2 62.1 46.8 6.2 0.9 0.5 2.3 -3.4 0.9 0.5 0.2 -24.6 2.7 21.5 85.7 
3 4364.0 51.8 1024.6 144.0 82.0 0.0 74.4 39.8 14.7 31.0 32.1 28.5 -32.6 51.1 14.8 2.7 -1.0 0.9 2.4 93.0 
4 596.0 127.1 255.1 229.2 4.6 0.0 50.0 40.6 4.2 2.6 1.5 2.3 -3.8 2.5 1.8 0.2 -20.6 2.9 24.5 87.8 
5 240.0 149.7 205.4 176.1 7.0 14.9 33.3 25.0 5.2 9.3 5.8 2.5 -3.8 9.4 5.7 0.2 -18.0 3.6 19.8 89.4 
6 136.0 206.2 259.4 232.8 6.5 43.5 52.2 48.4 2.9 2.5 1.5 4.3 -6.0 2.5 1.5 0.4 -15.5 3.6 18.2 94.5 
7 1012.0 148.8 169.2 158.1 2.4 45.0 53.5 49.1 1.9 2.2 1.3 1.0 -10.0 2.2 1.3 0.9 -11.5 1.9 14.0 89.7 
8 1488.0 81.7 503.8 240.0 42.1 0.0 59.8 27.7 10.2 48.0 31.2 9.7 -12.7 50.9 28.7 0.9 1.1 1.9 5.1 102.6 
9 8261.0 104.2 112.6 107.7 1.2 46.2 65.1 59.2 3.6 0.5 0.3 7.0 -3.3 0.5 0.3 0.6 -17.8 2.8 17.7 80.9 
10 11112.0 172.4 206.4 184.7 2.5 34.9 47.8 43.4 1.9 0.7 0.4 4.8 -4.4 0.7 0.4 0.4 -17.8 3.6 17.7 76.3 
11 2655.0 87.9 207.5 168.2 5.8 29.6 66.0 55.8 6.6 5.2 3.1 5.3 -5.6 5.1 3.2 0.5 -15.8 1.8 17.7 76.4 
12 502.6 151.4 169.8 162.9 2.3 34.3 50.5 47.0 2.6 1.4 0.8 9.2 -5.9 1.4 0.8 0.9 -17.3 2.8 17.1 82.3 
13 2058.0 156.3 585.8 209.8 53.8 0.0 61.4 46.1 22.8 28.4 26.1 11.7 -28.0 41.5 11.4 1.2 -2.9 3.4 12.9 84.9 
14 2412.6 152.5 160.3 156.1 0.9 29.8 39.8 33.5 2.1 0.6 0.3 4.5 -7.4 0.6 0.3 0.4 -15.3 3.9 14.9 85.6 
15 - - - - - - - - - - - - - - - - - - - - 
16 3847.0 69.6 157.0 138.7 2.9 30.0 53.4 49.1 2.4 1.3 0.8 4.0 -5.0 1.3 0.9 0.4 -16.4 3.5 14.9 88.2 
17 7023.0 130.7 134.1 132.4 0.5 50.0 56.2 52.7 1.0 0.2 0.1 1.7 -1.8 0.2 0.1 0.2 -27.0 4.5 17.5 93.0 
18 400.0 135.6 139.6 137.4 0.6 42.6 47.0 45.5 0.9 0.4 0.2 2.0 -2.9 0.4 0.2 0.2 -23.9 4.2 20.3 93.9 
19 - - - - - - - - - - - - - - - - - - - - 
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Table 57: Sustained vowel /i/ for TLM patients (complete data set) 
 
 Duration (ms) 
Minimum 
Fx (Hz) 
Maximum 
Fx (Hz) 
Average 
Fx (Hz) 
S.D. 
Fx 
(%) 
Minimum 
Qx (%) 
Maximum 
Qx (%) 
Average 
Qx (%) 
S.D. 
Qx 
(%) 
Jitter 
First 
(%) 
Jitter 
Second 
(%) 
Shimmer 
+ (%) 
Shimmer 
– (%) 
Jitter 
Factor 
(%) 
RAP 
(%) 
Shimmer 
dB (dB) 
NNE 
(dB) 
CPP 
HNR 
(dB) 
Mean 
SPL 
(dB) 
1 1733.6 157.8 166.1 162.3 1.1 57.1 59.8 58.4 0.5 1.3 0.8 8.2 -7.5 1.3 0.9 0.7 -16.5 3.3 16.4 103.5 
2 1021.0 104.8 253.4 216.2 11.4 24.8 53.4 45.2 4.6 9.5 5.4 6.9 -13.9 8.6 7.2 0.6 -8.2 2.2 14.5 87.0 
3 3738.7 205.2 223.1 212.6 1.2 33.8 46.7 39.9 2.4 1.2 0.7 3.7 -8.5 1.2 0.7 0.3 -16.2 2.1 17.0 91.8 
4 4984.0 151.9 162.2 156.7 0.9 25.5 43.7 30.6 3.2 0.6 0.4 4.6 -8.0 0.6 0.4 0.4 -16.6 1.9 16.8 90.9 
5 1499.0 179.0 186.7 182.5 0.8 42.0 56.2 48.9 3.2 0.4 0.3 3.0 -2.8 0.4 0.3 0.3 -21.9 3.7 18.9 93.9 
6 5553.0 204.0 211.5 207.9 0.5 39.0 47.4 44.2 1.9 0.3 0.2 2.1 -3.4 0.3 0.2 0.2 -21.3 3.3 19.6 90.7 
7 2013.3 164.1 170.1 167.1 0.7 57.7 62.5 60.1 0.8 0.1 0.1 1.7 -2.0 0.1 0.1 0.2 -26.5 5.7 19.0 100.9 
8 1861.6 210.7 229.1 219.0 1.2 62.2 67.1 64.7 1.1 1.0 0.6 3.4 -5.9 1.0 0.6 0.3 -11.6 5.8 15.5 97.1 
9 1207.6 173.1 197.7 183.2 2.0 42.7 51.8 45.4 1.7 0.6 0.3 2.8 -3.2 0.6 0.3 0.2 -19.2 3.4 18.1 90.0 
10 2507.0 147.0 181.3 177.8 0.8 37.5 43.3 40.3 1.0 0.7 0.4 3.0 -3.5 0.7 0.4 0.3 -24.7 3.6 17.7 92.4 
11 7496.0 201.6 214.9 207.9 0.8 35.9 41.0 38.3 0.8 0.7 0.4 4.8 -8.3 0.7 0.4 0.4 -16.6 2.8 18.9 98.3 
12 - - - - - - - - - - - - - - - - - - - - 
13 - - - - - - - - - - - - - - - - - - - - 
14 - - - - - - - - - - - - - - - - - - - - 
15 4112.0 78.2 199.6 165.9 5.1 16.2 48.4 39.0 4.2 2.8 1.6 5.3 -2.8 2.6 2.0 0.5 -18.1 2.0 22.6 76.2 
16 15241.0 146.5 158.3 151.8 0.9 33.0 49.1 43.3 1.6 0.2 0.1 4.9 -4.7 0.2 0.1 0.4 -20.6 4.9 19.2 79.1 
17 5507.0 119.8 126.7 123.7 1.1 54.2 62.4 59.0 1.6 0.3 0.2 4.2 -2.5 0.3 0.2 0.4 -26.2 2.6 23.5 73.6 
18 569.0 50.2 387.6 285.0 27.7 0.0 76.8 36.8 17.9 34.9 16.1 7.1 -6.8 26.7 36.5 0.7 0.7 2.2 15.2 72.7 
19 4982.0 61.0 1328.0 203.3 78.8 0.0 93.3 42.4 16.6 35.7 31.1 27.6 -4.9 50.5 19.2 1.4 -1.0 3.2 16.0 83.9 
20 4970.0 133.9 143.2 139.5 1.1 29.9 36.8 33.8 1.4 0.5 0.2 3.7 -3.8 0.5 0.2 0.3 -23.7 4.9 20.7 82.5 
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Table 58: Sustained vowel /a/ for RT patients (complete data set) 
 Duration (ms) 
Minimum 
Fx (Hz) 
Maximum 
Fx (Hz) 
Average 
Fx (Hz) 
S.D. 
Fx 
(%) 
Minimum 
Qx (%) 
Maximum 
Qx (%) 
Average 
Qx (%) 
S.D. 
Qx 
(%) 
Jitter 
First 
(%) 
Jitter 
Second 
(%) 
Shimmer 
+ (%) 
Shimmer 
– (%) 
Jitter 
Factor 
(%) 
RAP 
(%) 
Shimmer 
dB (dB) 
NNE 
(dB) 
CPP 
HNR 
(dB) 
Mean 
SPL 
(dB) 
1 2804.0 96.2 104.5 100.2 1.2 43.5 55.2 48.5 2.1 0.4 0.2 3.4 -3.8 0.4 0.2 0.4 -23.0 4.8 18.1 95.8 
2 252.0 176.1 207.2 190.3 3.3 0.0 47.7 39.0 13.5 2.7 1.4 13.5 -3.8 2.7 1.4 1.4 -25.2 4.3 20.6 87.9 
3 4308.0 55.8 688.2 112.4 81.5 0.0 73.5 42.0 15.1 29.5 30.4 46.4 -34.1 49.9 12.9 4.0 0.1 1.1 - 96.3 
4 112.0 118.4 207.5 196.3 2.4 43.2 48.1 45.5 1.3 2.0 1.1 9.5 -4.1 2.0 1.0 0.8 -16.1 4.5 16.5 90.2 
5 2456.0 138.4 158.7 148.5 2.3 30.7 46.8 36.9 4.4 0.9 0.5 5.7 -3.8 0.9 0.5 0.5 -17.8 4.4 15.9 88.3 
6 240.0 180.2 230.2 211.0 6.1 34.7 46.8 40.8 2.7 3.0 2.0 11.1 -17.7 3.0 2.0 0.9 -12.1 3.0 12.9 93.1 
7 3624.0 148.2 163.8 156.2 1.7 26.2 53.9 40.4 6.1 1.8 1.1 25.5 -26.2 1.8 1.1 2.4 -4.8 2.2 8.2 93.9 
8 1774.0 84.9 1200.0 253.1 80.8 0.0 58.6 42.0 14.3 44.5 47.1 16.4 -7.1 72.2 19.2 1.4 -0.6 5.1 9.4 101.3 
9 2498.0 88.7 112.3 104.7 4.1 39.6 58.0 46.4 3.6 1.2 0.6 6.6 -4.8 1.2 0.7 0.6 -12.8 3.5 11.9 86.9 
10 8069.0 71.3 485.2 150.8 9.5 28.3 52.5 38.8 5.7 1.2 0.7 9.6 -8.0 1.2 0.7 1.0 -16.0 2.7 13.6 81.1 
11 2336.0 170.3 188.0 180.1 1.9 39.8 62.2 48.3 5.5 1.6 0.9 6.3 -10.9 1.6 0.9 0.5 -16.0 3.0 15.7 74.8 
12 448.4 141.7 156.1 150.2 2.2 41.3 50.9 47.0 2.3 0.9 0.5 11.8 -9.1 0.9 0.5 1.0 -15.2 3.7 14.7 79.3 
13 3242.0 144.3 157.0 149.2 1.5 45.3 53.7 49.5 1.6 1.8 1.2 4.3 -3.4 1.8 1.2 0.4 -16.8 3.7 14.3 89.1 
14 - - - - - - - - - - - - - - - - - - - - 
15 - - - - - - - - - - - - - - - - - - - - 
16 2568.0 117.2 149.4 141.0 1.3 46.4 52.3 49.3 1.0 0.9 0.5 7.4 -4.9 0.9 0.5 0.6 -16.6 4.7 14.3 87.2 
17 13520.0 124.2 134.4 129.3 1.1 45.9 50.8 48.3 0.7 0.5 0.3 3.6 -4.3 0.5 0.3 0.3 -21.1 4.3 18.0 92.7 
18 1961.0 58.9 288.0 121.9 10.7 0.0 57.7 51.1 9.9 3.5 2.0 6.0 -4.8 3.7 2.3 0.5 -9.8 3.8 13.9 97.3 
19 - - - - - - - - - - - - - - - - - - - - 
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Table 59: Sustained vowel /a/ for TLM patients (complete data set) 
 Duration (ms) 
Minimum 
Fx (Hz) 
Maximum 
Fx (Hz) 
Average 
Fx (Hz) 
S.D. 
Fx 
(%) 
Minimum 
Qx (%) 
Maximum 
Qx (%) 
Average 
Qx (%) 
S.D. 
Qx 
(%) 
Jitter 
First 
(%) 
Jitter 
Second 
(%) 
Shimmer 
+ (%) 
Shimmer 
– (%) 
Jitter 
Factor 
(%) 
RAP 
(%) 
Shimmer 
dB (dB) 
NNE 
(dB) 
CPP 
HNR 
(dB) 
Mean 
SPL 
(dB) 
1 2977.0 163.6 186.0 169.2 2.5 44.1 62.5 55.1 5.2 0.8 0.5 10.0 -10.3 0.8 0.5 0.9 -14.9 3.6 12.5 107.7 
2 4987.0 205.0 217.9 210.4 0.9 35.1 48.1 42.9 2.2 0.5 0.3 5.8 -5.4 0.5 0.3 0.5 -17.3 2.9 18.9 89.9 
3 2047.0 99.2 261.1 208.7 5.5 28.4 43.6 35.8 2.7 2.4 1.5 6.1 -3.8 2.4 1.5 0.5 -20.7 4.0 16.8 96.2 
4 4737.0 152.9 161.1 157.5 0.9 32.4 43.6 38.4 2.9 0.5 0.3 8.7 -10.1 0.5 0.3 0.8 -13.5 2.5 15.0 90.3 
5 1563.0 173.0 187.3 181.1 1.2 43.0 51.1 48.4 1.3 0.4 0.2 3.8 -2.9 0.4 0.2 0.3 -25.1 6.6 19.3 99.3 
6 2274.0 184.5 190.5 187.4 0.6 39.3 43.5 41.5 0.7 0.5 0.3 4.8 -2.4 0.5 0.3 0.4 -21.8 4.3 18.9 90.4 
7 1318.0 163.8 170.7 167.7 0.8 55.9 60.4 58.4 0.7 0.2 0.1 1.4 -1.6 0.2 0.1 0.1 -27.4 7.1 22.2 105.7 
8 1192.0 194.3 207.0 199.0 1.6 55.6 63.0 60.5 1.4 0.3 0.1 2.1 -2.0 0.3 0.1 0.2 -26.3 6.9 21.0 107.5 
9 1009.0 150.2 160.2 153.7 1.3 37.5 44.2 41.5 1.6 0.3 0.1 8.3 -7.9 0.3 0.1 0.7 -17.7 4.0 15.7 90.4 
10 6833.0 167.0 181.4 175.3 0.8 25.3 55.2 34.2 2.9 0.6 0.4 5.0 -3.8 0.6 0.4 0.4 -18.8 4.1 18.0 90.8 
11 4997.0 189.7 198.9 194.6 0.7 34.9 40.2 37.5 0.8 0.7 0.4 11.1 -7.4 0.7 0.4 1.0 -16.6 3.8 16.2 96.2 
12 - - - - - - - - - - - - - - - - - - - - 
13 - - - - - - - - - - - - - - - - - - - - 
14 - - - - - - - - - - - - - - - - - - - - 
15 6739.0 55.2 1335.1 176.0 47.9 0.0 77.7 48.6 15.8 15.1 11.8 9.5 -6.2 19.0 11.1 0.7 -6.5 2.9 16.9 73.3 
16 10072.0 147.8 156.5 151.5 0.8 31.1 43.5 36.6 2.8 0.3 0.2 4.2 -4.0 0.3 0.2 0.4 -22.4 5.4 17.3 80.5 
17 11521.9 115.8 134.7 124.3 1.6 41.8 53.1 59.4 2.0 1.3 0.8 3.0 -3.5 1.3 0.8 0.3 -18.6 3.9 16.9 77.4 
18 664.0 57.2 1319.3 305.9 85.4 0.0 74.1 23.2 23.9 67.7 49.5 30.6 -32.4 80.6 46.4 4.2 0.8 2.0 6.6 64.3 
19 3409.0 152.6 984.3 163.1 32.0 0.0 88.2 46.6 3.6 3.6 4.3 7.4 -8.3 6.7 1.8 0.7 -9.3 3.3 14.2 79.4 
20 2349.0 133.4 144.2 137.3 1.1 35.3 39.7 37.5 0.6 0.8 0.5 7.2 -6.8 0.8 0.5 0.6 -19.5 4.9 16.0 88.1 
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Appendix 11: Complete data set: voice questionnaires for pre- 
and post- TLM patients 
 
Table 60: VHI-10 for pre-TLM patients (complete data set) 
 
Functional 
(VHI-10 F) 
(max=20) 
Physical 
(VHI-10 P) 
(max=12) 
Emotional 
(VHI-10 E) 
(max=8) 
Total 
(max=40) 
1 7 8 6 21 
2 12 11 2 25 
3 13 8 4 25 
4 6 5 2 13 
5 6 7 1 14 
6 9 7 2 18 
7 2 3 1 6 
8 6 6 0 12 
9 3 6 4 13 
10 9 3 1 13 
11 3 3 0 6 
12 0 0 2 2 
13 6 4 3 13 
14 3 4 2 9 
15 3 1 1 5 
16 18 12 8 38 
17 5 4 4 13 
18 2 4 0 6 
19 5 6 1 12 
20 4 5 2 11 
21 11 10 7 28 
22 7 6 2 15 
23 4 5 2 11 
24 8 5 6 19 
25 10 7 2 19 
26 0 0 0 0 
27 4 5 0 9 
28 3 6 2 11 
29 0 0 0 0 
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Table 61: VHI-10 for post-TLM patients (complete data set) 
 
Functional 
(VHI-10 F) 
(max=20) 
Physical 
(VHI-10 P) 
(max=12) 
Emotional 
(VHI-10 E) 
(max=8) 
Total 
(max=40) 
1 7 6 1 14 
2 2 2 1 5 
3 6 5 1 12 
4 12 10 4 26 
5 11 9 4 24 
6 7 5 2 14 
7 16 10 6 32 
8 2 0 0 2 
9 12 5 3 20 
10 10 7 2 19 
11 0 0 0 0 
12 3 0 0 3 
13 6 3 0 9 
14 1 1 2 4 
15 2 3 0 5 
16 15 9 8 32 
17 3 3 0 6 
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Table 62: VoiSS for pre-TLM patients (complete data set) 
 
 
 
  
 
Impairment 
(max=60) 
Emotional 
(max=32) 
Physical 
(max=28) 
Total  
(max=120) 
1 38 5 11 54 
2 40 6 8 54 
3 38 12 9 59 
4 30 2 8 40 
5 21 3 4 28 
6 32 7 6 45 
7 20 3 2 25 
8 39 0 11 50 
9 30 3 12 45 
10 23 4 6 33 
11 9 1 7 17 
12 8 0 9 17 
13 31 10 1 42 
14 25 14 5 44 
15 20 7 8 35 
16 54 22 7 83 
17 32 4 7 43 
 18 21 0 2 23 
 19 27 9 6 42 
20 20 6 7 33 
21 47 16 8 71 
22 31 11 7 49 
23 32 4 13 49 
24 29 12 8 49 
25 31 5 7 43 
26 0 0 2 2 
27 16 4 9 29 
28 31 4 4 39 
29 0 0 13 13 
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Table 63: VoiSS for post-TLM patients (complete data set) 
 
 
Impairment 
(max=60) 
Emotional 
(max=32) 
Physical 
(max=28) 
Total  
(max=120) 
1 27 12 12 51 
2 23 0 8 31 
3 25 0 3 28 
4 43 15 6 64 
5 43 9 8 60 
6 -  -  -  -  
7 34 14 6 54 
8 8 0 0 8 
9 40 11 11 62 
10 40 9 9 58 
11 1 0 10 11 
12 6 0 5 11 
13 25 4 5 34 
14 14 1 5 20 
15 21 0 6 27 
16 40 16 16 72 
17 12 0 6 18 
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Appendix 12: Complete data set: UW-QoLv4 questionnaire for pre- and post-TLM patients 
Table 64: UW-QoLv4 for pre-TLM patients (complete data set) 
 
Pain Appearance Activity Recreation  Swallowing Chewing Speech Shoulder Taste Saliva Mood  Anxiety Total (1200) 
1 50 75 100 100 100 100 30 100 100 100 75 70 1000 
2 50 100 50 50 100 100 70 30 100 100 75 70 895 
3 75 75 100 100 100 100 70 100 100 100 75 70 1065 
4 75 100 75 75 100 100 70 100 100 100 75 70 1040 
5 75 100 100 75 100 100 70 100 100 100 25 30 975 
6 75 100 100 100 70 100 70 30 100 100 100 100 1045 
7 75 100 100 100 100 100 30 100 100 100 75 70 1050 
8 75 100 100 100 100 100 100 100 100 100 75 70 1120 
9 75 100 100 100 100 100 100 100 100 100 100 70 1145 
10 100 100 100 75 100 100 30 100 100 100 75 70 1050 
11 100 100 100 75 100 100 100 70 100 30 50 30 955 
12 100 100 100 75 100 100 100 100 100 100 100 70 1145 
13 100 100 100 100 100 100 70 100 100 100 75 30 1075 
14 100 100 100 100 100 100 70 100 70 100 100 100 1140 
15 100 100 100 100 100 100 100 100 100 100 75 70 1145 
16 100 100 100 100 100 100 100 100 100 100 100 70 1170 
17 100 100 100 100 100 100 100 100 100 100 100 70 1170 
18 50 100 50 50 100 100 100 100 70 70 100 70 960 
19 50 100 75 75 70 100 70 70 70 70 100 100 950 
20 100 100 50 50 100 100 70 0 100 100 75 30 875 
21 100 100 50 50 100 100 70 100 70 100 75 30 945 
22 100 100 50 100 100 100 70 100 70 100 75 70 1035 
23 100 100 75 75 100 100 70 100 100 100 75 30 1025 
24 100 100 100 100 100 100 70 100 100 100 75 100 1145 
25 100 100 100 100 100 100 70 100 100 100 75 100 1145 
26 100 100 100 100 100 100 70 100 100 100 100 70 1140 
27 100 100 100 100 100 100 70 100 70 100 100 100 1140 
28 100 100 100 100 100 100 100 100 100 100 75 70 1145 
29 100 100 100 100 100 100 100 100 100 100 100 100 1200 
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Table 65: UW-QoLv4 for post-TLM patients (complete data set) 
 
Pain Appearance Activity Recreation  Swallowing Chewing Speech Shoulder Taste Saliva Mood  Anxiety Total (1200) 
1 100 50 50 50 70 50 70 0 70 100 25 30 665 
2 100 100 100 100 100 100 100 100 100 70 100 70 1140 
3 100 100 100 75 100 100 70 100 100 100 100 70 1115 
4 100 100 100 100 100 100 70 100 100 100 75 70 1115 
5 100 100 50 50 100 100 100 30 70 100 75 70 945 
6 100 100 75 100 100 100 70 100 100 100 75 70 1090 
7 100 100 75 75 100 100 100 100 100 100 75 70 1095 
8 100 100 100 100 100 100 100 100 100 100 100 100 1200 
9 100 100 50 100 70 100 70 100 100 100 25 70 985 
10 50 100 50 75 100 100 70 30 100 70 100 100 945 
11 75 100 100 100 100 100 100 70 100 100 100 100 1145 
12 100 100 50 75 100 100 100 100 100 100 100 100 1125 
13 100 100 75 75 100 100 100 100 100 100 100 100 1150 
14 100 100 100 100 70 100 70 100 70 30 75 70 985 
15 100 100 100 100 100 100 100 100 100 100 100 100 1200 
16 100 100 100 100 100 100 70 70 70 100 100 70 1080 
17 100 100 100 100 100 100 100 100 100 100 100 100 1200 
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Table 66: UW-QoLv4 domain scores for all pre-TLM patients (complete data set) 
 N 0 25 30 50 70 75 100 Mean 
% Best 
Score 
Pain 
29 0 0  4  7 18 87.1 
62.1 
Appearance 
29 0 0  0  2 27 98.3 
93.1 
Activity 
29 0 0  4  3 21 88.8 
72.4 
Recreation 
29 0 0  4  7 18 86.9 
62.1 
Swallowing 
29 0  0  2  27 97.9 
93.1 
Chewing 
29 0  0  0  29 100.0 
100 
Speech 
29 0  3  16  10 76.2 
34.5 
Shoulder 
29 1  2  2  24 89.7 
82.8 
Taste 
29 0  0  6  23 93.8 
79.3 
Saliva 
29 0  1  2  26 95.5 
89.7 
Mood 
29 0 1  1  16 11 81.9 
37.9 
Anxiety 
29 0  6  16  7 69.0 
24.1 
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Table 67: UW-QoLv4 domain scores for included pre-TLM patients (complete data set) 
 N 0 25 30 50 70 75 100 Mean 
% Best 
Score 
Pain 
17 0 0  2  7 8 83.8 
47.1 
Appearance 
17 0 0  0  2 15 97.1 
88.2 
Activity 
17 0 0  1  1 15 95.6 
88.2 
Recreation 
17 0 0  1  5 11 89.7 
64.7 
Swallowing 
17 0  0  1  16 98.2 
94.1 
Chewing 
17 0  0  0  17 100.0 
100 
Speech 
17 0  3  7  7 75.3 
41.2 
Shoulder 
17 0  1  2  14 90.0 
82.4 
Taste 
17 0  0  0  17 98.2 
100 
Saliva 
17 0  1  0  16 95.9 
94.1 
Mood 
17 0 1  1  9 6 79.4 
35.3 
Anxiety 
17 0  3  12  2 66.5 
11.8 
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Table 68: UW-QoLv4 domain scores for post-TLM patients (complete data set) 
 N 0 25 30 50 70 75 100 Mean 
% Best 
Score 
Pain 17 0 0  1  1 15 95.6 88.2 
Appearance 17 0 0  1  0 16 97.1 94.1 
Activity 17 0 0  5  3 9 80.9 52.9 
Recreation 17 0 0  2  5 10 86.8 58.8 
Swallowing 17 0  0  3  14 94.7 82.4 
Chewing 17 0  0 1 0  16 97.1 94.1 
Speech 17 0  0  8  9 85.9 52.9 
Shoulder 17 1  2  2  12 82.4 70.6 
Taste 17 0  0  4  13 92.9 76.5 
Saliva 17 0  1  2  14 92.4 82.4 
Mood 17 0 2  0  5 10 83.8 58.8 
Anxiety 17 0  1  9  7 80.0 41.2 
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Table 69: UW-QoLv4 rank within past 7 days for pre-TLM patients (complete data set) 
 Pain Appearance Activity Recreation  Swallowing Chewing Speech Shoulder Taste Saliva Mood  Anxiety 
1 1 1 0 0 0 1 0 0 0 0 0 0 
2 1 0 0 0 0 0 1 0 1 0 0 0 
3 1 0 0 0 0 0 1 0 0 0 0 1 
4 0 0 0 0 0 0 1 0 0 0 1 1 
5 1 0 0 0 0 0 0 0 0 0 0 1 
6 1 0 0 0 1 0 0 1 0 0 0 0 
7 0 0 0 0 0 0 0 0 0 0 0 0 
8 0 0 0 0 0 0 1 0 0 0 0 1 
9 0 0 0 0 0 0 0 0 0 0 0 1 
10 0 0 0 0 0 0 1 0 0 0 1 1 
11 0 0 0 0 0 0 1 0 0 1 0 1 
12 0 0 0 0 0 0 0 0 0 0 0 1 
13 0 0 0 0 0 0 0 0 0 0 0 1 
14 0 1 0 0 0 0 1 0 0 0 1 0 
15 0 0 0 0 0 0 0 0 0 0 0 1 
16 0 0 1 0 0 0 1 0 0 0 0 0 
17 0 0 0 0 0 0 0 0 0 0 0 0 
18 0 0 1 0 0 0 1 0 0 0 0 1 
19 0 0 0 0 1 0 1 0 0 0 0 0 
20 0 0 1 0 0 0 0 1 0 0 0 0 
21 0 0 1 0 0 0 1 0 0 0 0 1 
22 0 0 0 0 0 0 0 0 0 0 0 1 
23 0 0 1 0 0 0 0 0 0 0 1 1 
24 0 0 0 0 0 0 1 0 0 0 0 0 
25 0 0 0 0 0 0 0 0 0 0 0 0 
26 0 0 0 0 0 0 1 0 0 0 0 1 
27 0 0 0 0 0 0 0 0 0 0 0 1 
28 0 0 0 0 0 0 0 0 0 0 0 1 
29 0 0 0 0 0 0 0 0 0 0 0 0 
Total 5 2 5 0 2 1 13 2 1 1 4 17 
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Table 70: UW-QoLv4 rank within past 7 days for post-TLM patients (complete data set) 
 Pain Appearance Activity Recreation  Swallowing Chewing Speech Shoulder Taste Saliva Mood  Anxiety 
1 0 0 0 0 0 1 1 0 0 0 1 1 
2 0 0 0 0 0 0 0 0 1 0 0 0 
3 0 0 0 0 0 0 0 0 0 0 0 0 
4 0 0 0 0 0 1 0 0 0 1 1 1 
5 0 1 0 0 0 1 0 0 0 0 0 0 
6 0 0 0 0 0 0 1 0 0 0 1 1 
7 0 0 0 0 0 1 0 0 0 1 1 0 
8 0 0 0 0 0 0 0 0 0 0 0 0 
9 0 0 0 0 0 0 0 0 0 0 0 0 
10 0 0 0 0 0 0 1 1 0 0 0 0 
11 0 0 0 0 0 0 0 0 0 0 0 0 
12 0 0 0 0 0 0 0 0 0 0 0 0 
13 0 0 0 0 0 0 1 0 0 0 0 0 
14 0 0 0 0 0 0 0 0 1 1 0 0 
15 0 1 0 0 1 0 1 0 0 0 0 0 
16 0 1 0 0 0 0 1 0 0 0 1 0 
17 0 0 0 0 1 0 1 0 1 0 0 0 
Total 0 3 0 0 2 4 7 1 3 3 5 3 
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Table 71: UW-QoLv4 domain issue seen as most important in past seven days for pre- 
and post- TLM patients (complete data set) 
 
N 
Number of pre- 
TLM patients 
choosing domain 
Number of  post- 
TLM patients 
choosing domain 
Total number of 
patients choosing 
domain 
Rank 
order 
Pain 46 5 0 5 =4 
Appearance 46 2 3 5 =4 
Activity 46 5 0 5 =4 
Recreation 46 0 0 0 12 
Swallowing 46 2 2 4 =8 
Chewing 46 1 4 5 =4 
Speech 46 13 7 20 =1 
Shoulder 46 2 1 3 11 
Taste 46 1 3 4 =8 
Saliva 46 1 3 4 =8 
Mood 46 4 5 9 3 
Anxiety 46 17 3 20 =1 
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Table 72: UW-QoLv4 global question scores for pre-TLM patients (complete data set) 
 How would you rate 
your health-related 
QOL? (n=14) 
Your Health-
related QOL is? 
(n=15) 
Overall QOL? (n=15) 
1 50 60 60 
2 - - - 
3 - - - 
4 - - - 
5 50 60 60 
6 - - - 
7 50 60 60 
8 - - - 
9 50 80 80 
10 - - - 
11 - - - 
12 - - - 
13 - - - 
14 50 80 80 
15 - - - 
16 - - - 
17 50 80 80 
18 50 60 80 
19 50 60 60 
20 - - - 
21 25 40 40 
22 50 60 60 
23 - - - 
24 50 60 60 
25 50 80 80 
26 50 80 80 
27 - - - 
28 50 80 80 
29 - 100 100 
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Table 73: UW-QoLv4 global question scores for post-TLM patients (complete data set) 
 
How would you rate 
your health-related 
QOL? 
Your Health-
related QOL is? 
Overall QOL? 
1 - - - 
2 - - - 
3 50 60 60 
4 50 60 60 
5 
   
6 50 60 60 
7 50 20 20 
8 50 80 80 
9 - - - 
10 25 60 40 
11 100 100 100 
12 100 75 75 
13 75 60 80 
14 50 60 60 
15 50 60 60 
16 50 80 80 
17 100 80 80 
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Table 74: UW-QoLv4 global questions for all pre-TLM patients (complete data set) 
 
  
 
N 0 20 25 40 50 60 75 80 100 Mean 
% Best 
Scores 
A. Health-related QOL 
compared to month before 
had cancer 
14 0  1  13  0  0 48.2 0 
B. Health-related QOL 
during the past 7 days 
15 0 0  1  7  6 1 69.3 6.7 
C. Overall QOL during the 
past 7 days 
15 0 0  1  6  7 1 70.7 6.7 
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Table 75: UW-QoLv4 global questions for included pre-TLM patients (complete data 
set) 
 
  
 
N 0 20 25 40 50 60 75 80 100 Mean 
% Best 
Scores 
A. Health-related QOL 
compared to month before 
had cancer 
6 0  0  6  0  0 50 0 
B. Health-related QOL 
during the past 7 days 
6 0 0  0  4  2 0 70 0 
C. Overall QOL during the 
past 7 days 
6 0 0  0  3  3 0 70 0 
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 Table 76: UW-QoLv4 global questions for post-TLM patients (complete data set) 
 
 
  
 N 0 20 25 40 50 60 75 80 100 Mean SE 
% Best 
Scores 
A. Health-related QOL 
compared to month 
before had cancer 
14 0  1  8  1  3 61.5 5.9 21.4 
B. Health-related QOL 
during the past 7 days 
14 0 1  0  7  3 1 65.8 4.5 7.1 
C. Overall QOL during 
the past 7 days 
14 0 1  1  7  4 1 65.8 4.9 7.1 
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Appendix 13: Complete data set: perception rating for pre- 
and post- TLM patients  
Table 77: GRBAS scores for pre and post-TLM patients (complete data set) 
 
Pre-TLM Post-TLM 
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(0
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1 2 2 1 1 0 2 0 1 1 2 
2 3 3 2 2 2 1 0 1 1 1 
3 1 1 1 0 0 - - - - - 
4 2 1 1 1 2 - - - - - 
5 3 2 2 2 2 3 2 3 2 3 
6 1 1 1 1 1 - - - - - 
7 2 1 2 1 1 3 2 2 2 2 
8 2 1 2 1 1 2 2 2 1 2 
9 2 1 2 1 1 2 1 2 2 2 
10 1 1 1 0 0 2 1 2 2 2 
11 0 0 0 0 0 2 1 2 2 2 
12 1 0 1 1 1 - - - - - 
13 2 1 2 1 1 - - - - - 
14 3 3 0 0 3 - - - - - 
15 2 2 2 2 1 - - - - - 
16 3 2 2 1 2 2 2 2 2 0 
17 1 1 0 1 0 1 0 1 1 1 
18 3 3 1 2 2 2 1 1 1 1 
19 3 3 2 2 3 2 1 2 2 1 
20 2 1 1 2 0 - - - - - 
21 3 2 3 1 3 - - - - - 
22 1 1 0 1 0 - - - - - 
23 2 1 2 1 2 1 1 0 0 1 
24 2 1 1 1 2 - - - - - 
25 2 2 2 1 2 3 3 2 2 2 
26 2 2 1 0 0 - - - - - 
27 0 0 0 0 0 2 1 2 1 1 
28 2 2 2 1 2 2 1 2 1 0 
29 0 0 0 0 0 - - - - - 
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Appendix 14: Complete data set: sustained vowels for pre- and post-TLM patients  
Table 78: Sustained vowel /i/ for pre-TLM patients (complete data set) 
 Duration (ms) 
Minimum 
Fx (Hz) 
Maximum 
Fx (Hz) 
Average 
Fx (Hz) 
S.D. 
Fx 
(%) 
Minimum 
Qx (%) 
Maximum 
Qx (%) 
Average 
Qx (%) 
S.D. 
Qx 
(%) 
Jitter 
First 
(%) 
Jitter 
Second 
(%) 
Shimmer 
+ (%) 
Shimmer 
– (%) 
Jitter 
Factor 
(%) 
RAP 
(%) 
Shimmer 
dB (dB) 
NNE 
(dB) 
CPP 
HNR 
(dB) 
Mean 
SPL 
(dB) 
1 1506.0 142.3 149.9 146.3 1.1 34.3 38.0 36.2 0.8 0.5 0.3 2.5 -2.7 0.5 0.3 0.2 -27.0 3.2 23.1 88.3 
2 527.0 74.9 177.5 124.6 32.9 23.4 47.2 35.1 9.0 36.8 23.4 18.2 -14.5 36.3 24.8 1.6 1.5 1.1 6.1 83.9 
3 1561.0 166.8 185.3 175.3 1.5 40.2 56.7 49.2 3.6 1.0 0.6 4.6 -9.4 1.0 0.6 0.4 -17.2 3.0 17.3 83.9 
4 2507.0 159.2 172.0 165.5 1.3 34.3 43.0 37.2 1.4 0.8 0.4 5.2 -6.0 0.8 0.4 0.5 -19.1 1.9 17.5 87.2 
5 789.6 55.3 254.6 220.3 9.0 0.0 61.7 38.3 10.1 7.7 4.4 5.0 -9.4 7.0 6.3 0.4 -5.7 2.1 18.1 88.6 
6 2921.0 144.4 163.4 153.7 2.4 35.8 56.0 42.5 4.0 2.7 1.8 18.2 -10.9 2.7 1.8 1.8 -8.9 1.5 11.8 87.9 
7 - - - - - - - - - - - - - - - - - - - - 
8 1389.0 134.5 145.3 139.2 1.3 42.5 49.6 45.2 1.3 0.5 0.2 3.2 -4.7 0.5 0.2 0.3 -20.7 2.1 20.6 83.9 
9 2786.0 163.8 174.2 168.7 1.1 48.4 54.7 51.1 0.9 0.2 0.1 3.4 -3.9 0.2 0.1 0.3 -20.3 2.7 21.0 84.8 
10 1286.0 185.0 192.4 188.6 0.7 55.3 57.6 56.5 0.5 0.2 0.1 2.4 -3.2 0.2 0.1 0.2 -18.9 6.8 20.8 94.9 
11 10730.0 184.9 191.9 188.7 0.6 38.8 45.9 42.6 1.1 0.3 0.2 3.6 -4.0 0.3 0.2 0.3 -18.5 5.9 15.8 92.0 
12 542.0 185.4 201.6 194.8 1.5 38.1 41.5 39.6 0.8 0.7 0.3 3.7 -6.2 0.6 0.3 0.3 -19.2 2.3 18.6 91.7 
13 180.0 152.7 163.7 159.8 1.6 42.0 45.7 43.9 0.9 1.0 0.6 11.4 -15.4 1.0 0.6 1.1 -11.2 3.1 13.5 87.5 
14 1269.0 52.8 702.7 197.4 41.4 0.0 85.8 37.0 15.0 32.8 22.5 23.1 -32.3 35.9 21.2 2.6 -1.5 2.4 11.9 91.3 
15 972.0 178.3 184.5 181.5 0.7 37.1 42.7 39.7 1.2 0.7 0.4 2.4 -4.3 0.6 0.4 0.2 -23.6 2.6 21.2 89.1 
16 8631.0 123.9 130.6 127.6 1.0 28.8 38.9 34.9 1.4 0.4 0.3 3.3 -3.8 0.4 0.3 0.3 -24.3 1.8 21.5 78.1 
17 2396.0 146.5 160.6 152.0 1.4 30.5 44.7 35.5 3.1 1.2 0.7 5.6 -4.4 1.2 0.7 0.5 -21.9 2.8 19.9 80.9 
18 437.0 65.0 623.0 187.8 39.2 0.0 41.4 26.6 8.9 37.5 22.9 18.3 -18.7 37.6 26.6 2.3 1.0 1.1 2.5 87.7 
19 1239.0 52.5 905.8 231.3 57.1 0.0 78.6 36.8 23.5 60.1 41.7 18.8 -23.9 67.0 36.0 1.9 -0.4 1.6 4.9 92.7 
20 1383.0 149.1 156.6 152.2 1.0 39.6 43.4 41.8 0.7 0.5 0.3 2.3 -3.3 0.5 0.3 0.2 -25.3 2.9 22.4 92.9 
21 - - - - - - - - - - - - - - - - - - - - 
22 - - - - - - - - - - - - - - - - - - - - 
23 1592.8 218.4 233.3 225.1 1.3 33.3 48.6 39.5 3.3 0.5 0.3 7.7 -7.5 0.5 0.3 0.7 -15.0 3.2 15.8 92.9 
24 9962.0 202.9 222.2 210.4 0.8 32.9 40.0 36.6 1.0 0.6 0.3 1.6 -1.6 0.6 0.3 0.1 -32.0 4.1 25.6 88.1 
25 932.0 147.0 952.4 156.3 43.1 15.7 76.5 27.9 4.5 2.5 5.0 9.6 -4.6 7.7 0.9 0.7 -18.5 1.9 19.4 87.6 
26 4340.0 136.8 148.0 142.7 1.4 61.1 69.4 66.2 0.8 1.1 0.7 5.6 -6.4 1.1 0.7 0.5 -13.1 2.7 13.4 87.1 
27 4068.0 169.0 181.5 175.5 1.3 35.9 40.4 38.1 0.7 0.3 0.1 1.4 -2.5 0.3 0.1 0.1 -27.0 3.6 22.0 88.8 
28 752.0 204.3 228.5 216.2 2.1 0.0 46.6 41.6 4.0 2.6 1.6 6.3 -8.5 2.6 1.6 0.6 -15.7 2.1 16.6 92.3 
29 4507.0 138.0 143.1 140.5 0.7 47.8 54.9 51.3 1.0 0.2 0.1 2.8 -2.7 0.2 0.1 0.2 -24.1 4.3 18.5 88.5 
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Table 79: Sustained vowel /i/ for post-TLM patients (complete data set) 
 
 Duration (ms) 
Minimum 
Fx (Hz) 
Maximum 
Fx (Hz) 
Average 
Fx (Hz) 
S.D. 
Fx 
(%) 
Minimum 
Qx (%) 
Maximum 
Qx (%) 
Average 
Qx (%) 
S.D. 
Qx 
(%) 
Jitter 
First 
(%) 
Jitter 
Second 
(%) 
Shimmer 
+ (%) 
Shimmer 
– (%) 
Jitter 
Factor 
(%) 
RAP 
(%) 
Shimmer 
dB (dB) 
NNE 
(dB) 
CPP 
HNR 
(dB) 
Mean 
SPL 
(dB) 
1 1425.0 153.9 159.8 156.9 0.7 58.8 64.4 61.0 1.0 0.4 0.2 3.1 -6.5 0.4 0.2 0.3 -21.6 4.2 20.8 89.3 
2 273.0 138.7 142.0 140.6 0.5 34.8 37.2 35.9 0.6 0.3 0.1 2.0 -4.0 0.3 0.1 0.2 -27.2 2.7 24.8 89.5 
3 - - - - - - - - - - - - - - - - - - - - 
4 670.0 55.6 1136.4 368.3 84.3 0.0 84.6 29.1 29.6 94.8 54.3 33.5 -31.9 96.2 55.6 3.0 -0.3 0.6 0.3 62.7 
5 1546.0 64.4 242.4 190.5 13.5 0.0 67.6 41.6 9.5 12.6 6.6 9.0 -9.9 10.7 10.9 0.8 -4.8 1.6 11.8 84.4 
6 1541.0 258.5 273.0 266.7 1.0 37.7 45.0 41.5 1.4 1.0 0.6 3.1 -3.8 1.0 0.6 0.3 -23.5 3.8 26.5 100.5 
7 - - - - - - - - - - - - - - - - - - - - 
8 1893.0 126.3 136.8 131.1 1.3 34.7 39.7 36.9 0.9 1.0 0.6 7.2 -7.2 1.0 0.6 0.6 -19.9 1.8 17.8 70.9 
9 1351.0 149.9 179.1 166.5 2.2 32.6 46.4 41.2 1.8 2.4 1.5 7.2 -4.5 2.4 1.5 0.6 -19.8 1.8 19.2 72.9 
10 22.6 76.0 222.7 163.4 38.6 0.0 76.2 32.3 32.2 56.7 36.3 11.2 -7.9 54.5 41.1 1.0 2.2 0.5 -1.5 90.9 
11 4883.0 189.9 207.6 198.4 1.6 39.5 45.7 42.3 1.1 2.4 1.6 2.8 -3.5 2.4 1.6 0.2 -19.6 5.6 20.0 79.1 
12 721.0 207.9 221.0 213.3 1.3 30.7 34.2 32.5 0.8 0.5 0.3 1.6 -2.2 0.5 0.3 0.1 -30.3 4.8 25.1 91.0 
13 - - - - - - - - - - - - - - - - - - - - 
14 - - - - - - - - - - - - - - - - - - - - 
15 - - - - - - - - - - - - - - - - - - - - 
16 2543.0 171.0 192.1 179.4 1.9 29.5 37.0 32.9 1.4 1.9 1.2 8.7 -5.9 1.9 1.2 0.8 -14.2 2.1 18.1 79.2 
17 1229.0 160.3 176.6 170.3 1.8 18.3 30.9 23.9 2.7 1.8 1.1 5.0 -3.3 1.8 1.1 0.4 -21.5 2.8 20.4 80.4 
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Table 80: Sustained vowel /a/ for pre-TLM patients (complete data set) 
 Duration (ms) 
Minimum 
Fx (Hz) 
Maximum 
Fx (Hz) 
Average 
Fx (Hz) 
S.D. 
Fx 
(%) 
Minimum 
Qx (%) 
Maximum 
Qx (%) 
Average 
Qx (%) 
S.D. 
Qx 
(%) 
Jitter 
First 
(%) 
Jitter 
Second 
(%) 
Shimmer 
+ (%) 
Shimmer 
– (%) 
Jitter 
Factor 
(%) 
RAP 
(%) 
Shimmer 
dB (dB) 
NNE 
(dB) 
CPP 
HNR 
(dB) 
Mean 
SPL 
(dB) 
1 2061.0 139.5 159.4 148.6 2.4 34.3 41.4 38.0 1.3 2.9 1.8 12.4 -12.0 2.9 1.8 1.1 -13.1 2.1 13.8 83.3 
2 77.0 155.7 168.9 162.8 2.3 29.9 40.8 32.7 3.3 2.8 1.6 20.3 -14.6 2.7 1.6 1.8 -10.3 1.5 7.6 95.9 
3 168.0 170.5 175.3 172.3 0.7 25.8 32.3 30.6 1.4 0.8 0.5 5.4 -8.9 0.8 0.5 0.5 -16.5 3.8 15.0 96.8 
4 1939.0 159.8 170.0 163.7 1.1 33.7 43.9 37.4 1.8 0.5 0.3 11.1 -7.9 0.5 0.3 1.0 -15.9 2.9 14.9 89.6 
5 297.0 24.5 218.1 166.2 18.7 21.1 44.1 36.0 5.4 20.6 12.5 15.0 -13.0 19.5 14.8 1.3 -0.8 1.9 9.3 95.5 
6 2464.0 148.3 157.8 152.4 0.9 37.5 45.7 41.6 1.9 0.4 0.2 7.7 -5.0 0.4 0.2 0.7 -14.6 3.6 15.3 87.0 
7 - - - - - - - - - - - - - - - - - - - - 
8 1273.0 115.7 125.2 119.9 1.4 0.0 44.7 41.3 3.5 0.8 0.4 4.4 -5.4 0.8 0.4 0.4 -21.0 3.3 18.5 83.1 
9 1975.0 135.8 147.5 141.0 1.7 20.0 25.4 22.5 1.2 0.5 0.2 6.7 -7.2 0.5 0.2 0.6 -15.8 3.2 15.0 85.1 
10 1183.0 143.6 149.4 146.4 0.8 36.1 39.6 37.3 0.6 0.4 0.3 3.4 -6.5 0.4 0.3 0.3 -19.1 4.1 16.8 99.1 
11 3105.0 149.7 159.4 153.6 1.1 32.0 39.6 35.8 1.4 0.4 0.2 4.7 -4.7 0.4 0.2 0.4 -20.3 5.2 16.6 97.9 
12 358.0 195.3 203.9 198.8 1.1 36.3 45.7 41.7 2.3 0.7 0.4 7.4 -3.9 0.7 0.4 0.7 -22.4 3.3 20.7 89.3 
13 56.0 129.2 131.3 130.6 0.5 35.8 40.2 37.7 1.5 0.5 0.4 6.0 -12.9 0.5 0.4 0.5 -16.4 3.4 17.3 89.5 
14 519.0 56.4 679.8 305.2 49.9 0.0 58.2 19.6 18.4 73.9 50.0 90.6 -77.5 77.6 46.7 9.7 -0.3 2.2 -23.2 92.0 
15 737.0 163.5 174.7 169.4 1.2 26.6 35.4 32.2 1.8 0.1 0.7 6.2 -8.3 1.1 0.7 0.5 -16.9 4.0 16.3 93.3 
16 9979.0 120.3 915.8 168.0 95.2 0.0 89.5 34.7 10.5 18.0 31.2 11.7 -16.7 47.6 6.7 1.3 -3.0 2.7 12.9 77.4 
17 2053.9 143.2 168.5 157.5 2.6 31.7 44.0 37.9 2.5 2.4 1.4 7.2 -8.3 2.4 1.4 0.6 -16.8 2.4 16.7 75.3 
18 75.9 51.6 117.7 71.1 38.3 44.9 62.1 55.0 6.7 52.2 39.1 130.1 -99.9 61.6 24.3 9.1 - 0.0 - 88.5 
19 393.0 60.6 121.0 104.2 9.7 36.7 62.9 53.9 6.3 10.9 6.3 26.2 -28.8 10.5 7.2 2.5 0.3 1.0 1.8 93.2 
20 1482.0 142.9 149.2 145.7 0.7 36.4 39.4 37.8 0.6 0.4 0.2 9.1 -8.9 0.4 0.2 0.8 -14.2 3.0 14.5 91.6 
21 - - - - - - - - - - - - - - - - - - - - 
22 - - - - - - - - - - - - - - - - - - - - 
23 2415.0 210.7 225.9 216.7 0.9 45.3 54.1 50.2 1.5 0.6 0.4 11.8 -6.5 0.6 0.4 1.0 -14.4 5.1 13.9 94.6 
24 1237.0 205.7 221.3 213.4 1.2 26.0 32.5 29.2 1.1 1.2 0.7 3.7 -3.2 1.2 0.7 0.3 -24.3 4.9 20.8 87.5 
25 725.0 150.3 158.2 154.1 1.2 25.5 41.2 29.3 3.0 0.4 0.2 7.4 -7.9 0.4 0.2 0.6 -16.6 2.7 16.8 87.6 
26 3891.0 91.1 189.1 124.3 7.2 0.0 80.7 71.0 4.1 5.3 3.2 14.3 -13.1 5.2 3.3 1.3 -3.1 3.0 9.4 97.2 
27 3865.0 164.8 174.2 168.9 1.2 35.5 43.3 40.4 1.7 0.2 0.1 1.7 -1.7 0.2 0.1 0.2 -30.3 5.1 25.2 90.0 
28 547.0 115.7 261.2 228.8 7.4 0.0 47.0 37.2 12.9 7.3 4.4 18.5 -14.7 6.9 5.3 1.6 -6.9 2.6 11.9 91.3 
29 5580.0 135.4 142.5 138.8 0.9 44.0 48.7 46.9 0.8 0.3 0.1 2.6 -1.9 0.3 0.1 0.2 -26.6 5.3 21.2 91.0 
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Table 81: Sustained vowel /a/ for post-TLM patients (complete data set) 
 Duration (ms) 
Minimum 
Fx (Hz) 
Maximum 
Fx (Hz) 
Average 
Fx (Hz) 
S.D. 
Fx 
(%) 
Minimum 
Qx (%) 
Maximum 
Qx (%) 
Average 
Qx (%) 
S.D. 
Qx 
(%) 
Jitter 
First 
(%) 
Jitter 
Second 
(%) 
Shimmer 
+ (%) 
Shimmer 
– (%) 
Jitter 
Factor 
(%) 
RAP 
(%) 
Shimmer 
dB (dB) 
NNE 
(dB) 
CPP 
HNR 
(dB) 
Mean 
SPL 
(dB) 
1 1196.0 139.6 180.4 155.4 1.8 44.6 51.8 46.7 1.1 1.5 1.0 6.1 -6.6 1.5 1.0 0.5 -16.5 3.7 13.6 86.7 
2 120.0 174.9 184.8 180.2 1.7 30.0 35.6 32.2 1.5 0.5 0.3 9.7 -9.5 0.5 0.3 0.9 -18.8 3.8 14.9 99.6 
3 - - - - - - - - - - - - - - - - - - - - 
4 1021.0 50.1 1342.3 326.4 106.4 0.0 85.7 36.5 29.3 86.3 64.2 41.9 -37.1 107.2 44.5 4.4 -0.4 0.7 0.3 72.4 
5 1903.5 60.9 236.1 192.0 6.2 0.0 50.0 40.3 7.1 4.5 2.5 11.9 -12.2 4.2 3.3 1.0 -7.1 1.9 10.9 82.8 
6 759.0 75.3 258.0 183.9 27.0 20.6 82.1 43.4 10.0 24.2 12.9 23.5 -18.7 22.1 15.9 2.1 -0.5 1.6 5.1 91.8 
7 - - - - - - - - - - - - - - - - - - - - 
8 1301.0 116.0 128.8 122.1 2.0 26.8 44.7 35.1 3.5 1.4 0.8 8.1 -6.9 1.4 0.8 0.7 -18.8 2.7 16.6 70.3 
9 1126.0 144.4 159.1 151.6 2.0 26.7 37.7 32.1 2.2 0.8 0.4 10.3 -9.0 0.8 0.4 0.9 -16.9 3.2 15.1 74.7 
10 130.5 65.2 540.2 155.5 68.8 0.0 74.6 38.8 24.8 35.6 33.4 13.8 -28.4 50.7 20.1 1.3 0.0 1.2 2.1 91.6 
11 1534.0 156.7 164.2 160.6 1.1 36.7 42.6 40.0 1.4 0.4 0.2 3.3 -2.6 0.4 0.2 0.3 -23.8 5.7 17.9 87.9 
12 1297.0 200.8 209.6 205.2 0.9 26.9 31.6 29.1 1.1 0.4 0.3 2.9 -2.9 0.4 0.3 0.3 -24.6 5.7 21.4 94.1 
13 - - - - - - - - - - - - - - - - - - - - 
14 - - - - - - - - - - - - - - - - - - - - 
15 - - - - - - - - - - - - - - - - - - - - 
16 1338.0 167.3 191.1 174.3 1.6 19.8 31.3 23.1 1.5 2.0 1.3 12.0 -11.7 2.1 1.3 1.0 -10.9 2.6 13.4 81.9 
17 921.0 155.3 175.4 164.6 2.0 14.3 26.3 19.7 2.9 2.5 1.5 7.0 -7.1 2.5 1.5 0.6 -18.7 3.2 18.3 80.2 
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Appendix 15: Comparison of quality of life and voice outcome 
in patients included and excluded from pre- and post- TLM 
comparison  
Table 82: Comparison of quality of life and voice outcome in patients included and 
excluded from pre- and post- TLM comparison 
 VH1-10 
Median score (IQR) Included Excluded p value 
Functional (VHI-10 F) 5 (3,9) 5 (2.3,6.3) 0.535 
Physical (VHI-10 P) 6 (4,7) 4.5 (0.8, 5) 0.101 
Emotional (VHI-10 E) 2 (1,2) 2 (1.8, 2.3) 0.412 
Total 13 (11,18) 12 (4.3, 13.5) 0.453 
 VoiSS 
Median score (IQR) Included Excluded p value 
Impairment 31 (21,32) 27 (17,30.3) 0.208 
Emotional 4 (3,5) 8.5 (1.5,11.3) 0.222 
Physical 7 (6,9) 8 (6.5,8) 0.726 
Total 43 (29,49) 41 (29,45.25) 0.726 
UW-QOL v4 
Mean Included Excluded p value 
Pain 83.8 91.7 0.278 
Appearance 97.1 100.0 0.163 
Activity 95.6 79.2 0.043 
Recreation  89.7 83.3 0.402 
Swallowing 98.2 97.5 0.812 
Chewing 100.0 100.0 1.000 
Speech 75.3 77.5 0.767 
Shoulder 90.0 89.2 0.936 
Taste 98.2 87.5 0.041 
Saliva 95.9 95.0 0.870 
Mood  79.4 85.4 0.338 
Anxiety 66.5 72.5 0.540 
Perceptual rating 
Mean Included Excluded p value 
G 1.8 1.8 0.956 
R 1.4 1.5 0.734 
B 1.3 1.3 0.857 
A 0.9 1.0 0.821 
S 1.0 1.3 0.437 
TOTAL 6.4 6.9 0.752 
Acoustic analysis on /i/ 
Mean Included Excluded p value 
Minimum Fx (Hz) 141.7 148.3 0.759 
Maximum Fx (Hz) 176.2 379.4 0.077 
Average Fx (Hz) 164.2 183.8 0.177 
S.D. Fx (%) 4.5 14.8 0.199 
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Minimum Qx (%) 34.2 26.6 0.356 
Maximum Qx (%) 48.2 54.0 0.299 
Average Qx (%) 41.2 40.6 0.889 
S.D. Qx (%) 2.9 4.8 0.431 
Jitter First (%) 4.3 10.6 0.404 
Jitter Second (%) 2.7 7.3 0.356 
Shimmer + (%)  6.2 7.4 0.640 
Shimmer – (%) -6.1 -8.0 0.492 
Jitter Factor (%) 4.2 11.8 0.345 
RAP (%) 3.0 6.7 0.435 
Shimmer dB (dB)  0.6 0.7 0.560 
NNE (dB) -16.9 -17.0 0.982 
CPP 2.9 2.8 0.871 
HNR (dB) 17.9 16.1 0.522 
Mean SPL (dB) 86.9 89.9 0.077 
Acoustic analysis on /a/ 
Mean Included Excluded p value 
Minimum Fx (Hz) 136.0 132.9 0.884 
Maximum Fx (Hz) 228.7 176.0 0.431 
Average Fx (Hz) 156.6 156.6 0.999 
S.D. Fx (%) 10.8 6.9 0.657 
Minimum Qx (%) 26.1 29.4 0.616 
Maximum Qx (%) 45.4 51.2 0.361 
Average Qx (%) 36.4 45.1 0.071 
S.D. Qx (%) 3.0 3.9 0.546 
Jitter First (%) 4.2 7.9 0.514 
Jitter Second (%) 4.2 5.5 0.789 
Shimmer + (%)  9.3 22.5 0.309 
Shimmer – (%) -8.8 -18.7 0.322 
Jitter Factor (%) 6.6 8.7 0.768 
RAP (%) 2.4 4.2 0.508 
Shimmer dB (dB)  0.9 1.8 0.315 
NNE (dB) -14.4 -15.1 0.866 
CPP 3.0 3.3 0.703 
HNR (dB) 14.8 15.1 0.935 
Mean SPL (dB) 88.2 91.3 0.236 
Acoustic analysis of connected speech 
Mean Included Excluded p value 
Mean DFx1 (Hz) 158.0 156.0 0.894 
Mean DFx2 (Hz) 144.2 153.8 0.427 
Fx Coherence (%) 41.3 43.2 0.835 
CFx (%) 20.4 21.6 0.895 
Mean DAx1 (Hz) 85.2 86.9 0.336 
Mean DAx2 (Hz) 85.4 87.8 0.182 
Ax Coherence (%) 50.0 47.2 0.714 
CAx (%) 7.5 8.2 0.784 
Mean DQx1 (Hz) 38.0 42.1 0.194 
Mean DQx2 (Hz) 38.2 42.8 0.206 
Qx Coherence (%) 25.5 27.5 0.706 
CQx (%) 39.5 39.2 0.974 
AxFx1 &2 (%) 54.2 54.8 0.949 
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